9th Survey

6 BioSpectrum | June 2011 | www.BioSpectrumIndia.
com | A CyberMedia Publication

Industry Overview
20
BioContent
47
India Biotech
Surges to $4 bn
Grows 21.5%
Registers `18,399.34 cr
South catches up with
the west
Survey methodology
32
25
Revenue in `crore
Biotech industry in India in
FY 2010-11 has picked up critical
mass. In dollar terms, the industry
has touched the $4 billion mark,
clocking `18,399.34 crore
Segment Overview
34
BioPharma Gets lions share
BioPharma continues to dominate the biotech
industry with 61.77% share in the overall revenue
BioServices Grows over 20 percent
BioServices has increased by three percent in the
segment revenue in 2010-11
BioAgri Fast track growth continues
BioAgri has increased its share in the last ve years
from less than ve percent to over 14 percent
BioIndustrial Takes baby steps
BioIndustrial segment grew at 10.98 percent
in 2010-11
BioInformatics Set for a growth spurt
BioInformatics segment has increased exports busi-
ness revenue in 2010-11 to claim 42 percent share
40
46
49
50
BioServices 18.82
BioPharma 61.77
B
i
o
A
g
r
i

1
4
.
3
8
B
i
o
I
n
d
u
s
t
r
i
a
l

3
.
6
3

B
i
o
I
n
f
o
r
m
a
t
i
c
s

1
.
4
1
Industry Segment Share (%)
Total industry revenue `17249.34 cr
Asia Overview
Asia clocks
$128.26 billion
Country Market Share (%)
Turn to Page 120 for details
Life science industry in the Asia Pacic region has rebounded
and how! From a measly 3.4 percent growth in 2009 the
industry recorded double-digit growth of 16.6 percent,
clocking $128.26 billion in 2010
A CyberMedia Publication | www.BioSpectrumIndia.com | June 2011 | BioSpectrum 7
Rank Companies Pg No.
1 Biocon 51
2 Serum Institute of India 52
3 Panacea Biotec 53
4 Nuziveedu Seeds 54
5 Reliance Life Sciences 55
6 Quintiles India 56
7 NovoNordisk 58
8 Rasi Seeds 60
9 Mahyco 62
10 Transasia 64
11 Ankur Seeds 66
12 Syngene International 68
13 Bharat Biotech 70
14 Indian Immunologicals 72
15 Krishidhan Seeds 74
16 Shantha Biotech 76
17 Novozymes South Asia 78
18 Bharat Serums 80
19 Jubilant Life Sciences 82
20 EliLilly 84
Company Ranking (21-50) 86
Overall Revenue Ranking 106
Top 20 companies by revenue
BioSpecial
BioSpectrum-ABLE Survey
Records the Biotech
Industry Pulse
Column by Dr Satya
Dash, COO, ABLE
Denmark calls for
Asian investment
Interview: Mr Freddy Svane,
Ambassador, Royal Embassy
of Denmark, New Delhi
BioNews 112
BioResearch 117
BioEvent 118
Bangalore India Bio 2011:
The 11
th
edition of Indias premier
biotech event saw participation
from 800 delegates
LastWord 124
BioEdit 09
107
BioContent
109
Call for Proposals
(15th June 2011-1st August 2011)
Department of Biotechnology (DBT) invites proposals from Indian Biotechnology Companies under the
Biotechnology Industry Partnership Programme (BIPP), a Government partnership with industry for support
on a cost sharing basis for development of novel and high risk futuristic technologies mainly for viability gap
funding and enhancing existing R&D capacities. BIPP has been initiated under Biotechnology Industry Research
Assistance Programme (BIRAP), a unique initiative of DBT being implemented in partnership with ABLE and
BCIL to nurture R&D and innovation in Biotech Industry. Biotech Consortium India Limited (BCIL) is the BIPP
Management Agency and will ensure maintenance of strict condentiality of the proposals as per DBT norms.
The proposals can be submitted:
by an Indian Company alone; or by an Indian Company along
public sector R&D institution(s), organization(s), laboratory (ies),
university (ies) etc.; or by a consortium of Indian Companies; or
by a consortium of Indian Companies along with public sector
R&D institution(s), organization(s), laboratory (ies), university
(ies) etc.
(*Companies in the process of obtaining DSIR recognition may also
apply along with the proof of application to DSIR. However, the nal
decision on such applications would be subject to their getting DSIR
recognition)
Who can apply?
A single or consortia of Indian for prot
company(ies) - Small, Mediumor Largehaving
DSIR* recognized in-house R&D unit(s). An
Indian Company is dened as one which is
registered under The Indian Companies
Act, 1956 and in which 51% (or more) of the
ownership is held by Indian citizens (includ-
ing NRIs).
How to Apply?
Proposals are required to be submitted online only. To submit a proposal online, please follow the following steps:
Log on the BIRAP website (www.birapdbt.nic.in)
If you are a registered user, log-on using the credentials, else you need to register your company with by clicking on New User
Registration.
In case of new user registration, a computer generated password would be sent to the email-id provided at the time of registration.
The password can be changed later.
Once you login, you would be navigated to the page displaying BIPP link.
Click on the BIPP link under Programmes and the active call would be highlighted.
Click on the new call and proceed towards proposal submission.
Further details on How to submit a proposal would be available in the BIPP User Guide available on the website.
The proposals should be submitted on or before 1st August, 2011.
Company User Registration is open round the clock.
Online Proposal Submission would begin from 15th June, 2011.
No Hard Copy to be submitted, Proposals submitted online only would be considered.
Last date for Submission of Proposals: 1st August 2011
Detailed guidelines for the scheme
including eligible project categories to be supported
are available at
http://dbtindia.nic.in/uniquepage.asp?id_pk=680;
http://www.birapdbt.nic.in/programmes.php
For further details, please contact:
Dr. Renu Swarup, Advisor Incharge-BIPP,
Department of Biotechnology, Block No: 2, 7th Floor,
CGO Complex, Lodi Road, New Delhi 110 003, India;
E-mail: [email protected]; [email protected]
Key Features of the Programme
Supports:
Large, medium, small scale companies; start-ups on cost sharing basis
High risk, discovery linked innovation
Accelerated technology development
Evaluation and validation of biotech products
Indigenous discovery, innovation and technology to products
Products of national relevance or public benet
Varying models of grants, loans or grant + loan available
Biotechs sweet smell of growth
A
fter two years of comparatively stagnant growth, Indias biotech indus-
try has got back into its groove. In the last scal year of 2010-11, the
industry has topped the 20 percent annual growth mark once again
after a gap of two years.
According to the 9
th
BioSpectrum-ABLE Biotech Industry Survey 2011, done in
April-May, the industry, has grown by 21.5 percent to reach `17,400 crore in
revenues in 2010-11. In dollar terms, it is slightly less than the $4 billion. But on
adding the estimated revenues of `1,150 crore generated by the nearly 400 pri-
vate and public educational institutions from their biotech courses, the overall
revenues crosses the $4 billion ( `18,400 crore) mark for the rst time ever.
The industry had its annual gathering at Bangalore India Bio in early May. It is
time for the industry to come together once again to pat each other and exchange some high ves.
Indias biotech industry has few saviors. The most prominent savior is the BioAgri industry. With
the cotton farmer lapping up every Bt cotton seed produced by the two dozen companies, this sec-
tor is on a growth path. With ve BioAgri companies in the 9th BioSpectrum-ABLE Top 20 Rank,
the revenues from this sector are providing a cushion to the industry collectively.
Another remarkable fact this time is the higher than industry growth achieved by some of the
prominent members of the BioSpectrumABLE Top 20 companies, the industry has a healthy pic-
ture to present. The Top ve companies have grown in excess of 25 percent in the last scal year.
Interestingly, the share of the Top 20 companies in the overall industry revenues has declined by
seven percent, from 53 to 45 percent this year. This indicates that companies beyond the Top 20
list are also gaining traction and contributing signicantly to the overall growth. As the industry
matures, the share of the Top 20 companies should decline gradually. Overall, the industry gener-
ated over `3,000 crore in revenues over the previous year. The Top 10 companies accounted for
nearly two-thirds of the net income generated by the industry collectively.
Biocon has maintained its No.1 rank for the second consecutive year, backed by strong growth in
its key markets. The diversied portfolio built up in the last few years is adding muscle to Biocons
growth. The No.2 company, Serum Institute of India has also recovered from its previous years
slump, thanks to the robust sales of the newly introduced swine u vaccine. Bharat Biotech has
surged past its industry rival and pioneer Shantha Biotech in revenues. Shantha Biotech, now a
part of the Sano Pasteur Group, had a few setbacks due to the withdrawal of some products from
the market last year.
This survey has completed nine years. Even after nine years, the landscape of the biotech cluster
remains more or less the same. The western and southern biotech clusters account for an over-
whelming share of the industry with the northern cluster just in double digit share. The eastern
region continues to remain insignicant in the overall biotech scheme of things. The southern and
western clusters are neck-to-neck in the revenue race with very little to separate these two domi-
nant regions. The government is pushing the industry to the eastern parts of the country. It has
set up some research centers which should form the nucleus
of the sector in the coming decades.
The details of the 9
th
BioSpectrum-ABLE Industry Survey 2011
are available in the magazine. We have tried to provide more
tables and analysis with the limited data shared by the indus-
try for this purpose. I look forward to the suggestions to make
the next edition of the survey even more useful to everyone.
BioEdit
Narayanan Suresh
Chief Editor
[email protected]
10 BioSpectrum | June 2011 | www.BioSpectrumIndia.com | A CyberMedia Publication
A worthy tribute
The cover story Biotech Drugs:
The Wave Arrives was a much-de-
served tribute to the resilient bio-
tech entrepreneurs in India. The
achievements that India has made
in the eld of biological drugs is
very commendable. I am sure that
Indian biotech companies will
achieve more success in the future.
I wish them all the best!
Nisha Siriparappu, Hyderabad
Growing sector
The article on organic farming in
India made for an interesting read.
It provided key information on
the relevant statistics in relation
to India and the various business
opportunities in this emerging
eld. I have been inspired by the
huge market potential the segment
offers.
Maushmi Rai, Bangalore
Inspiring studies
The PPP series on the success sto-
ries of Bigtec Labs and Bharat Se-
rums & Vaccines was very inspir-
ing. The fact that these companies
have become success stories due to
the funding given by SBIRI instills
hope and exemplies the benets
of public-private partnerships. I
commend BioSpectrum on this
inspiring series.
Rakesh O M, Kochi
BioMail
We welcome your
suggestions and
valuable comments.
Please e-mail us your
views on the
magazine at
[email protected]
rom Online Readers
F
www.biospectrumasia.com
www.biospectrumindia.com
Chief Editor: E Abraham Mathew
Group Editor: N Suresh
Executive Editor: Nandita Singh
Associate Editor: Narayan Kulkarni
Sub Editor: Saptarshi Chaudhuri, Uma Kelath
Asst Manager - Design: Sareeta Sajjan;
Shridhar G Kulkarni
Associate VP - Sales: Aninda Sen
Sr Manager - Sales: Gurunath S A
VP, Print & Circulation Services: Rachna Garga
GM, Print Services: T Srirengan
Circulation: Jagdeep Khanna, C Ramachandran,
Raghavendra S, Raju Salve, Sudhir Arora
Audience Servicing: Sarita Shridhar,
(E-mail: [email protected])
Audience Development: Ekta Sharma
(E-mail:[email protected])
Manager Commercial: CP Kalra
Our ofces
Editorial ofce - Bangalore
401, 4th Floor, MBC, 134 Infantry Road, Bangalore - 560 001
Tel.: +91-80-43412000
Fax: +91-80-22862971
Chennai
Asst Bureau Manager: Venkatesh L
5-B, 6th Floor, Gemini Parsn Apartments
599, Anna Salai, Chennai-600006
Tel.: +91-44-28221712, 28229116 Fax: +91-44-28222092
Delhi/NCR
Asst Manager - Marketing: Sonia Sharma
Correspondent: Rahul Koul
B-35, Sector 32, Gurgaon, Haryana - 122 001
Tel: +91-124-48522222 Fax: +91-124-2380694
Kolkata
Regional Manager (East): Sandeep Roy Chowdhury
23/54, Gariahat Road, Ground Floor, Near South City College,
Kolkata - 700029, Phone: +91-33-65250117 / 65250118 /
65341101, [email protected]
Mumbai
Manager Sales: Indraneel Basu Ray
Asst Editor: Nayantara Som
501 /502 fth Floor Acropolis, Military Road, Marol,
Andheri (East )Mumbai 400059
Phone: +91-22-29204142 / 43 / 29204144
Fax: +91-22-29203964
Pune
Asst Bureau Manager: Vandana Chouhan
Flat No. 9, F Block, Popular Heights 3, Koregaon Park,
Pune 411001. Tel: +91-20-65000996
Mobile: +91-9890664656, Email: vandanac@cybermedia.
co.in
Secunderabad
Asst. Bureau Manager: Syed Liyaqath Hussain
Room No. 2, 5 & 6, 1st Floor, Srinath Commercial Complex,
SD Road, Secunderabad -500 003
Tel.: +91-40-27841970, 27841665; Fax: +91-40-27898134
BioSpectrum Asia ofce
Associate VP - Asia Pacic: Kingshuk Sircar
Asst. Manager (Sales & Marketing): Stanrick Tan
Senior Correspondent: Amrita Tejasvi
Cyber Media (Singapore) Pte Ltd
1, Northbridge Road, # 14-03 High Street Centre,
Singapore 179094
Tel.: +65-63369142/43/44, Fax: +65-63369145
Email: [email protected], sales@biospectrumasia.
com
USA
Media Representative: Leslie Hallanan
Avani Media Inc.
69a Liberty Ship Way
Sausalito, CA 94965, USA
Tel.: +1 415 331 2150, Fax: +1 415 289 0402
e-mail: [email protected]
CyberMedia News
Srinivas Rasoor, Sudhakaran P, Divya G, Prasoon S, Saheer K,
Pankaj M, Akanksha P
Corporate ofce - Cyber House
Tel: +91-124-4822222 Fax: +91-124-2380694
Printed and published by Pradeep Gupta on behalf of Cyber
Media (India) Ltd. Printed at Rakesh Press, A-7 Naraina
Industrial area, Phase II, New Delhi - 110 028 and Published
from D-74, Panchsheel Enclave, New Delhi 110 017
Editor: N Suresh
Distributed in India by Mirchandani & Co., Mumbai
Print Service: Dot Print, New Delhi
Corporate Website: www.cybermedia.co.in
(Asias rst Life Sciences portal)
Vol 6; Issue 06; June 2011
A worthy tribute
The cover story Biotech Drugs:
The Wave Arrives was a much-de-
served tribute to the resilient bio-
tech entrepreneurs in India. The
achievements that India has made
in the eld of biological drugs is
very commendable. I am sure that
Indian biotech companies will
achieve more success in the future.
I wish them all the best!
Nisha Siriparappu, Hyderabad
Growing sector
The article on organic farming in
India made for an interesting read.
It provided key information on
the relevant statistics in relation
to India and the various business
opportunities in this emerging
eld. I have been inspired by the
huge market potential the segment
offers.
Maushmi Rai, Bangalore
Inspiring studies
The PPP series on the success sto-
ries of Bigtec Labs and Bharat Se-
rums & Vaccines was very inspir-
ing. The fact that these companies
have become success stories due to
the funding given by SBIRI instills
hope and exemplies the benets
of public-private partnerships. I
commend BioSpectrum on this
inspiring series.
Rakesh O M, Kochi
BioMail
Vol 6; Issue 5; May 2011
We welcome your
suggestions and
valuable comments.
Please e-mail us your
views on the
magazine at
[email protected]
Indias life science companies
entering the nancial market with
their initial public offering is good
news. This is a positive signal and
would denitely prove benecial
to many biotech companies.
Atul Shrivastav, Pune
I have been an avid reader of
BioSpectrum for the last two
years. I have found the coverage
to be vast and informative.
However, I nd the layout of
BioSpectrum website not-so
reader-friendly. I would suggest
that the online presentation is
made better.
Sonia Pardesi, Mumbai
rom Online Readers
F
www.biospectrumindia.com
Chief Editor: E Abraham Mathew
Group Editor: N Suresh
Executive Editor: Nandita Singh
Associate Editor: Narayan Kulkarni
Sub Editor: Saptarshi Chaudhuri, Uma Kelath
Asst Manager - Design: Sareeta Sajjan;
Shridhar G Kulkarni
Associate VP - Sales: Aninda Sen
Sr Manager - Sales: Gurunath S A
VP, Print & Circulation Services: Rachna Garga
GM, Print Services: T Srirengan
Circulation: Jagdeep Khanna, C Ramachandran,
Raghavendra S, Raju Salve, Sudhir Arora
Audience Servicing: Sarita Shridhar,
(E-mail: [email protected])
Audience Development: Ekta Sharma
(E-mail:[email protected])
Manager Commercial: CP Kalra
Our ofces
Editorial ofce - Bangalore
401, 4th Floor, MBC, 134 Infantry Road, Bangalore - 560 001
Tel.: +91-80-43412000
Fax: +91-80-22862971
Chennai
Asst Bureau Manager: Venkatesh L
5-B, 6th Floor, Gemini Parsn Apartments
599, Anna Salai, Chennai-600006
Tel.: +91-44-28221712, 28229116 Fax: +91-44-28222092
Delhi/NCR
Asst Manager - Marketing: Sonia Sharma
Correspondent: Rahul Koul
Tel: +91-124-48522222 Fax: +91-124-2380694
Kolkata
Regional Manager (East): Sandeep Roy Chowdhury
23/54, Gariahat Road, Ground Floor, Near South City College,
Kolkata - 700029, Phone: +91-33-65250117 / 65250118 /
65341101, [email protected]
Mumbai
Manager Sales: Indraneel Basu Ray
Asst Editor: Nayantara Som
501 /502 fth Floor Acropolis, Military Road, Marol,
Andheri (East )Mumbai 400059
Phone: +91-22-29204142 / 43 / 29204144
Fax: +91-22-29203964
Pune
Asst Bureau Manager: Vandana Chouhan
Flat No. 9, F Block, Popular Heights 3, Koregaon Park,
Pune 411001. Tel: +91-20-65000996
Mobile: +91-9890664656, Email: vandanac@cybermedia.
co.in
Secunderabad
Asst. Bureau Manager: Syed Liyaqath Hussain
Room No. 2, 5 & 6, 1st Floor, Srinath Commercial Complex,
SD Road, Secunderabad -500 003
Tel.: +91-40-27841970, 27841665; Fax: +91-40-27898134
BioSpectrum Asia ofce
Associate VP - Asia Pacic: Kingshuk Sircar
Asst. Manager (Sales & Marketing): Stanrick Tan
Senior Correspondent: Amrita Tejasvi
Cyber Media (Singapore) Pte Ltd
1, Northbridge Road, # 14-03 High Street Centre,
Singapore 179094
Tel.: +65-63369142/43/44, Fax: +65-63369145
Email: [email protected], sales@biospectrumasia.
com
USA
Media Representative: Leslie Hallanan
Avani Media Inc.
69a Liberty Ship Way
Sausalito, CA 94965, USA
Tel.: +1 415 331 2150, Fax: +1 415 289 0402
e-mail: [email protected]
CyberMedia News
Srinivas Rasoor, Sudhakaran P, Divya G, Prasoon S, Saheer K,
Pankaj M, Akanksha P
Corporate ofce - Cyber House
Tel: +91-124-4822222 Fax: +91-124-2380694
Printed and published by Pradeep Gupta on behalf of Cyber
Media (India) Ltd. Printed at Rakesh Press, A-7 Naraina
Industrial area, Phase II, New Delhi - 110 028 and Published
from D-74, Panchsheel Enclave, New Delhi 110 017
Editor: N Suresh
Distributed in India by Mirchandani & Co., Mumbai
Print Service: Dot Print, New Delhi
Corporate Website: www.cybermedia.co.in
(Asias rst Life Sciences portal)
Vol 6; Issue 06; June 2011
Industry: Market Share % by Segment
Industry: Market Share % by Country
L
ife science industry in the Asia Pacic region has
rebounded and how! From a measly 3.4 percent
growth in 2009 the industry recorded double-
digit growth of 16.6 percent, clocking $128.26
billion in 2010.
Pharma made up the major chunk of this revenue with 92
percent segment share, MedTech followed with 6.6 per-
cent share and biotech made up the rest. Interestingly,
the biopharma share in the pharma segment has gone up
to seven percent of the pharma segment share. This is an
improvement over last two years, when it hovered at just
about ve percent. This mix, it is expected will continue to
evolve in favour of biopharma. Biotech share in the overall
revenue is just about one percent as biopharma as a sub-
segment in this survey has been combined with pharma.
If that is allocated to biotech, it will come to about eight-
to-nine percent of the overall revenue. The revenues of
publicly listed companies
accounted for 48 percent
of the overall market of
$128.26 billion.
Countrywise, China with a market size of about $57 bil-
lion makes up for 44 percent of the overall market and
along with India has been responsible for this growth of
16.6 percent, recorded by the BioSpectrum Asia Pacic
Life Sciences Industry Survey 2010. Rising prevalence of
chronic diseases, booming population, economic growth,
improved regulations on foreign direct investment will
continue to attract foreign interest in China and conse-
quently, market growth. Multinational pharmaceutical
companies are also increasingly investing in research
facilities in China indicating the improved business and
regulatory climate in China.
Asia clocks
Grows 16.6%
$128.26 bn
BioSpectrum Top 20 Survey
Asia Pacific Life Sciences Industry
O
ve
ra
ll in
d
u
stry re
ve
n
u
e
: $
1
2
8
.2
6
b
n
AsiaOverview
Revenue in $ million
Publicly Listed Companies: % Market Share by Country
9.90%
15.60%
27.25%
3.27%
42.20%
0.62%
1.15%
China India ANZ S Korea Taiwan Malaysia Singapore
Overall publicly listed companies revenue: $67.4 bn
Publicly Listed Companies: % Growth by Country
Country Revenue
CY 2010
Revenue
CY 2009
Revenue
CY 2008
Revenue
CY 2007
% Growth
over 2009
South Korea 6677.57 5518.4 4984.61 5536.19 21.01
Australia & New Zealand 10525.17 9050.45 7542.17 6252.36 16.29
India 18380.06 14585.56 14381.55 14082.6 26.02
Taiwan 2207.64 2019.92 1380.74 725.7 9.29
China 28464.46 22043.81 14520.12 5286.78 29.13
Singapore 417.46 321.13 273.6 155.94 30.00
Malaysia 778.48 698.83 649.31 7.63 11.40
India in terms of growth is second
only to China. Most of the companies
in India have grown in the range of
20-30 percent. On an average, the
publicly listed companies revenue
overall in India has grown by 26 per-
Top 20 companies make up
about 55 percent share of the
overall revenue of the publicly
listed companies in the APAC
region.
Top 20 companies revenue
at $35.82 billion in 2010 has
grown by 29 percent over 2009
Top 20 companies revenue of
$27.82 billion.
cent over the last year. The year 2010
saw stepped-up activity in Malaysia
too, attracting foreign direct invest-
ment to give the life science industry
in the country a booster shot. In-
dias biotech major Biocon, which is
ranked at No 20 in the country rank-
ing in 2010 invested $161 million
in Malaysia.
In Australia, the top three companies
continue to dominate the market
with 85 percent market share.
While this survey has thrown up no
surprises, it certainly establishes
that the growth in 2010 was back
on track and better times are ahead.
The market capitalization (MCap) of
the leading companies has increased
signicantly. CSL from Australia has
increased its MCap by 23 percent to
$14.81 billion. Cipla, one of Indias
leading companies has increased its
MCap by a whopping 87 percent from
$3.48 billion to $6.54 billion. Anoth-
er Indian company Biocon has gone
up by 166 percent to $1.86 billion in
2010 from $697 million in 2009.
In India and China, a
number of companies
have plans to go for
an initial public offering, which is a
reection of growth, the region has
witnessed. There is stepped-up activ-
ity and palpable enthusiasm seen in
the investments that the companies
are making in the research & devel-
opment. The average R&D spend in
Asia Pacic region in 2010 was re-
corded at 12.34 percent, an improve-
ment over 9.44 percent spent on R&D
in 2009.
BS
AsiaOverview
Company % Share Split in the Top 20 Publicly Listed Companies Revenue
Asias Top 20 Publicly Listed Life Science Companies by Revenue (2010)
Rank Company Country Revenue
CY 2010
Revenue
CY 2009
Revenue
CY 2008
Revenue
CY 2007
%
Growth
over
2009
1 Sinopharm China 10226.54 6884.09 5588.51 48.55
2 CSL Australia 5093.01 4033.37 2846.27 2971.29 26.27
3 Sigma Pharmaceuticals Australia 2698.43 2592.35 2846.27 2300.22 4.09
4 Shenzhen Accord Pharmaceutical China 1929.75 1601.42 20.50
5 North China Pharmaceutical China 1519.44 714.24 737.48 547.04 112.74
6 Yunnan Baiyao Group China 1488.24 837.42 77.72
7 Cipla India 1348.51 1176.68 1046.93 978.05 14.60
8 Ranbaxy Laboratories India 1327.56 1047.66 1062.72 1164.96 26.72
9 Dr Reddys Laboratories India 1178.00 955.19 852.33 870.15 23.33
10 Resmed Australia 1158.30 1160.16 887.89 0.62 -0.16
11 China Pharmaceutical Group China 1000.57 913.33 9.55
12 Lupin India 929.84 725.31 645.51 683.52 28.20
13 Aurobindo Pharma India 865.19 663.12 548.17 542.29 30.47
14 The United Laboratories International China 836.91 601.80 496.46 39.07
15 Dong-A South Korea 740.97 640.85 559.75 635.93 15.62
16 Cochlear Australia 714.63 550.07 468.61 487.10 29.92
17 Mindray Medical International China 704.30 659.71 665.00 374.30 6.76
18 Dabur India India 700.30 679.63 3.04
19 Green Cross South Korea 692.14 514.57 411.33 442.30 34.51
20 Sun Pharma India 673.99 609.48 794.59 685.34 10.59
Revenue in $ million
The No. 1 company, Chinas
Sinopharm, has improved its
share in the Top 20 revenue by
growing 48 percent. It not only
retains the top slot and leads
the tally but has also crossed
the $10 billion mark.
Top 20 Companies Revenue: $35.82 bn
AsiaOverview
China
Country Rank Revenue CY 2010 % Share in 2010
1-3 13675.73 48.04
4-5 2488.81 8.74
6-10 3427.09 12.04
11-20 3804.46 13.37
Others 5068.37 17.81
Grand Total 28464.46 100
India
1-3 3854.06 20.97
4-5 1795.03 9.77
6-10 3045.04 16.57
11-20 3440.83 18.72
Others 6245.1 33.98
Australia
1-3 8949.74 85.03
4-5 849.85 8.07
6-10 354.31 3.37
11-20 227.74 2.16
Others 143.53 1.36
Legend: Country Rank: Publicly listed companies in the
particular country; Revenue CY 2010: Revenue for the calender
year 2010; % Share in 2010: Companies percentage share in
the total revenue of publicly listed companies country wise
C
hina leads with ve companies having revenues
in excess of $1 billion. In fact, Chinas No. 1
company, Sinopharm, which is also Asias No.
1 company for the second consecutive year in
2010 has grown by 48 percent and crossed the $10 bil-
lion revenue milestone. In addition to Sinopharm, other
Chinese companies have also grown at a fast clip North
China Pharmaceutical (113 percent growth), Yunnan Bai-
yao Group (78 percent growth), and Shenzhen Neptunus
Bioengineer grew by a remarkable 51 percent. This is a
sampling of the boom that is happening in China.
Compared to this, India, the other fast growing market in
the region, has just two billion dollar companies among
the countrys Top 20 list, however, a bunch of stable
growing companies make up the rest of the industry.
Australia has three companies over a billion dollars. And
among other regions, it is likely that a couple of South Ko-
rean companies may cross this milestone in 2011. China,
India, Australia continue to remain the Top 3 countries
in the region, closely followed by South Korea and the
others.
The global pharma players have already recognized the
opportunities available in Chinas fast growing pharma-
ceutical market. Sano-Aventis expanded its R&D pres-
ence in China by opening a new research center. Eli Lilly
announced plans to launch 15 new products in China over
the next ve years. And Medtronics started its operation
in China.
With an increase in investment and competition from
multinationals, the local big pharma companies are pre-
paring to face new challenges in the growing market.
Consolidation is being adopted as one of the strategies by
the local pharma companies to counter the competition
from multinationals.
China dominates the
billion-dollar club
TOP 3 COUNTRIES
BS
AsiaOverview
Industry Revenue (2006-11)
17249.34
14199
12137
10272
8541
2
0
0
6
-
0
7

2
0
0
7
-
0
8

2
0
0
8
-
0
9

2
0
0
9
-
1
0

2
0
1
0
-
1
1
India Biotech Surges to
B
iotech Industry in India in FY 2010-11 has picked up critical mass.
In dollar terms, the industry has touched the $4 billion mark, clock-
ing `18,399.34 crore. Of this, the biotech industry contributes
`17,249.34 crore while the life science education market makes-up
for the remaining `1,150 crore. This year, the BioSpectrum ABLE survey has
expanded the scope to include the education market survey estimates in the
overall industry revenue. In-depth analysis of the education market is under
process and will be published in the August 2011 issue of the publication.
The biotech industry in FY 2010-11 clocked `17,249.34 crore, growing 21.5 per-
cent over the last years revenue of `14,199 crore. The market share across seg-
ments has recorded minor changes with BioPharma claiming 61 percent share
in the industry revenue. BioAgri remained the fastest growing segment record-
ing 28 percent growth over last year, followed by BioServices (23 percent) and
BioPharma (20.7 percent). Many services companies have taken a hit this year
on account of changes in the complexion of business at the global level.
The revenue split between exports and domestic sales has also recorded mi-
nor shifts ranging between two-to-ve percent. The exports across segment
made up 51 percent of the overall revenue contributing a total of `8,852.34
crore. The ratio between exports and domestic sales stands at 51:49, which is
a sign of a robust industry.
Biocon retained its top slot of No.1 company in the overall revenue ranking,
growing at a healthy 26 percent. Of the Top 20 companies, Shantha Biotech
and Jubilant Life Sciences faced a drop in revenue while Ankur Seeds has
posted a spectacular growth.
The Top 20 fastest growing companies have all recorded a growth of over 29
percent. While the No. 1 company in this list has grown over 400 percent from
a small base of `3.8 crore the No 2 company, Ankur Seeds, has grown 197 per-
cent from a fairly decent base of `109.5 crore. No. 3 slot is also occupied by a
seed company, Krishidhan Seeds, which grew at 107 crore.
Comparing the growth by region, the south region has caught up with the west,
improving its share in the overall Indian biotech industry to 44.22 percent in
2010-11 from 39 percent in 2009-10. The west regions share is 43.60 percent.
Top 10 companies in the south have contributed `4,816.47 crore (27 percent)
of the total biotechnology industry while Top 10 companies from west have
about 21.17 percent of the total industry contributing `3,651.25 crore.
In terms of the number of companies, south continued its dominance with
175 companies, while west has 139 companies and north is yet to cross the 50
gure mark. It has 48 companies. The industry has 362 companies.
Read on for detailed analysis, in the following pages of BioSpectrum.
Grows 21.5% Registers `18,399.34 cr
IndustryOverview
Revenue in `crore
Purification
Purification
C
M
Y
CM
MY
CY
CMY
K
CoverStory
Company Name Page No
3M India 21
Agilent Technologies 61, 65
Alfa Laval 45
Analytica Anacon India 31
Avantor 57
Beckman Coulter 59
Bhat Biotech 87
Biogentek 29, 37
Bioscreen Instruments 81
Chromous Biotech 85
Dept of Biotechnology 4, 8
Esco Biotech 89
Frost & Sulivan 93
GE India Industrial 69
GE Life Sciences 7, 41, 113
Himedia Laboratories 13
Imperial Life Sciences 1
India Lab Expo 2011 119
Invitrogen Bioservices India 126
Kerry Biosciences 125
Medi Analytika India 35
Merck Millipore 79, 83
Pall Filteration Pte Ltd 39
Pall Life Sciences 5
PDP Couriers 67
Phenomenex 15
RCC Laboratories 19
Sci - Plas 25
Shreetech Associates 91
Spinco Biotech 73
TA Instruments 77
Thermofisher Scientific 17
Technology Review 95, 99
USA-India Chamber
of Commerce
104, 105
Waters India 63
West Pharma 75
World Courier 11
Yasham Life Sciences 71
Advertisers Index
SURVEY & RANKING METHODOLOGY
BioSpectrum conducted this survey jointly with the Association of Biotechnology
Led Enterprises (ABLE). BioSpectrum and ABLE have jointly been doing this exer-
cise since 2003 with assistance from CyberMedia Research, the market analysis outt
of CybeMedia, the publisher of BioSpectrum. A detailed questionnaire (survey form)
was sent to over 200 companies to capture the needed information for the analysis.
This was done during April-May 2011. Companies shared information with us to the
extent it was possible by them.
The revenues considered for the analysis are biotech products sales and service
gures. In several cases, where revenue gures were not available, estimates were
arrived in discussion with industry experts. These are denoted (*) as BioSpectrum
Estimates.
This year in the list of Top 20 companies, biotech focused companies across the life
sciences spectrum have been considered, including diagnostics space. An overall list-
ing of companies (Page 106) by revenue has been done for your reference.
Biotech suppliers revenues are not considered/included in this analysis.
BioPharma segment included products made by fermentation/animal cell culture
(not animal extracts) and plant cell culture (not plant extracts).
The BioAgri segment analysis includes only the GM seeds and molecular markers
and related products. So, the hybrid seeds business is not a part of the agri-business
sales values.
The BioServices segment analysis includes the contract as well as clinical research
services revenue.
For all the ranking purposes, we have taken the biotech business only into consid-
eration. Wherever TURNOVER is mentioned, it means, sales turnover from biotech.
Therefore, turnover wherever mentioned is not necessarily the total sales turnover
of the company.
IndustryOverview
0
5000
10000
15000
20000
2006-07 2007-08 2008-09 2009-10 2010-11
145
395
926
1102
5973
190
410
1201
1572
6899
220
478
1413
2062
7883
231
564
1936
2639
8829
625.94
2480
3245.97
BioInformatics
BioIndustrial
BioAgri
BioServices
BioPharma
*All figures in `Crore
India Biotech Industry (2006-2011)
BioServices 18.82
BioPharma 61.77
B
i
o
A
g
r
i

1
4
.
3
8
B
i
o
I
n
d
u
s
t
r
i
a
l

3
.
6
3

B
i
o
I
n
f
o
r
m
a
t
i
c
s

1
.
4
1
IndustryOverview
BioPharma continues to dominate the biotech
industry with 61.77% share in the overall revenue,
followed by BioServices with 18.82% and BioAgri
with 14.38% contribution. BioIndustrial and BioIn-
formatics make up the rest of the industry revenue
The fastest growing sector, BioAgri, has increased
its market share in the last five years from less
than five percent to over 14 percent in the 2011
industry revenue.
Industry Segment Share (%)
242.43
10655
Total
8541
Total
10272
Total
12137
Total
14199
Total
17249.34
Total industry revenue `17249.34 cr
0
10
20
30
40
50
60
0
10
20
30
40
50
60
0
10
20
30
40
50
60
0
10
20
30
40
50
60
0
10
20
30
40
50
60
BioPharma Segment Growth (Year-on-Year) (%) BioServices Segment Growth (Year-on-Year) (%) BioAgri Segment Growth (Year-on-Year) (%)
BioIndustrial Segment Growth (Year-on-Year) (%)
BioInformatics Segment Growth (Year-on-Year) (%)
2010-11
Segment Exports Domestic Total % Share
Exports
% Share
Domestic
Biopharma 5535.40 5109.60 10645 52 48
BioServices 2986.29 259.68 3245.97 92 8
BioAgri 74.40 2405.60 2480 3 97
BioIndustrial 150.23 475.71 625.94 24 76
Bioinformatics 106.02 146.41 252.43 42 58
Total 8852.34 8397.00 17249.34
2009-10
Segment Exports Domestic Total % Share
Exports
% Share
Domestic
Biopharma 4767.66 4061.34 8829 54 46
BioServices 2507.05 131.95 2639 95 5
BioAgri 58.08 1877.92 1936 3 97
BioIndustrial 124.08 439.92 564 22 78
Bioinformatics 73.92 157.08 231 32 68
Total 7530.79 6668.21 14199 53.04 46.96
Biotech Industry Exports vs Domestic
IndustryOverview
FY 2006 2007 2008 2009 2010
20.57
12.00
14.26
15.50
26.87
23.00
27.98
31.17
42.65
53.06
28.10
37.01
17.65
29.70
54.85
10.98
17.99
16.59
3.80
5.33 9.28
5.00
15.79
31.03
20.83
The domestic BioSer-
vices market has in-
creased by three percent
in 2010-11 over last
years five percent share
in the segment revenue
BioInformatics compa-
nies have increased
exports business revenue
in 2010-11 to claim 42
percent segment share
with more focus on cus-
tomers in the US & Europe
Growth of biologics in the
domestic market gave an
eight percent boost to the
BioPharma segment which
clocked about 21 percent
growth in 2010-11
Cheaper biochemical
alternatives dragged down
the growth of BioIndustrial
segment. It grew at 10.98
percent in 2010-11, a drop
of 7.01 percent over previ-
ous years growth
FY 2006 2007 2008 2009 2010 FY 2006 2007 2008 2009 2010
FY 2006 2007 2008 2009 2010 FY 2006 2007 2008 2009 2010
Rank Company
Revenue in ` Crore
Change over
2008-09 (%)
Change over
2009-10 (%)
2010-11 2009-10 2008-09 2010 (%) 2011 (%)
1 Biocon 1483.00 1180.00 912.34 29.34 25.68
2 Serum Institute of India 1041.00 850.00 1114.00 -23.70 22.47
3 Panacea Biotec 928.41 703.10 597.14 17.74 32.05
4 Nuziveedu Seeds 610.00 476.86 363.96 31.02 27.92
5 Reliance Life Sciences* 490.00 450.00 8.89
6 Quintiles India* 476.25 375.00 27.00
7 NovoNordisk 462.00 362.00 316.00 14.56 27.62
8 Rasi Seeds 371.88 358.78 376.84 -4.79 3.65
9 Mahyco* 364.90 312.00 211.12 47.78 16.96
10 Transasia 350.00 186.00 88.17
11 Ankur Seeds 325.00 109.50 80.35 36.28 196.80
12 Syngene International 318.00 252.00 224.60 12.20 26.19
13 Bharat Biotech * 298.34 271.66 241.05 12.70 9.82
14 Indian Immunologicals 283.00 272.75 224.75 21.36 3.76
15 Krishidhan Seeds 276.13 133.23 63.25 110.64 107.26
16 Shantha Biotech* 272.00 334.23 247.00 35.32 -18.62
17 Novozymes South Asia * 242.00 224.00 205.50 9.00 8.04
18 Bharat Serums 226.00 175.00 140.00 25.00 29.14
19 Jubilant Life Sciences 210.00 249.30 241.50 3.23 -15.76
20 EliLilly 204.00 186.72 164.00 13.85 9.25
*BioSpectrum Estimates
Top 20 Life Science Companies by Revenue (2010-11)
IndustryOverview
Agri companies lead the Top 20 tally of the fastest
growing companies with over 100 percent growth. In
fact, Ankur Seeds recorded
a spectacular 197 percent
growth
Semler Research India
has grown over 400
percent from a very small
base of `3.8 crore
Among the Top 20
companies by revenue,
seven companies made it
to the list of Top 20 fastest
growing companies. Diagnostics company Transasia
made the cut here as well
Fastest growing 20 companies contributed 17
percent share to the overall industry revenue
The Top 20
companies in 2010-
11 have grown by
an average of 33%,
whereas in 2009-
10 these grew at an
average of 19%
The Top 20
companies list
is dominated by
biopharma and agri
companies
Top 20
companies
contribute 54% to
the overall industry
revenue
Top 20 Homegrown Life Science Companies by Revenue (2010-11)
Rank Company
Revenue in ` Crore
Change over
2008-09 (%)
Change over
2009-10 (%)
2010-11 2009-10 2008-09 2010 (%) 2011 (%)
1 Biocon 1483.00 1180.00 912.34 29.34 25.68
3 Panacea Biotec 928.41 703.10 597.14 17.74 32.05
4 Nuziveedu Seeds 610.00 476.86 363.96 31.02 27.92
6 Rasi Seeds 371.88 358.78 376.84 -4.79 3.65
7 Mahyco* 364.90 312.00 211.12 47.78 16.96
8 Transasia 350.00 186.00 88.17
9 Ankur Seeds 325.00 109.50 80.35 36.28 196.80
11 Bharat Biotech * 298.34 271.66 241.05 12.70 9.82
14 Shantha Biotech* 272.00 334.23 247.00 35.32 -18.62
16 Bharat Serums 226.00 175.00 140.00 25.00 29.14
18 Siro Clinpharm* 202.00 150.00 280.00 -46.43 34.67
19 Cadila Healthcare* 190.59 147.48 93.70 57.40 29.23
20 Tulip Group 185.63 182.48 187.09 1.73
IndustryOverview
Top 20 Life Science Companies by Growth (2010-11)
Rank Company
Revenue in ` Crore
Change over
2008-09 (%)
Change over
2009-10 (%)
2010-11 2009-10 2008-09 2010 (%) 2011 (%)
1 Semler Research India 19.70 3.80 418.42
2 Ankur Seeds 325.00 109.50 80.35 36.28 196.80
4 Transasia 350.00 186.00 88.17
5 Richcore Life Sciences 7.34 3.91 3.21 87.72
6 Metahelix 11.00 6.00 9.67 -37.95 83.33
7 JK Agrigenetics 50.66 32.50 26.00 25.00 55.88
8 Excel Industries 12.13 8.24 7.90 4.30 47.21
9 Anthem Biosciences 78.00 53.00 32.34 63.88 47.17
10 Bayer CropScience* 31.50 22.50 40.00
11 Pfizer (Wyeth India)* 73.35 53.00 37.00 43.24 38.40
12 Themis Medicare* 124.00 90.00 97.50 -7.69 37.78
13 Siro Clinpharm* 202.00 150.00 280.00 -46.43 34.67
14 GlaxoSimtheKline * 163.00 123.34 83.48 47.75 32.16
15 Panacea Biotec 928.41 703.10 597.14 17.74 32.05
16 Dr Reddys Laboratories* 82.50 62.50 40.00 56.25 32.00
17 Aventis Pharma* 90.00 68.34 36.00 89.83 31.69
18 Zenotech Laboratories 8.56 6.57 8.30 -20.84 30.29
19 Rossari Biotech* 72.00 55.38 30.01
20 Cadila Healthcare 190.59 147.48 93.70 57.40 29.23
A CyberMedia Publication | biospectrumindia.com | OCTOBER 2010 | BIOSPECTRUM | 71
Welcome to the world of insights
Laboratory Technology / Analysis / Biotechnology / analytica Anacon India Conference
analytica Anacon India is part of the exhibition network analytica worldwide - the most important marketplace
in the world for marketable products and solutions in the analysis, laboratory technology and biotechnology
sectors. It is a business and networking platform and a driving force behind future trends and innovations.
1214 OCTOBER 2011 l BOMBAY EXHIBITION CENTRE l MUMBAI
6th International Trade Fair for Laboratory Technology, Analysis, Biotechnology and Diagnostics
www.analyticaindia.com
For more information:
Ms. Tanu Ailawadi
Phone: +91 11 47168888 Email: [email protected]
T
he south region has caught up with the west, im-
proving its share in the overall Indian biotech
industry to 44.22 percent in 2010-11 from 39
percent in 2009-10. It is slightly above the west
regions share of 43.60 percent. Top 10 companies in the
south have contributed `4,816.47 crore (27 percent) of
the total biotechnology industry revenue, while Top 10
companies from west have about 21.17 percent of the to-
tal industry contributing `3,651.25 crore. Biocon from
the south region continued to retain its position as the
No. 1 biotechnology company with `1,480 crore followed
by Serum Institute of India from west with `1,041 crore.
The north region with `2,100.66 crore has 12.18 percent
share in the overall industry. In terms of number of com-
panies, south continued its dominance with 175 compa-
nies, while west has 139 companies and north is still to
cross 50 gure mark. It had 48 companies.
In south, Karnataka is one of the active states focusing
much on biotechnology. To support the biotech industry,
Karnataka government has nally signed an agreement
with Alexandria Equities Management (India) for devel-
oping Bangalore Helix, a biotechnology park built on pub-
lic-private partnership on 56 acres of land in Bangalore.
The park built at a cost of `500 crore will come up in a re-
cord two-year time and the construction will commence
from October 2011. Karnataka has signed MoU with two
companies during Global Investors Meet in June 2010
HPCL and Nandan Biomatrix, which will be investing
about `557 crore and `96 crore, respectively on Green
R&D centre and Bio Investment Eco Industrial Zone.
Karnataka is also planning to start sector specic parks
agri-biotech park in Dharwad (with the University of Ag-
ricultural Sciences), a marine park in Mangalore (with the
State Fisheries Department), a veterinary park at
Bidar (with the Veterinary University) and a nu-
traceuticals and pharma products park in Mysore
(along with the Central Food Technological Re-
search Institute).
In Andhra Pradesh, Lepakshi Knowledge Hub
is setting up Lepakshi Knowledge Park in Hy-
derabad. It is spread on 700 acres of land with
R&D labs, pilot plants focusing on sectors such as
healthcare, pharma, biotech, medical devices and
healthcare delivery. Lonza, the leading supplier to
the life science industry is also setting up its R&D
facility in 26 acres, in Andhra Pradesh. Sri Bio-
tech is coming up with `30 crore project, focused
on agri-biotech research in Andhra Pradesh.
During the year, Tamil Nadu government pro-
posed to set up a marine biotechnology park near
Mahabalipuram, in about 300 acres. At the same
time, the state is in the process of setting up a bio-
technology core facility at TICEL Bio-Park II at
a cost of `19.30 crore. The facility would provide
scientic and incubation support to the biotech
industry.
In north, during the year, Mayar Biotech SEZ lo-
South and west, both claim 44
percent market share each
South region improves its share
over last year by five percent
Gujarat tops in attracting
investments
South catches up with the west
IndustryOverview
West South North
2006-07
2007-08
2008-09
2009-10
2010-11
4100
Cluster Trend (2006-2011)
R
e
g
i
o
n
w
i
s
e

r
e
v
e
n
u
e

i
n

`
c
r
o
r
e
4452.37
5260.84
6631.01
7521.00
3416
4368.63
5084.02
5537.68
7627.68
1025
1452.98
1792.14
2030.48
2100.66
Top Companies in West
Rank Company
Revenue in
` Crore
% Share in
Region
% Share
in industry
revenue
2010-11
1 Serum Institute of India 1041.00 13.84 6.04
3 Mahyco* 364.90 4.85 2.12
4 Transasia 350.00 4.65 2.03
5 Ankur Seeds 325.00 4.32 1.88
6 Krishidhan Seeds 276.13 3.67 1.60
7 Bharat Serums 226.00 3.00 1.31
8 Siro Clinpharm* 202.00 2.69 1.17
9 Cadila Healthcare* 190.59 2.53 1.10
10 Tulip Group 185.63 2.47 1.08
Top 10 West 3651.25 48.55 21.17
Total West 7521.00 100.00 43.60
Top Companies in South
Rank Company
Revenue in
` Crore
% Share in
Region
% Share
in industry
revenue
2010-11
1 Biocon 1483.00 19.44 8.60
2 Nuziveedu Seeds 610.00 8.00 3.54
3 Quintiles India* 476.25 6.24 2.76
4 NovoNordisk 462.00 6.06 2.68
5 Rasi Seeds 371.88 4.88 2.16
6 Syngene International 318.00 4.17 1.84
7 Bharat Biotech * 298.34 3.91 1.73
8 Indian Immunologicals 283.00 3.71 1.64
9 Shantha Biotech* 272.00 3.57 1.58
10 Novozymes South Asia * 242.00 3.17 1.40
Top 10 South 4816.47 63.14 27.92
Total South 7627.68 100.00 44.22
Top Companies in North
Rank Company
Revenue in
` Crore
% Share in
Region
% Share
in industry
revenue
2010-11
1 Panacea Biotec 928.41 44.20 5.38
2 Jubilant Life Sciences 210.00 10.00 1.22
3 EliLilly 204.00 9.71 1.18
4 RFCL (Diagnova) 103.00 4.90 0.60
5 Max Neeman International 48.04 2.30 0.28
Top 5 North 1493.81 71.11 8.66
Total North 2100.66 100.00 12.18
cated at Gurgaon stepped-up its ef-
forts to attract biotech companies.
An Indo-German Science and Tech-
nology Centre (IGSTC) was also in-
augurated at Gurgaon to promote
research and focus on public-private
partnerships. Initially, three projects
in the biotechnology space have been
taken up.
Besides, Lucknow Biotech Park has
also taken many initiatives to pro-
mote the agri-biotech sector in the
region. The work at biotech parks
at three locations Sitapura-Jai-
pur, Chpanki-Bhiwadi and Borandi
in Rajasthan has also witnessed
progress, and is expected to attract
investors in coming times. The year
saw Himachal Biotech Park getting
clearance from the state government
and assistance from the central gov-
ernment. The 200 crore biotech park
coming up on 35 acre land near Na-
lagarh in Solan district is expected
boost the employment and other -
nancial requirements of the region
besides attracting the investors from
India and abroad.
In the west, government of Gujarat has
signed a total of 35 biotechnology re-
lated MoUs during Vibrant Gujarat-
Global Investors Meet, in January
2011, with investment commitment
of around `5,858 crore, spread over
coming ve-to-six years. Nectar Life
Science India, a Chandigarh-based
company, is making a whopping in-
vestment of around `3,500 crore in
two phases, in the state, in predomi-
nantly biotech projects and into pro-
duction of vitamins and co-enzymes.
In addition to medium-to-large com-
panies, another 14 companies, have
committed an average investment of
`9-10 crore. Some of these companies
are Dos Advanced Agro-Biotech, Phy-
to-concentrates, Gujarat Agroland,
Centurion Labs, Biotron, Poshak Bio-
research, Sabre Machinery.
Besides, promotion and support
from the state governments, the Department of Biotechnology is stepping-up
efforts to promote the biotech R&D activities in North East Region, which is
one of the worlds biodiversity hotspots. BS
IndustryOverview
I
ndia BioPharma market comprising primarily of vaccines, thera-
peutic drugs, insulin, animal biologicals, statins and diagnostics,
continued to grab the largest share of the total biotech industry
revenue of `17,249.34 crore in 2010-11. The biopharma market
accounted for `10,655 crore, with over 60 percent of market share in
2010-11. It accounted for `8,829 crore, taking 62 percent market share
in 2009-10.
Vaccines
Vaccines sector within biopharma segment witnessed a continued
growth of 12 percent during 2010-11. With the revenue of `2,441.6 crore
in 2010-11, vaccines sector claimed the largest pie in the biopharma seg-
ment. In 2009-10 the vaccines sector had sales of `2,180 crore. The vac-
BioPharma
Gets lions
share
Top 20 BioPharma Companies by Revenue (2010-11)
Rank Company
Revenue in ` Crore
Change over
2008-09 (%)
Change over
2009-10 (%)
2010-11 2009-10 2008-09 2010 (%) 2011 (%)
1 Biocon 1483.00 1180.00 912.34 29.34 25.68
3 Panacea Biotec 928.41 703.10 597.14 17.74 32.05
5 NovoNordisk 462.00 362.00 316.00 14.56 27.62
6 Bharat Biotech * 298.34 271.66 241.05 12.70 9.82
8 Shantha Biotech* 272.00 334.23 247.00 35.32 -18.62
9 Bharat Serums 226.00 175.00 140.00 25.00 29.14
11 Eli Lilly 204.00 186.72 164.00 13.85 9.25
12 Cadila Healthcare* 190.59 147.48 93.70 57.40 29.23
13 GlaxoSimtheKline * 163.00 123.34 83.48 47.75 32.16
14 Concord Biotech 126.17 111.07 97.10 14.39 13.60
15 Themis Medicare* 124.00 90.00 97.50 -7.69 37.78
16 Intas Biopharma* 110.00 115.00 89.27 28.82 -4.35
17 Aventis Pharma* 90.00 68.34 36.00 89.83 31.69
18 Novartis* 89.65
19 Haffkine Biopharma 86.00 168.98 -49.11
20 Dr Reddys Laboratories* 82.50 62.50 40.00 56.25 32.00
BioPharma accounted
for 61.77 percent of the
total industry revenue and
grew by 20.68 percent over
2009-10
The Top 20 BioPharma
companies contributed
close to `8,000 crore
BioPharma clocks `10,655
crore in FY 2010-11
SegmentOverview
Biotech Schools
A CyberMedia Publication | biospectrumindia.com | AUGUST 2010 | BIOSPECTRUM | 97
cine market will continue to drive
the growth of the biopharma seg-
ment, growing in the range of 10-13
percent in the next ve years. The
factors that will drive this include,
launch of new generation vaccines
from both multinational and local
companies; education and aware-
ness about disease prevention;
increase in disposable income and
participation by government.
During 2010, three Indian com-
panies Serum Institute of In-
dia, Cadila Healthcare and Bharat
Biotech launched H1N1 swine
u vaccine. In June, Ahmedabad-
based Indian pharmaceutical ma-
jor Cadila Healthcare was the rst
to launch indigenous vaccine against
H1N1 in India under the brand Vaxi-
u-S.
VaxiFlu-S is an egg-based, inacti-
vated vaccine, based on conventional
technology developed by Cadilas re-
searchers at its Vaccine Technology
Center (VTC) in Ahmedabad (India).
VTC further plans to develop a wide
spectrum of vaccines against bacte-
rial, viral and protozoal infections.
The Indian government has been
importing H1N1 vaccine from global
pharma major Sano-Aventis.
In July 2010, Serum Institute of In-
dia (SII), one of Indias largest vac-
cine manufacturers, launched its
indigenously developed intra-nasal
H1N1 vaccine under the brand name,
Nasovac. A live attenuated inuenza
vaccine (LAIV) Nasovac, is a single-
dose vaccine tted at the top of the
syringe, and about 0.25 ml is ad-
ministered in each nostril, mimick-
ing the path followed by the virus, to
enter the body. The product is priced
at half the price of similar vaccines,
marketed by Indian and foreign com-
panies. The price of a single dose of
Nasovac costs `160. Initially, SII
looked at the Indian market for the
product. However, it is looking at re-
ceiving the WHO pre-qualication,
as it intends to market the product in
100 countries.
In mid-October 2010, Bharat Bio-
tech, another Indian leader, launched
Indias rst indigenously developed
cell culture H1N1 swine u vaccine
under the brand name HNVAC. This
claims to be the only u vaccine to be
manufactured in cell culture in the
developing world, a highly sterile and
controlled manufacturing process,
instead of eggs.
Bill and Melinda Gates, during their
visit to India in March 2011, an-
nounced that they would pool in
grants to fund late stage clinical tri-
als to Pune-based Serum Institute of
India and Hyderabad-based, Bharat
Biotech International, for pneumonia
and rotavirus vaccines. Though the
companies havent revealed the exact
value of the grants, reports say that
the foundation is looking at grant-
ing around $30 million for late stage
clinical trials of rotavirus vaccines.
With the revenue of
`2, 441.6 crore in 2010-11,
vaccines sector claimed
the largest pie in the
biopharma segment
SegmentOverview
The pricing pressure and com-
petition in the market continue
to downplay the high growth (in
terms of value) of vaccine market
as against growth in terms of vol-
ume.
India, known as vaccine manu-
facturing hub, witnessed a major
setback during last year. Shantha
Biotechnics, the rst Indian com-
pany to launch an r-DNA vaccine
in 1997, faced a signicant drop
in its revenue, as it had to recall
its ve-in-one vaccine Shan5
from across global markets fol-
lowing safety concerns. The WHO,
which was procuring Shan5 vac-
cine from Shantha Biotech under a
long-time contract, worth $340 mil-
lion covering the period 2010-2012,
advised Shantha Biotech for this
product batch recall.
In addition, Haffkine Bio-Pharma-
ceutical, a Mumbai-based public en-
terprise engaged in the manufacture
and supply of wide range of biologi-
cal and non-biological products com-
prising bacterial and viral vaccines,
witnessed signicant drop in the rev-
enue, because the company, last year,
was not able to get the global tender
from agencies, such as UNICEF.
However, Serum Institute of India,
Panacea Biotec, Bharat Biotech and
multinationals such as GlaxoSmith-
Kline, Pzer (Wyeth), MSD Pharma-
ceuticals, Sano Pasteur have done
well by registering growth of over 10
percent during 2010-11.
Diagnostics
Driven by a rise in chronic diseases
and investments in the healthcare
infrastructure, diagnostics and ther-
apeutics business had a positive im-
pact on the diagnostic sector. The di-
agnostic market is estimated to be at
`2,440 crore for 2010-11 registering
growth of 22 percent over last years
market of `2,000 crore. The diagnos-
tics market comprises biochemical
testing market, hematology, microbi-
ology, immunology, coagulation, uri-
nalysis, critical care and molecular
diagnostics. On a broader level, this
market comprises diagnostic instru-
ments, reagents and services which
is further split into organized and
unorganized sectors. The organized
segment has reported strong growth
to expand its reach in rural and semi-
urban areas. Just like vaccine mar-
ket, diagnostic market too is a highly
competitive segment. The prices for
diagnostic kits/tests have dropped
signicantly in the last 10 years with
an increase in imports from China.
Major MNC companies in the diag-
nostic market include Roche, Sie-
mens (which has acquired Bayer Di-
agnostics), Johnson & Johnson and
Abbott while homegrown names in
the top league include Tulip Group,
J Mitra & Co, Transasia Biomedicals,
RFCL (Diagnova), Span Diagnostics
and Trivitron. This growth is driven
from the gradual acceptance of the
concept of preventive and personal-
ized medicine.
The rising prevalence of diseases,
improving affordability of patients
and increasing penetration of health
insurance have contributed substan-
tially to spur demand for diagnostic
services in the country. With the con-
tinuous increase in demand, the mar-
ket is expected to post around 22-25
percent growth in the coming years.
This growth is expected to drive high
investments in the primary health-
care sector.
Of the many subsectors in diagnos-
tics, molecular diagnostics is emerg-
ing as one of the fastest growing seg-
ments of the diagnostics market. The
main reason for such a tremendous
growth is the unique ability of molec-
ular diagnostic to treat a wide range
of infectious and genetic diseases.
Realizing such a huge potential, vari-
ous companies are pouring invest-
ments in this segment. On the other
hand, the biochemical testing mar-
ket is likely to account for the largest
share of the diagnostics market.
Therapeutics
The total biologics market in India
witnessed a growth of over 35 per-
cent and stood at over Rs 2,000 crore
for year ending 2010 as against Rs
1,480 crore for the year ending 2009.
For 2010, the human insulin and an-
alogues market stood at over Rs 780
crore and erythropoietin stood at Rs
103 crore.
In insulin market, Novo Nordisk In-
dia is leading the market with close to
60 percent of the market followed by
Eli Lilly with about 26 percent. The
other major players in the market
include Aventis, Biocon, Wockhardt
and Shreya Lifesciences.
Today, there are 20 recombinant
therapeutic products approved for
marketing in the Indian market. And,
Indian companies have established
capabilities to manufacture about
15 of these recombinant therapeutic
The diagnostic market is
estimated to be at `2, 440
crore for 2010-11 registering
growth of 22 percent over
last years market of `2,000
crore
products. Out of these, the products
that have a large share in the market
include Human insulin Erythropoi-
etin Hepatitis-B vaccine (recombi-
nant surface antigen-based), Human
Growth Hormone, Granulocyte Col-
ony Stimulating Factor (GCS-F) and
Streptokinase. Close to 50 brands
are being marketed in India by Bio-
con, Shantha Biotechnics, Bharat Se-
rums and Vaccines, Virchow Biotech,
Zenotech, Reliance Life Sciences,
Bharat Biotech International, Wock-
hardt, Shreya Life Sciences, Intas
Biopharmceutcials and Shreya Life
Sciences-manufacturing an average
of ve brands in India and about 72
recombinant therapeutic products
are at different stages of clinical tri-
als. From just six top Indian compa-
nies with manufacturing capabilities
in recombinant therapeutic products
in 2005, the number has more than
doubled to about 15 companies in
2011.
Dr Reddys Laboratories that sells bi-
ologic products Grafeel and (gener-
ic Filgrastim) and Reditux, (generic
Rituximab) has launched Peg-grafeel
in May 2011. Priced at `8,865, the
product represents a breakthrough in
the pricing of this complex molecule.
It is priced at approximately 25 per-
cent of the originator brand in India,
and is priced 95 percent lower than
the US price for peglgrastim. This
breakthrough in pricing has been
enabled by the companys vertically
integrated global manufacturing net-
work. Besides, it has another 11 bi-
osimilars in various stages of devel-
opment and commercialization.
India will see launch of many biosim-
ilar products in the next two years,
as many biopharma companies have
been working on these products for
the last few years and are now in dif-
ferent phases of clinical trials. With
the launch of these products the bio-
pharma market will see growth of
over 25 percent by 2012.
BS
SegmentOverview
T
he bioServices sector
clocked total revenues of Rs
3,245.97 crore in 2010-11,
registering a growth of 23
percent over last years (2009-10) to-
tal segment revenue of `2,639 crore.
This constitutes about 19 percent of
the total biotech industry revenue for
the scal.
Compared to the previous two scals,
where the CRO industry was hard hit
by the global downturn in particular,
scal 2010-11 saw some positive de-
velopments in this segment. Compa-
nies as well as the Indian government
(the DCGI in particular) authorities
were proactive in creating a favorable
environment for clinical trials. Con-
solidation in the global landscape, in
the form of mergers and acquisitions,
had its cascade effect on the Indian
BioServices
Grows over
20 percent
BioServices segment clocked sales of `3,245.97
crore registering a growth of 23 percent for
FY 2010-11
MNCs continue to dominate the market
Total number of clinical trials stood at 1,584
in 2011
Indian CROs aggressively looking at expansion to
South East Asian markets
Sector to grow at 20-30 percent over the next
three years
CRO industry. However, in spite of
the fall in the number of global clini-
cal trials, the clinical research sector
witnessed a growth of 23 percent over
last year as the country saw a rise in
the number of local clinical trials.
A good number of global companies
are now looking at India to conduct
large scale global trials. While low
costs and large patient pool still re-
main the crucial deciding factors for
attracting these companies, skilled
investigators and emphasis on quality
are some of the rising factors contrib-
uting to the segments growth. Above
all, India is gradually emerging as a
drug discovery destination rather
than a mere drug development desti-
nation, as more companies are look-
Top 10 Services Companies by Revenue (2010-11)
Rank Company
Revenue in ` Crore
Change over
2008-09 (%)
Change over
2009-10 (%)
2010-11 2009-10 2008-09 2010 (%) 2011 (%)
1 Quintiles India* 476.25 375.00 27.00
3 Siro Clinpharm* 202.00 150.00 280.00 -46.43 34.67
4 Lambda Therapeutic Research * 128.00 145.00 30.00 383.33 -11.72
5 Ecron Acunova 125.00 97.00 28.87
6 Diagnosearch Life Sciences * 121.00 97.00 24.74
7 Veeda Clinical Research 120.00 112.00 7.14
8 Vimta Labs* 96.50 88.42 81.60 8.36 9.14
9 Synchron Research Services* 63.00 57.00 10.53
10 Max Neeman International 48.40 40.00 15.00 166.67 21.00
SegmentOverview
flap GE.indd 1 5/30/2011 4:44:37 PM
flap GE.indd 1 5/30/2011 4:44:37 PM
ing at innovative and novel products.
In terms of key therapeutic areas, the
CROs are focusing on oncology, neu-
rology, respiratory, diabetes, anti-
infective, psychiatry, endocrinology,
central nervous system, cardiovas-
cular system. Diabetes takes the top
spot due to the large population suf-
fering from diabetes.
Players operating in the Indian seg-
ment include multinational CROs,
Indian CROs, multinational pharma-
ceutical companies and Indian phar-
maceutical companies. While the
rst three categories of companies
are into global trials, Indian pharma
companies usually look at conduct-
ing primarily local trials. The Indian
market is still dominated by multi-
national CROs. Major global play-
ers include Quintiles, PPD, Parexel,
ICON, Pharmanet, Kendle, i3 InVen-
tiv, Omnicare Clinical Research, In-
veresk Research, MDS and SCIREX
Corporation.
Major Indian players include Siro
Clinpharm, GVK Bio, Clininvent,
Ecron Acunova, CliniRx, Asian Clini-
cal Trials, Jubilant Clinsys, Vimta
Labs, Lotus, Lambda Therapeutics,
Clinigene, Max Neeman Medical and
International, Synchron Research,
iGate (now Diagnosearch Life Sci-
ences), Veeda Clinical Research and
Actimus Biosciences.
According to estimates, there are
around 30 CROs conducting BA/BE
trials, 50 CROs looking at phase I-IV
trials. Major companies looking at
BA/BE studies include Lambda Syn-
chron, BA Research, Veeda Clinical
Research, Vimta, Bioserve, Accutest,
Accunova and Lotus Labs. In India,
there are only a few companies into
phase I trials (due to issues of large
scale investments in infrastructure).
The much favored business model
followed by most of the homegrown
CROs is to commence their business
with a focus on BA/BE studies and
then gradually move up the value
chain, once they develop their com-
petency. This model is an emerging
trend and will stay so for some years.
Since June 2009, the DCGI made it
mandatory that all clinical trials have
to be registered with the Clinical Tri-
als Registry of India (CTRI) before
a single subject is recruited for the
study. As of January 2011, according
to the CTRI, the total number of tri-
als stood at 1,584 as against 806 tri-
als between January-December 2010.
Quintiles India conducts the largest
number of trials in the country.
There are a total of 2,000 investiga-
tors overseeing clinical trials across
various sites in India. India still faces
the challenge of a dire paucity of in-
vestigators as well as lack of sites. Es-
timates point out that India requires
an additional 25-30 percent more
investigators. Industry experts opine
that this shortage can be overcome
by by tapping tier II and III cities and
towns and by constant training on
GCP and GLP to these investigators.
Homegrown CROs are also aggres-
sively looking at expanding to other
markets of the world, the South East
Asian markets in particular. A direct
presence in these countries will give
Indian CROs the advantage of close
proximity to their clients. Other up-
coming destinations include East-
ern Europe and Africa. East Europe
offers advantages like large patient
pool, low cost and proximity to mul-
tinational companies present in West
and Central Europe.
About two-three CROs are doing
phase I trial, 15-20 CROs are in-
volved in phase II trials, 12-15 CROs
are involved in phase III and 20-25
CROs are doing Bio Avaibility /Bio
Equivalence (BA/BE) studies. In
India, most clinical CROs carry out
phase II-IV studies. Very few CROs
carry out phase I studies. The num-
ber of BA/BE CROs would be around
100.
Siro Clinpharm, in early 2011, an-
nounced the start of their operations
in Malaysia thus expanding reach in
the Asian continent. They already
have consolidated their position in
Western as well as Eastern Europe.
Veeda Clinical Research again, to-
wards May 2011, announced from
its Ahmedabad headquarters, that
the nal steps had been put in place
for the commissioning of its CRC
Veeda (Malaysia) phase I unit in the
Ampang Hospital in Kuala Lumpur
in Malaysia, most likely to be called
CVM. Having established a presence
in Thailand, Synchron Research is
looking at tapping the growing South
East Asian market, with Vietnam be-
ing the favoured destination.This is
due to the rise of the pharmaceutical
sector in this region, coupled with the
inux of a large number of multina-
tional companies into this region.
Looking into the future, the CRO in-
dustry will continue to grow at a rate
of 20-30 percent in the next three
years. The segment will also see the
entry of a number of small-sized
homegrown CROs into the market
looking at BA/BE studies. Also, being
on the growth mode, Indian CROs
will look at outbound acquisitions
both big and small. Mandatory res-
gistration of all clincial trials in India
has brought about the much-needed
transparency into the system and this
in turn will lead to a rise in the num-
ber of global companies outsourcing
clinical trials to India.
As of January 2011,
according to the Clinical
Trials Registry of India ,
the total number of trials
stood at 1,584 as against
806 trials between January-
December 2010
BS
SegmentOverview
T
he BioAgri market clocked total revenue sales
of `2,480 crore in 2010-2011 as against `1,936
crore in 2009-2010. This accounts for 14.38 per-
cent of the total biotech revenues. Bt cotton has
been a roaring success with 95 percent of Indian farmers
adopting the technology. India today is the fourth largest
country in the world under Bt cotton cultivation.
The total land area under Bt cotton in 2010-2011 was
9.46 million hectare, which is over 85 percent of the total
land under cotton cultivation in the country. In the scal
2009-2010, the total land acreage under Bt cotton culti-
vation was 8.4 million hectare. Maharashtra with about
3.142 million hectare has the highest area under Bt cotton
acreage followed by Gujarat at 2.354 million hectare and
Andhra Pradesh at 1.399 million hectare. Punjab, Hary-
ana, Rajasthan and Karnataka are other important states
undertaking Bt cotton cultivation.
Currently, Bt cotton is cultivated in nine states Punjab,
Haryana, Madhya Pradesh, Gujarat, Rajasthan, Maha-
rashtra, Karnataka, Tamil Nadu and Andhra Pradesh.
According to the latest global report by the International
Service for the Acquisition of Agri-biotech Applications
(ISAAA) Maharashtra, Andhra Pradesh, Karnataka, Tam-
il Nadu and Gujarat are major Bt cotton growing states in
the country.
The total production of Bt cotton was estimated to be
around 29.5 million bales. According to survey data, Gu-
jarat with over 9 million bales was the largest producer of
Bt cotton followed by Maharashtra with over 6.20 million
bales and Andhra Pradesh with 5.33 million bales.
In the recent years, there has been an increasing trend
to adopt multiple gene (mostly two genes) Bt cotton
hybrids by cotton farmers in India. The rst two-gene
event MON15985, commonly known as BollgardII (BGII)
was developed by Mahyco and sourced from Monsanto,
featured the two genes cry1Ac and cry2Ab, and was ap-
proved for sale for the rst time in 2006 four years after
the approval of the single gene event MON531 Bt cotton
hybrids in 2002-03. An estimated number of 32 million
packets of Bt cotton seeds (Bollgard I and II) were sold in
BioAgri market touches `2,480
crore in 2010-2011
The total land area under Bt
cotton in 2010-2011 was 9.4
million hectare
The total production of Bt cotton
was estimated to be around 29.5
million bales
Nuziveedu Seeds is the largest
seller of Bt seeds
SegmentOverview
Fast track
growth
continues
BioAgri
Area under Bt cotton in
2010 kharif season
Region
Area
(in lakh hectare)
North 11.16
Central 62.70
South 20.5
Total 94.36
Zone States
MRP approved
BGI BGII
North Punjab, Haryana, Rajasthan 825 1000
Central Gujarat, Maharashtra, Madhya Pradesh 830 930
South Andhra Pradesh, Karnataka,Tamil Nadu 830 930
The price for one packet of cotton (450 grams) plus
seed for refugia as approved in different states
2010-2011, with a majority of seeds sold being Bollgard II as against 28 mil-
lion packets sold in 2009-2010. Monsanto alone licenses the Bt technology to
around 50 seed companies in India.
While there has been an overall increase in the production of Bt cotton in the
country, the prices of Bt cotton packets also saw a rise in price points (per
packet) across most of the states in India. The price of one packet of Bt cotton
(BG-I) was `830 whereas the price of a packet of BG-II seeds clocked up to
`930 in states of Gujarat, Maharashtra, Madhya Pradesh, Andhra Pradesh,
Karnataka and Tamil Nadu. In 2009-2010, Bollgard I and II seeds were priced
at `650 and `750 respectively.
The BioAgri market comprising Bt cotton seeds today is primarily dominated
by Indian homegrown companies. Indian companies are producing and mar-
keting 80 percent of the total cotton seed produced in the domestic market.
In the year 2009, there were 35 companies offering seeds of Bt hybrid cotton.
The top six companies were Indian companies.
Nuziveedu Seeds from Andhra Pradesh by far is the largest seller of Bt seeds.
The company, presently, has a market share of 40 percent. Nuziveedu is fol-
lowed by Rasi Seeds and Mahyco. Other players who have been signicant
contributors in the market include Nath Biogene, Tulsi, Bio Seeds, Vibha,
Krishidhan Seeds, JK seeds, Ajeet Seeds and Ankur Seeds. Most of the Bt
cotton seed companies are located in Andra Pradesh, Maharashtra and
Tamil Nadu.
Though there is an increase in demand for Bt technology-based products,
market reports state that cotton pestpink bollwormhas developed resis-
tance to Bollgard I variety in some districts of Gujarat. The company, which
has developed the technology, noted
that resistance is natural and ex-
pected. The company also pointed
out that pink bollworm resistance to
Cry1Ac protein in Gujarat to early
use of unapproved Bt cotton seeds
by farmers and limited refuge plant-
ing. The company further said no
resistance has been observed in the
variety anywhere in the country, in-
cluding Gujarat.
With the success of Bt cotton in In-
dia, a number of vegetable crops are
in the pipeline with Bt Brinjal set to
be the rst food crop to be commer-
cialized. Other crops include Bt Rice,
Bt maize, Bt Tomato and Bt Cauli-
ower. While commercialization of
Bt Brinjal is expected by end of 2011,
Bt Rice is expected to hit the market
by 2012. Farmers are willing to adopt
new technologies. The private sector
is growing and playing a big role in
driving the Bt revolution.
Projected sale of BGI & BGII for 2011-12
States
BGI BGII Total QTY
(BGI +
BGII)
Qty* MRP+ Qty* MRP+
Maharashtra 40 830 123 930 163
Gujarat 6 830 50 930 55
MP 10 830 12 930 23
Andhra Pradesh 11 830 79 930 90
Karnataka 4 830 16 930 20
Tamilnadu 1 830 5 930 6
Punjab 11 925 14 1000 25
Haryana 12 925 14 1000 26
Rajasthan 4 925 8 1000 12
ALL INDIA 103 317 420
Qty * in Lakh Pkts MRP - Rs/pkt 450gms+Refugia
State-wise split of Bt
cotton production (lakh bales)
State 2009-10 (R) 10-11 (E)
Punjab 14.25 16.47
Haryana 14.75 13.84
Rajasthan 11.00 6.46
Gujarat 98.00 106.82
Maharashtra 63.00 77.31
Madhya Pradesh 15.00 18.04
Andhra Pradesh 52.00 65.68
Karnataka 9.00 10.15
Tamil Nadu 5.00 6.71
Orissa 2.00
Others 1.00 2.00
Loose Supply 12.00 #
Total 295.00 325.48
Source: Central Institute for Cotton Research (CICR)
# loose cotton consumed but not accounted for in state-wise
production & including Orissa
(R ) Revised estimate; (E) Estimates
SegmentOverview
Top 10 Agri Companies by Revenue (2010-11)
Rank Company
Revenue in ` Crore
Change over
2008-09 (%)
Change over
2009-10 (%)
2010-11 2009-10 2008-09 2010 (%) 2011 (%)
1 Nuziveedu Seeds 610.00 476.86 363.96 31.02 27.92
2 Rasi Seeds 371.88 358.78 376.84 -4.79 3.65
3 Mahyco* 364.90 312.00 211.12 47.78 16.96
4 Ankur Seeds 325.00 109.50 80.35 36.28 196.80
6 Monsanto* 161.00 142.00 345.00 -58.84 13.38
7 Ajeet Seeds* 87.50 103.00 -15.05
8 JK Agrigenetics 50.66 32.50 26.00 25.00 55.88
10 Nath Seeds 27.49 22.10 24.39
Bt Brinjal: Still in deep-freeze
In October 2009, Indias biotech regulator, GEAC, gave
its nod to the countrys rst genetically-modied (GM)
food crop, a transgenic variety of Bt brinjal. However,
the GM food era did not begin even with the regulatory
approval. Stringent opposition and an activist minister
stalled further progress in the elds and eventually to the
consumers table. A year-and-a-half later, though there
have been some key developments on this front, Bt brin-
jal is nowhere close to reaching the consumers.
Even after the regulatory approval, all that the coun-
try has now on the Bt brinjal front is a scientic report
brought out by Indias leading science academies. The
scientic view is that the moratorium on the introduction
of Bt brinjal should be lifted because there is no evidence
of any safety hazard. However, the environment minister,
Mr Jairam Ramesh, who was instrumental in stalling the
progress of Bt brinjal is not convinced, terming the ex-
perts report as one lacking in depth.
In mid-December 2010, the academies submitted a mod-
ied report to the environment ministry. ABLE-AG, an
association of biotech crop developers, noted that the
contents of (the) academies report were based on scien-
tic facts and this latest report is in line with many other
scientic and opinions published by other leading scien-
tic establishments of the world.
However, the government of India, on one side has
been promoting Bt technology and on the other side, it
has been continuously interfering in the activities of the
companies. In March 2011, even as the moratorium on
commercialization of Bt brinjal stands, Union Environ-
ment and Forests Minister Jairam Ramesh has asked the
Genetic Engineering Approval Committee (GEAC) to im-
mediately withdraw its permission to Monsanto for eld
trials of Bt maize in Bihar.
The GEAC, in December 2010, gave permission for eld
trials of BRL-II of Bt corn developed by Monsanto at ve
locations for rabi 2011 Bihar (two locations), Tamil
Nadu, Karnataka, and Andhra Pradesh and at nine
locations for kharif 2011 Bihar (two locations), Tamil
Nadu, Karnataka, Andhra Pradesh, Uttar Pradesh, Rajas-
than, Gujarat and Madhya Pradesh.
Recently, an independent joint panel of Indias Genetic
Engineering Appraisal Committee and eminent scientists
on gene technology favored the lifting of the moratorium
and limited release of Bt brinjal under strict monitoring
during the rst meeting of the expert panel held on April
27, 2011 in New Delhi. The majority of the scientists who
were part of the expert panel, invited by the GEAC to ex-
amine new safety standards for Bt brinjal and deliberate
on issues relating to the moratorium on the commercial
release of Bt Brinjal, opined that there was no need to-
carry out any further tests since the safety of Bt gene in
brinjal has been established by the safety tests that had
already been carried out and that more time must not be
lost in conducting more tests and eld trials. Scientists
of the expert panel viewed that sufcient long-term stud-
ies have been done and in case additional tests are to be
implemented, parallel testing could be conducted along
with the partial release of Bt brinjal for cultivation.
SegmentOverview
BS
Top 5 BioIndustrial Companies by Revenue (2010-11)
Rank Company
Revenue in ` Crore
Change over
2008-09 (%)
Change over
2009-10 (%)
2010-11 2009-10 2008-09 2010 (%) 2011 (%)
2 Advanced Enzymes 154.00 121.00 88.60 36.57 27.27
3 Rossari Biotech* 72.00 55.38 30.01
4 Zytex 21.00 18.00 14.00 28.57 16.67
5 Maps (India) 19.60 19.10 19.17 -0.37 2.62
BioIndustrial
Takes baby steps
T
he bioIndustrial market in India clocked `625.94
crore in 2010-2011, growing at a rate of 10.98
percent for 2010-2011, as against `564 crore in
2009-2010.
India has a marginal share in the global market for indus-
trial enzymes, which is estimated to be at about $3.3 bil-
lion (`14,904.4 crore). The segment is forecasted to grow
at a CAGR of 15 percent till 2015.
Industrial enzyme consumption in India, is in the various
sub-segments of detergents, pharmaceuticals, food and
beverages and animal feed with detergents and pharma-
ceuticals having a lions share of the market. Other seg-
ments include textiles, leather and pulp.
Leading players in the segment include Novozymes, Da-
nisco, Advanced Enzymes, Rossari Biotech, Maps (In-
dia), Zytex and Lumis, Kerry Biosciences. Novozymes
continues to remain the top enzyme player in the market
commanding a market share of 50 percent. Advanced En-
zymes takes the second spot with a market share of 20
per cent. Rossari Biotech takes 13 percent, Maps (India)
(6 percent), Zytex (3 percent) and Lumis, Richcore Life
Sciences, Titan Chemcials, Kerry Biosciences split the re-
maining market share between themselves.
Though there is a prevailing domestic demand, the seg-
ment is largely export driven. Major export markets in-
clude the US (global share of 40 per cent), Europe (global
share 25 percent) China (Global share: 20 percent). Oth-
ers include Rest of Asia (Global share of 15 percent). Re-
alizing the potential of the opportunities outside India,
many Indian companies are expanding their base outside
the country even into difcult markets such as China.
Advanced Enzymes for instance, will start its European
and Chinese subsidiaries for market expansion. And this
is how the company expects to achieve its `1,000 crore
revenue-milestone in the next ve years.
The investment in research and development by the In-
dian companies continues to remain on the conservative
side. Few companies have their own R&D and manu-
facturing set-ups. The common strategy for most of the
homegrown companies is to import enzymes from for-
eign companies and then resell them into the Indian mar-
kets. India has a small share in the total global market
due to the declining price points of enzymes every year.
The price drop can be as much as 10 percent depending
on the type of enzyme.
MNCs have dominated the market for a number of years,
yet the segment is gradually witnessing the entry of In-
dian companies, who are building capacity and capability
to compete with the MNCs.
The bioIndustrial market in
India clocked `625.94 crore in
2010-2011
Novozymes remains leading
player
Exports continue to drive the
homegrown companies
SegmentOverview
BS
Top 3 BioInformatics Companies by Revenue (2010-11)
T
he bioInformatics segment, which is the small-
est of industry segments constituting barely two
percent of the market share in the overall indus-
try revenue, grew by 4.95% in FY 2010-11. The
segment clocked `242.43 crore in this scal as compared
to `231 crore in FY 2009-10. The major players in the seg-
ment, Strand Life Sciences and Ocimum Biosolutions col-
lectively contributed `107 crore to the overall revenue.
The factors contributing to this growth include tracking of
discovery activities, data analysis, and pharma research.
The different sub verticals covered under it are Informat-
ics, Omics, Lab information, Clinical Data Management
and Biostatistics.
Most of the companies in this segment are small-scale
enterprises located in cities such as Pune, Mumbai, Ban-
galore and Hyderabad. Innovative companies such as
Strand Life Sciences, Ocimum Biosolutions, V Life Sci-
ences, SysArris, Cell works, CytoGenomics and Molecular
Connections are working towards speeding up the cause
of the core life science business.
The segment is also getting a push with large IT compa-
nies such as Cognizant, HCL, Wipro, TCS joining the fray.
However, BioSpectrum Survey 2011 does not include rev-
enues of these IT companies in its analysis, as that will
skew the survey results.
The latest trends in the eld that can contribute to the
future growth of the segment include translational bioin-
formatics, personalized medicine and genomics. Next ve
years will see the sector wriggle out of its current position
and take the centerstage. Host of developments are tak-
ing place in the genomics and molecular research that will
likely boost the bioinformatics industry. Signicant ad-
vances in the eld of proteomics
and related technologies will
inuence the way research and
diagnostic analysis are per-
formed. With the increase in
R&D investments by various
companies and the government support, it is clear that
in the years to come, the bioinformatics market will post
a steady growth.
During the year, Ocimum Biosolutions, a leading bioin-
formatics company has closed funding worth $8 million
from multiple sources, including founders and existing
shareholders, in order to cater to the growing demand for
its integrated genomic services and to provide unparal-
leled, hassle-free user experience by enhancing its RaaS
(Research as a Service) platform. The company is in the
process of building a state-of-the art integrated campus
in Patancheru, Hyderabad. Part of the funds will be uti-
lized into completing the 360,000 sq ft facility spread
across four blocks.
Ocimum started providing BioIT consulting services to
enable R&D for organizations in the life sciences indus-
try. It also launched its quantitative real-time polymerase
chain reaction (qRT-PCR) services in India. This technol-
ogy is already in use at Gene Logic, an Ocimum Biosolu-
tions company.
In the last quarter of 2010, Strand Life Sciences, another
leading name in the sector, announced the creation of a US-
based subsidiary Strand Scientic Intelligence, Inc (Strand
SI) to commercialize its innovative Scientic Intelligence
solutions at the global level. The company also announced
the worldwide release of Avadis NGS, a software applica-
tion for next-generation sequence (NGS) analysis.
BioInformatics
Set for a growth spurt
Rank Company
Revenue in ` Crore
Change over
2008-09 (%)
Change over
2009-10 (%)
2010-11 2009-10 2008-09 2010 (%) 2011 (%)
1 Ocimum Biosolutions 65.00 41.40 47.57 -12.97 57.00
2 Strand Life Sciences 42.00 35.00 35.00 0.00 20.00
3 Geschickten 0.65
BS
SegmentOverview
Biocon posts strong growth
rides emerging market
With an impressive growth rate of 26 percent in
FY 2010-11, Biocon has been able to leverage new
market opportunities and deliver multi-sectoral growth
R
egistering a total revenue
of `1,483 crore in FY 2010-
11 as compared to `1,180
crore in the FY 2009-10,
Biocon recorded an impressive growth
of 25.68 percent. The company has
therefore secured its number one po-
sition in the BioSpectrum-ABLE Top
20 Survey 2011.
The company continued its forward
march, on the back of strong growth
in the sales of immunosuppressants,
statins and the branded formulations.
Products that gained share in the
portfolio, include Atorvastatin and
Rosuvastatin. Biocons immunosup-
pressants portfolio also grew by 35
percent.
The company launched its biosimi-
lar insulin in numerous emerging
markets within South America, North
Africa and East Asia. Presently, Bio-
con is in talks with Biotech Corp to
manufacture biopharma products and
formulations in Malaysia. The compa-
nys multiple collaborations with My-
lan, Optimer, Amylin and Vaccinex
are making steady progress. Its in-
vestment in a biotech start-up, IAT-
RICa continues to look promising.
During the FY 2010-11, the com-
pany divested its stake in its German
subsidiary, AxiCorp GmbH, to the ex-
isting group of promoter shareholders.
AxiCorp was the licensee for Biocons
biosimilar insulin and glargine in Ger-
many and had the sole responsibility
for commercializing these products.
Biocon entered into a global alliance
with Pfizer in October 2010 for com-
mercializing biosimilar insulin and
insulin analogs.
The oncology division of Biocon
posted a strong 41 percent growth
this year with in-licensed brand,
Abraxane, contributing significantly.
Evertor, the first global generic of
everolimus, has been witnessing a
strong ramp since its launch in Janu-
ary 2011. Biocons pipeline of innova-
tive and biosimilar molecules as well
as marketing partnerships will fuel
its expansion in India and in other
markets in 2011.
Dr Kiran Mazumdar-Shaw, CMD,
Biocon, said, FY11 has delivered
strong multi-sectoral growth. Emerg-
ing markets have realized significant
and sustained growth for our APIs,
while our branded formulations have
scripted business success in the India
market. Licensing income from Pfizer
and others has contributed materi-
ally to profit generation during this
fiscal.
The R&D pipeline of Biocon has
achieved significant milestones spear-
headed by a key IND filing with the
US FDA for its oral insulin program,
IN105. Biocons coveted T1h program,
a novel anti-cd6 targeting monoclonal
antibody, is also entering phase III
clinical trials for psoriasis.
Biocons BVX-20 is a novel human-
ized monoclonal antibody that binds
to CD20, a protein located on both
normal and malignant B-cells. The
company has submitted an applica-
tion to the regulator for phase I trials
of the same. The phase I clinical trial
is expected to be initiated in Q1 of FY
2012. To support its expanding busi-
ness operations, the company is look-
ing forward to increase its employee
strength by around 1,000 in the next
fiscal year.
CompanyRanking
CMD
Dr Kiran Mazumdar-Shaw
Business
Biopharmaceuticals
Start-up Year: 1978
Address: 20th KM Hosur Road,
Electronic City, Bangalore-560100
Tel: +91-80-28082808
Fax: +91-80-28523423
Website: www.biocon.com
Rank
R
e
v
e
n
u
e
1
B
iocon
`1483 crore
1
4
8
3
1
1
8
0
9
1
2
.
3
4
8
7
6
.
9
3
8
4
9
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
Revenue in ` crore
BS
H1N1 vaccine boosts
Serum Institute topline
Serum Institute of India is riding high on its success
of H1N1 vaccine but is facing stiff competition in the
overall vaccine sector
S
erum Institute of India (SII)
clocked total sales revenue
of an estimated `1,041
crore for FY 2010-11 with a
growth of 22.47 percent as compared
to `850 crore in 2009-10. The launch
of its H1NI vaccine helped the com-
pany witness an increase in its reve-
nue during the year. Competition and
pricing pressure in the vaccine sector
continue to drag down the companys
growth.
SII successfully launched its indig-
enously developed intra-nasal H1N1
vaccine under the brand name, Nas-
ovac. With this launch, SII became
the third manufacturer in the coun-
try to market vaccines against swine
flu, the other two companies being
Cadila Healthcare (VaxiFlu-S) and
Sanofi Aventis (whose vaccines were
imported by the Indian Government).
Presently, the manufacturing facility
of the company has a production ca-
pacity of 50 million doses of the swine
flu vaccine. The company received an
order from the Government of India
to the tune of 10 crore vaccines.
In March 2011, the Bill and Melin-
da Gates Foundation announced that
it would fund a part of SIIs clinical
trial for rotavirus vaccines and pneu-
mococcal vaccines. These vaccines
will be sold globally at half the price
of vaccines sold by big-wigs such as
GSK and Merck. Last year, the com-
pany also launched its EPO product
into the market, thus finally setting
foot in the growing recombinant ther-
apeutics segment.
In the past, SIIs products have been
supplied to international health agen-
cies like the WHO, UNICEF, PAHO
and also to more than 140 countries
across the globe. Its vaccines are be-
ing used in the national immuniza-
tion programs of several countries.
One of them is the HIB vaccine, an
indigenously manufactured product
launched in March 2007. SII supplied
this vaccine to the Global Alliance for
Vaccines and Immunization (GAVI),
Pan American Health Organization
(PAHO) and UNICEF. The vaccine
is available under the brand name,
SiiHIB Pro.
Since its inception, SII has in-
vested significantly in R&D and its
efforts are yielding results. Notable
successes made by the company are:
pilot production of measles vaccine
on human diploid cells; industrial
column chromatography and affinity
chromatography for separation of im-
munoglobulins; monitoring of quality
of vaccines in the field; clinical trials
of new products and clinical trial of
human diploid rabies vaccine.
The company has a partnership
with Syracuse University, where-
in the former awarded `1.06 crore
($250,000) to a team of researchers
led by Robert Doyle, to develop new
oral vaccines against tetanus and
rotavirus to treat a severe form of
diarrhea that affects children world-
wide.
SII also set up the Serum Bio Phar-
ma Park, Indias first biotech special
economic zone (SEZ), in 2006. The
Park is adjoining the companys ex-
isting manufacturing unit and is a
sector-specific SEZ meant for biotech-
nology and pharmaceutical firms.
The premises has already been pre-
qualified by the WHO.
Chairman
Dr CS Poonawalla
Business
Manufacturing and
marketing of lifesaving
immunologicals
Start-up Year: 1966
Address: 212/2, Hadapsar, Off Soli
Poonawalla Road,
Pune- 411028
Tel: +91-20-26993900
Fax: +91-20-26993921
Website: www.seruminstitute.com
Rank
`1041 crore
R
e
v
e
n
u
e
CompanyRanking
2
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
1
0
4
1
8
5
0
1
1
1
4
.
0
0
1
9
8
7
.
0
0
9
5
0
.
9
5
Serum
Institute of India
Revenue in ` crore
BS
Panacea Biotec grows 30
percent, its highest so far
Leveraging on effective business strategy and
successful execution, Panaceas biotech revenue
soared upto `928.41 crore, a growth of 32 percent
F
or Panacea Biotec, the year
2010-11 has been the year of
collaborations and launch of
new products. The company
registered a turnover of `928.41 crore
in 2010-11 with an impressive growth
of 32.05 percent over last years rev-
enue of `703.19 crore. This is consid-
ered to be the firms highest revenue
since its foray into the biotech arena.
The company recorded a net turn-
over of `1,130 crore with a growth
rate of 28 percent over last year. The
revenue of the vaccine business of
the company stood at `833.22 crore,
whereas the revenue from the thera-
peutics segment stood at `4.87 crore.
The revenue from biochemicals and
other related products was `90.32
crore.
Panacea Biotec has spread its op-
erations to more than 35 countries
in Latin America, South East Asia,
CIS and Africa. The company set up
wholly owned subsidiaries in strate-
gic markets like US, Germany, Swit-
zerland and UAE.
The company has collaborations
with corporations like Novartis Vac-
cines and Diagnostics, Sanofi Avent-
is, Netherlands Vaccine Institute, PT
BioFarma and National Institute of
Health Biotechnology Consortium of
India.
The company is a partner to the
UN Healthcare agencies in their po-
lio eradication initiative and supplies
millions of doses of WHO pre-quali-
fied polio vaccines. Panacea Biotec
has also introduced the next gen
inactivated polio vaccine (eIPV) in
collaboration with the Netherlands
Vaccine Institute. eIPV is registered
in Bangladesh and is in an advanced
stage of registration in more than 10
countries worldwide.
The company supplied more than
six billion doses of oral polio vaccine
to Government of India and UNICEF.
The company also launched its vac-
cines in Chile, Nepal and Pakistan
and has supplied to Botswana and
Switzerland. The firm is expected to
send its vaccines to Peru and Philip-
pines during Q1 of 2012.
During FY 2010-11, Panacea Bio-
tec launched PacliALL at the Indian
Cancer Congress 2011. This product
has been developed by Panaceas
state-of-the-art Global Research and
Development (GRAND) Center, Navi
Mumbai. Furthermore, the company
also launched EXEROZ-F and VER-
GRAF.
According to Dr Rajesh Jain, joint
managing director, We are extremely
happy with the significant financial
progress made in 2010-11. Our busi-
ness strategy and its flawless execu-
tion has helped us deliver this excel-
lent growth.
Recently, Panacea Biotec signed two
non-exclusive marketing agreements
with Laboratorios Clausen, Uruguay,
to market its Tacrolimus (Pangraf) in
defined markets in Europe.
Also, in a separate agreement of
technology exchange, Panacea Biotec
agreed to explore the possibility of
technology transfer of its product to
Laboratorios Clausen. In exchange,
Laboratorios Clausen would provide
technology of mycophenolate mofetil
(MMF) to Panacea Biotec.
JMD
Dr Rajesh Jain
Business
Pharmaceuticals,
biopharmaceuticals and
vaccines
Start-up Year: 1978
Address: B-1, Extn./G-3, Mohan
Cooperative Industrial Estate,
Mathura Road, New Delhi-110 044
Tel: +91-11-41679000, 41678000
Fax: +91-11-41679070, 26940199
Website: www.panaceabiotec.com
Rank
`928.41 crore
R
e
v
e
n
u
e
CompanyRanking
3
Panacea
Biotec
Revenue in ` crore
BS
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
9
2
8
.
4
1
5
9
7
.
1
4
6
7
8
.
4
1
7
0
1
.
1
3
7
0
3
.
1
0
Nuziveedu grows 28%,
retains spot No. 4
NSPL is looking to invest 15 to 20 percent of its
turnover in R&D and is ensuring that it successfully
communicates its innovations to farmers
T
he vision of Nuziveedu
Seeds Private Limited
(NSPL) is to be the most
preferred seed brand in In-
dia and to adopt proactive biotech
applications to strengthen its core
competence. In 2010-11, the company
sold about 70 lakh packets of BG I
and BG II varieties of seeds in India,
registering sales worth `610 crore as
compared to `476.86 crore in 2009-10.
During the end of December 2010,
NSL group, the parent company of
Nuziveedu, decided to hive-off the
seed business into a separate compa-
ny, in order to have a more effective
focus. Nuziveedu received a commit-
ment for investments upto `400 crore
from the global private equity major,
Blackstone Group.
Nuziveedu has set up an extensive
marketing network that gives it a
phenomenal advantage during the
sales window period. The marketing
network spread across 16 states in
India, comprises nine regional offic-
es, 5,000 distributors and more than
55,000 dealers and sub-dealers.
Nuziveedus extensive sales net-
work is toused to be one of the major
reasons for its No.1 position. Nuz-
iveedus competitors are yet to catch
up with the leader. The company is
known to increase its basket of offer-
ings.
Nuziveedu has been organizing
marketing campaigns in order to
successfully communicate its innova-
tions, ideas and services to the farm-
ers. These well-timed campaigns duly
inform the farmers how to increase
crop productivity and farm profitabil-
ity. Nuziveedu also conducts meetings
between distributors, dealers and
farmers to spread awareness about
its products, innovations, agronomic
practices and new technologies.
Nuziveedu pro-actively partici-
pates in the seed subsidy programs
that have been initiated by the
state governments and the cen-
tral government. Through these
programs, the company tries its
best to ensure that the farmers get
high quality seeds at a lower price.
NSPLs research and development
division has around 150 experienced
technicians and workers.
The main center, which is located
near Hyderabad, is spread across 600
acres and has been engaged in devel-
oping superior hybrids and improved
variations of different crops like, cot-
ton, maize, rice, bajra, jowar, sun-
flower and vegetables among others.
The company has multi-location
trial centers set up in different agro-
climatic zones to evaluate the adapt-
ability of various products and screen
them with respect to biotic and abi-
otic stress.
Nuziveedu tests its products at well
known national and international re-
search institutes such as, IRRI Phil-
ippines, ICAR and state agricultural
research institutes. The future plan
of the company is to expand research
to cover wheat, mustard, pigeon pea
and sweet sorghum and invest near-
ly 15 to 20 percent of its turnover
in R&D.
CompanyRanking
Chairman & MD
Dr M Prabhakar Rao
Business
Production and marketing
of agri-biotechnology
products
Start-up Year: 1990
Address: NSPL ICON,4 th Floor,
Road No: 12, Banjara Hills,
Hyderabad-500 034
Tel: +91-40-30514444
Fax: +91-40-23327919
Website: www.nuziveeduseeds.com
Rank
`610 crore
4
Nuziveedu
Seeds
R
e
v
e
n
u
e
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
6
1
0
4
7
6
.
8
6
3
6
3
.
9
6
2
9
1
.
8
8
1
8
9
.
3
3
Revenue in ` crore
BS
Reliance Life Sciences
rides on biosimilar wave
RLS is all set to establish itself as the leader in the
Indian biosimilars sector. It has an exhaustive biosimilars
pipeline and would launch two products in 2011
R
eliance Life Sciences (RLS)
is a research-driven bio-
technology-led life sciences
organization that is part
of Mukesh Ambanis Reliance Indus-
tries. The firm clocked an annual
sales revenue of `490 crore in 2010-
11 as compared to `450 crore in 2009-
10. Founded in 2002, RLS operates in
medical, plant and industrial biotech-
nology avenues.
RLS has the largest pipeline of bi-
osimilars and markets five biosimilar
products in India, including ReliFer-
on, ReliPoietin, ReliGrast, MIRel and
FostiRel. RLS is planning to launch
two biosimilars in the Indian market
during 2011 and is also looking to
increase its manufacturing capacity,
product and market volumes.
RLSs UK-based subsidiary, Reli-
ance GeneMedix, is focusing on de-
veloping and marketing biosimilars
in the European markets. Reliance
GeneMedix Irelands EPO product,
Epostim, is currently in its clinical
programme and the company is run-
ning validation programmes for regu-
latory submissions.
Apart from biosimilars, RLS also
develops and markets (both in India
and overseas), five plasma protein
products namely ReliSeal, AlbuRel,
ImmunoRel HemoRel and ReliPlas-
ma. In novel proteins discovery, RLS
made progress in its siRNA and fu-
sion proteins programs for anti-can-
cer and anti-viral indications and ex-
pects to move them into pre-clinical
development in 2011.
In the specialty pharmaceutical
business, RLS launched two APIs in
India and in semi-regulated markets.
The company had two DMFs filed for
for matinib and capecitabine in US.
RLS expanded its API manufactur-
ing facility and commissioned a new
oncology formulations facility. RLS
plans to further strengthen its spe-
cialty pharmaceuticals portfolio in
2011 with additional APIs and for-
mulated products, apart from filing
ANDAs for two oncology products.
In the regenerative medicine area,
RLS expanded its cord blood banking
business and introduced a stem cell
therapy for conjunctival disorders,
apart from progressing clinical trials
for stem cell therapies in neurology
and wound management.
Throwing light on the companys
game plan in the global landscape,
Mr KV Subramaniam, president,
RLS, told BioSpectrum that, We are
currently pursuing a multi-pronged
strategy for entering the global mar-
kets for our products and services.
This includes direct presence in the
markets as well as entering into part-
nerships. RLS considers exports as an
important part of its growth agenda
over the next three-to-five years.
Today, biopharmaceuticals has a 70
percent share in RLS overall busi-
ness, which includes, biosimilars,
plasma proteins and novel proteins.
The emerging markets would be the
key growth region for RLS global
strategy over the next three years.
These markets are growing at a
faster pace as compared to developed
markets (like US and EU), adds Mr
Subramaniam.
In the coming years, the company
is looking to venture in to Russia and
other CIS nations.
CompanyRanking
2
0
1
0
-
1
1
2
0
0
9
-
1
0
4
9
0
4
5
0
President and CEO
Mr K V Subramaniam
Business
Research initiatives
in medical, plant and
industrial biotechnology
Start-up Year: 2002
Address: Dhirubhai Ambani Life
Sciences Center, R-282, TTC
Industrial Area of MIDC,
Thane-Belapur Road, Rabale,
Navi Mumbai-400701
Tel: +91-22-67678000
Fax: +91-22-67678099
Website: www.rellife.com
Rank
`490 crore*
R
e
v
e
n
u
e
5
Reliance
Life Sciences
Revenue in ` crore
BS
Quintiles boosts
infrastructure, grows 27%
Quintiles has established a leading position in
conducting clinical studies and is now expanding its
operations by opening new facilities
Q
uintiles India, a fully in-
tegrated bio pharmaceu-
tical services company
offering clinical, commer-
cial, consulting and capital solutions,
registered a growth of 27 percent to
touch an estimated sales revenue of
`476.25 crore for 2010-11.
Looking at the growth of its servic-
es in India, Quintiles opened its new
phase I research facility in Hydera-
bad, in January 2011. Constructed in
partnership with the Apollo Group of
Hospitals, the new facility will com-
plement Quintiles existing phase
I facilities around the globe to help
customers navigate through complex
early development challenges.
The Quintiles team in Hyderabad,
under the leadership of executive di-
rector, Dr Ashish Jain, will work in
accordance to global standards and
procedures and will be connected to
sites in London, Uppsala and Kansas
through Quintiles global data net-
work. The 86-bed unit would evaluate
compounds that are developed both in
India and abroad. Data capture will
be linked electronically to Quintiles
other phase I units in UK, US, and
Sweden. Furthermore, this unique
phase I facility at Apollo Health City,
will house the offices of Quintiles and
append to its operations in Ahmeda-
bad, Bangalore, Delhi and Mumbai.
Several factors including, offices
spread across the country, a well-es-
tablished corporate infrastructure,
government policies favoring R&D,
growth in the health insurance sec-
tor, and availability of hospitals for
trials are helping the company sig-
nificantly.
Quintiles India has established a
leading position with a track record
of conducting clinical studies involv-
ing tens of thousands of patients in a
variety of therapeutic areas. It offers
various services such as, project man-
agement, clinical trial monitoring and
site management, regulatory affairs,
drug safety and pharmacovigilance,
quality assurance, medical and scien-
tific services.
Being the only global CRO in In-
dia, Quintiles study sites have been
inspected by the US FDA. While con-
ducting its studies, the firm follows
the Quintiles Global Standard Op-
erating Procedures and works in ac-
cordance to ICH GCP requirements.
It has participated in FDAs pivotal
and supportive studies, with patient
contribution from India accounting
for eight percent to 75 percent of the
data. Around 98 percent of the studies
conducted by Quintiles India are for
FDA or European regulatory bodies.
Quintiles Bangalore office offers
world-class, end-to-end data manage-
ment solutions, for paper as well as
electronic CRFs. Quintiles provides
services to the Central Cardiac Safety
Laboratory from its offices in Mumbai
and Bangalore. Since 2007, Quintiles
has operated a CAP-accredited cen-
tral clinical laboratory in Mumbai,
which offers central lab services for
Indian sites in global studies. This
lab is a part of Quintiles global cen-
tral lab network. All labs are connect-
ed through the proprietary Quintiles
Laboratory Information Management
System, which helps customers to op-
erate and report seamlessly across
the world.
CompanyRanking
CEO
Dr Farzaan N. Engineer
Business
Offering clinical,
commercial, consulting
and capital solutions
Start-up Year: 1997
Address: Nitesh Broadway 2B,
9/3, M.G. Road,
Bangalore-560001
Tel: +91-80-66552100
Fax: +91-80-41156255
Website: whttp://www.quintiles.
com/locations/asia/india/
Rank
`476.25 crore*
6
R
e
v
e
n
u
e
Quintiles India
2
0
1
0
-
1
1
2
0
0
9
-
1
0
4
7
6
.
2
5
3
7
5
Revenue in ` crore
BS
Continues to lead the
India insulin market
Novo Nordisk, one of the largest companies in the
world in diabetes care, presently accounts for 55
percent of the insulin market in India
T
he growth of the insulin
market in India helped
Novo Nordisk register a
growth of 27.62 percent with
sales revenue touching `462 crore in
FY 2010-11 as compared to previous
years revenue of `362 crore. Novo
Nordisk India, which is synonymous
with diabetes care in India, continues
to lead the insulin market with over
55 percent of the market share.
Established in the year 1990, Novo
Nordisk India is a subsidiary of Novo
Nordisk, one of the largest companies
in the world leading in the domain of
diabetes care products. It claims to
be introducing products and services
that have never before been seen in
the treatment of diabetes in India.
With products in diabetes care,
homeostasis management and hor-
mone replacement therapy, Novo Nor-
disk, has since the last decade tried
to change the way people live, when
they are struck by these unfortunate
but alarmingly common diseases.
Novo Nordisk is seeking to change
the future course of diabetes by using
innovation to produce novel methods
of diagnosis and treatment for diabe-
tes. Novo Nordisk has already pro-
duced an array of products that could
be used to treat and monitor diabetes.
To help treat diabetic patients, Novo
Nordisk has come up with a range
of biopharmaceuticals like modern
insulin, NovoNorm and Glucagen
Hypokit.
Apart from biopharmaceuticals,
the company also introduced insu-
lin delivery devices like durable pen
and prefilled pen. The company
boasts of revolutionizing treatment of
diabetes with the introduction of the
dial-insert-push technology of insulin
delivery.
Homeostasis management, which
is one of the areas of focus for Novo
Nordisk, has influenced the compa-
ny to produce a recombinant factor
VIIa, NovoSeven, for the treatment
of hemophilia A and B, an essential
product for patients whose blood
fails to coagulate at the appropriate
moment.
Another area of focus for the com-
pany is growth hormone therapy.
Novo Nordisk has produced devices to
help patients suffering from growth
hormone deficiencies like Turners
syndrome and chronic renal disease
with the help of their products like
Norditropin Nordilet.
Novo Nordisk says it will to help the
people who are suffering from diabe-
tes. In this regard the company has
established and maintained partner-
ships with external organizations.
As a part of its global initiatives, the
company launched Diabetes Aware-
ness Wishes and Needs (DAWN), pro-
gramme in India. The programme is
based on the largest global survey of
the psychosocial aspects of diabetes
until date. It involves more than 5,000
diabetic people and 3,800 healthcare
professionals in 13 countries. It is a
global Novo Nordisk initiative in col-
laboration with the International Dia-
betes Federation and an expert adviso-
ry panel. Today, the initiative conducts
activities in more than 30 countries.
CompanyRanking
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
4
6
2
3
6
2
3
1
6
MD
Mr Melvin Oscar D Souza
Business
Diabetes care, growth
hormone and homeostasis
maintenance products
Start-up Year: 1990
Address: Plot No.32, 47-50,
EPIP Area, Whiltefield,
Bangalore - 560 066
Tel: +91-80-40303200
Fax: +91-80-41123518
Website: www.novonordisk.co.in
Rank
`462 crore
7
Novo Nordisk
India
R
e
v
e
n
u
e
Revenue in ` crore
BS
Rasi records sluggish
growth, outlook positive
In FY 2010-11, Rasi Seeds recorded a growth of
just 3.7% but the company is expected to make
substantial gains during the current fiscal
R
asi Seeds reported biotech
sales revenue of `371.88
crore in FY 2010-11 as com-
pared to `358.78 crore in FY
2009-10. The reasons behind the slug-
gish growth has been attributed to de-
crease in seed production due to heavy
rainfall, which lashed parts of Tamil
Nadu in December 2009.
Rasi Seeds made rapid advances in
seed production and supply ventures
and has reached a commendable po-
sition by investing in R&D initiatives.
The company has sold about 42.5 lakh
packets of Bt cotton hybrids in nine
states during the 2010 kharif season.
Rasi Seeds received approval for the
commercial release of RCH 2 Bt in the
year 2004 and has subsequently devel-
oped an impressive line-up of 25 prod-
ucts under Bt and BG II, including RCH
134 Bt, RCH 20 Bt, RCH 118 Bt, RCH
138 Bt, RCH 2 BG II, RCH 515 BG II
and RCH 530 BG II among others.
The company also released RCHB
708 Bt under ELS segment, which is be-
ing rated as a high yielding hybrid. Rasi
has about 10,000 farmers for direct
seed production. Rasi Seeds is commit-
ted to serve the Indian farmers by fol-
lowing new and powerful technologies
in crop improvement.
It has set up state-of-the-art biotech-
nology laboratories and crop breeding
facilities at Attur, near Salem, Tamil
Nadu, with an investment of `10 crore
in 2008.
The R&D facility of Rasi has got rec-
ognition from the Department of Scien-
tic and Industrial Research, Ministry
of Science and Technology, Govern-
ment of India.
The R&D center has laboratories for
biotech research, crops research and
germplsam conservation. It also has
an insect bioassay laboratory, library,
documentation and other facilities
spread across an area of 40,000 sq
ft. Its biotech labs are equipped with
modern equipments such as PCR ma-
chines, refrigerated centrifuges, DNA
gel documentation system and various
DNA electrophoresis systems, includ-
ing nucleotide sequencing facility and
freeze-dryers.
In addition, the R & D center is well
equipped with infrastructural facili-
ties that include, research farm of 140
acres, a 55,000 sq ft transgenic green-
house, seed quality control laboratory
and state-of-the-art seed processing
facilities.
The crop biotechnology activities are
carried out in a well equipped plant
molecular biology laboratory.
The thrust of the center is now on
marker assisted selection, using DNA
markers for several important traits in
crops such as rice, wheat, cotton and
vegetables. This will involve integra-
tion of crop breeding and biotechnol-
ogy, including bioinformatics.
Rasi Seeds plans to intensify its
transgenic research in different eld
crops and vegetables for agronomically
important traits besides quality traits.
Rasi Seeds had signed an MoU with the
(Indian Agricultural Research Institute
(IARI), New Delhi, in 2008 for seed
production of public rice hybrid Pusa
RH 10 and marketing of the same in the
north zone of the country.
MD
Dr M Ramasami
Business
Production and marketing
of agri-biotechnology
products
Start-up Year: 1973
Address: 273, Kamrajnagar Road,
Attur, Salem-636102
Tel: +91-4282-241007, 242007
Fax: +91-4282-242558
Website: www.rasiseeds.com
R
asi Seeds
Rank
`371.88 crore
R
e
v
e
n
u
e
CompanyRanking
8
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
3
7
1
.
8
8
3
5
8
.
7
8
3
7
5
.
5
9
2
9
3
.
6
8
3
2
9
.
4
1
Revenue in ` crore
BS
Mahyco rides on a
strong R&D program
Diverse and progressive research in seeds has
helped Mahyco sustain its growth in the
biotechnology space
M
aharashtra Hybrid
Seeds Company Lim-
ited (Mahyco) is engaged
in R&D, production,
processing and marketing of 200 prod-
ucts in 35 crop species, including cere-
als, oilseeds, bre crops and vegetables.
Mahyco recorded biotech revenue of
`364.9 crore in 2010-11 as compared to
`312 crore in 2009-10. The continuous
growth in the sale of Bt cotton seeds,
since its launch in 2002, has helped
the company to continue to grow in the
biotechnology space.
Mahyco is credited with 21 notied
research varieties of seeds and caters to
the needs more than 100,000 farmers.
It has 27 production centers and has
a million seed processing capacity at
eight processing plants and more than
9,000 tonnes of dehumidied storage
for sensitive seed material. The pro-
duction and the processing network are
supported by a well developed all-India
marketing network, consisting of more
than 5,000 sales outlets.
The cornerstone of Mahycos success
has been a strong, diverse and progres-
sive R&D program. Mahyco was the
rst company in the world to success-
fully commercialize F1 hybrid cotton,
based on genetic and cytoplasmic male
sterility system.
Mahyco was also the rst company
in India to produce and market, hybrid
sorghum, pearl millet and sunower
and the rst company to receive the
Government of Indias approval in 2002
for commercialization of insect-tolerant
Bt cotton (Bollgard) followed by a supe-
rior Bt cotton (Bollgard II) in 2006.
The company has a state-of-the art
R&D center at Dawalwadi near Jalna,
Maharashtra, where hybrid breed-
ing programs are presenlty on-going
in over 30 crop species and support
program in plant pathology, entomol-
ogy, cytogenetics, biochemistry, tis-
sue culture, rapid cycling, biotech and
transgenic plant research are also be-
ing carried out. Mahyco also has ve
more research centers and 18 multi-
locational crop performance testing
centers distributed across the country.
Over 200 scientists are engaged in the
research programs at Mahyco.
The research focus at Mahyco Re-
search Center has been in the areas of
biotic and abiotic stress tolerance.
The company was involved in pigeon
pea and pearl millet breeding program
with ICRISAT for over a decade and
has also joined the Hybrid Rice De-
velopment Consortium, established by
IRRI.
Mahyco also shared Bt brinjal tech-
nology with public sector institutions
in India and abroad, including UAS,
Dharwad; TNAU, Coimbatore; IIVR,
Varanasi; BARI, Bangaladesh; and
UPLB, Philipines.
Mahyco has participated in a number
of projects under the aegis of the De-
partment of Biotechnology (DBT),
Government of India, and has entered
into numerous partnerships with pub-
lic institutions and private companies
to bring the best technologies to Indi-
an farmers. To name a few, Mahyco is
sourcing sucking pest tolerance genes
from the Bose Institute, Kolkata and
chickpea pod borer resistance genes
from Assam Agricultural University
(AAU), Jorhat.
CompanyRanking
Founder & Chairman
Dr B R Barwale
Business
Solutions for GM crop
testing
Start-up Year: 1964
Address: PO Box 76, Jalna, Au-
rangabad Rd, Dawalwadi, Dist.-
Jalna, Maharastra- 431203
Tel: +91-2482-233881, 233882
Fax: +91-2482-262002
Website: www.mahyco.com
Rank
`364.9 crore*
9
Maharashtra Hybrid
Seed Company (Mahyco)
R
e
v
e
n
u
e
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
3
1
2
2
1
1
.
1
2
Revenue in ` crore
3
6
4
.
9
BS
3M India 21
Agilent Technologies 61, 65
Alfa Laval 45
Analytica Anacon India 31
Avantor 57
Beckman Coulter 59
Bhat Biotech 87
Biogentek 29, 37
Bioscreen Instruments 81
Chromous Biotech 85
Dept of Biotechnology 4, 8
Esco Biotech 89
Frost & Sulivan 93
GE India Industrial 69
GE Life Sciences 7, 41, 113
Himedia Laboratories 13
Imperial Life Sciences 1
India Lab Expo 2011 119
Invitrogen Bioservices India 126
Kerry Biosciences 125
Medi Analytika India 35
Merck Millipore 79, 83
Pall Filteration Pte Ltd 39
Pall Life Sciences 5
PDP Couriers 67
Phenomenex 15
RCC Laboratories 19
Sci - Plas 25
Shreetech Associates 91
Spinco Biotech 73
TA Instruments 77
Thermofisher Scientific 17
Technology Review 95, 99
USA-India Chamber
of Commerce
104, 105
Waters India 63
West Pharma 75
World Courier 11
Yasham Life Sciences 71
Advertisers Index
Transasia expands into
international markets
Transasia continues its run in the international
markets. The company entered the US, Italy and
Turkish markets in FY 2010-11
M
umbai-based Transasia
Bio-Medicals Limited, a
manufacturer and export-
er of diagnostic instru-
ments in India, witnessed a growth of 88
percent in 2010-11 by generating total
sales revenue of `350 crore as compared
to `186 crore in 2009-10. Transasia
has acquired 40 percent market in the
haematology segment and is looking to
enlarge its market share in several seg-
ments including oncology, diabetes, car-
diovascular and infectious diseases.
The company has a 32-year track
record in the industry and has suc-
cessfully developed and manufactured
hi-tech in vitro diagnostic (IVD) instru-
ments and reagents. Started in 1979 as
a marketing rm for a few imported
diagnostic equipments, Transasia to-
day has over 30,000 installations,
supported by a network of 65 service
centers and zonal ofces spread across
all the major cities. Fiscal 2010-2011,
saw some eye-catching developments
within the companys strategy, both
in terms of market expansion and in-
crease in its product basket. Says Mr
Suresh Vazirani, CMD, Transasia Bio-
Medicals, We have expanded into in-
ternational markets, where there is a
potential for growth. We have made an
entry in the US, Italy and Turkish mar-
ket this year, after our entry in Czech
Republic and Russia in the last year.
In order to boost its product basket,
Transasia is looking at striking alli-
ances with leading diagnostic compa-
nies in the world. Today, it has three
manufacturing facilities in India, one
each in Germany, Czech Republic, Italy
and US.
On Jan 14, 2011, Erba Diagnostics
Mannheim GmbH, a 100 percent Ger-
many-based subsidiary of Transasia,
acquired a 100 percent stake in Diasis
Diagnostik Sistemler Ticaret Ve Sanayi
A S, Istanbul, Turkey. Diasis is an ISO
9001/2000 and ISO 13485/2003 cer-
tied company that is involved in the
development, production and market-
ing of products for IVD in the eld of
biochemistry, haematology and urine
analysis.
Transasia, with the help of Erba Di-
agnostics, also acquired a majority
stake in a US-based IVD company, Ivax
Diagnostics. Ivax is a fully integrated in
vitro diagnostics company that devel-
ops, manufactures and distributes pro-
prietary diagnostic reagents, test kits
and instrumentation for autoimmune
and infectious diseases, in the US and
other international markets.
Transasia also has an alliance called
the Sysmex Network Communication
System (SNCS), an internet based on-
line customer service launched in col-
loboration with Sysmex.
The company now has major expan-
sion plans up its sleeve. If the IVD
market continues to grow at 12-15 per-
cent, we are looking at a growth rate of
30-40 percent year-on-year. We will
see ve-to-10 product launches this
year in 2011, says Dr Gurumukh Ad-
vani, president, sales and marketing.
While small labs and government labs
have been the main focus until date,
the company is now looking at extend-
ing its products to corporate hospitals,
CROs and chain laboratories. The com-
pany is also looking to scale up its infra-
structure in several locations in India,
including Mumbai, Baddi (Himachal
Pradesh) and Daman.
CompanyRanking
CMD
Mr Suresh Vazirani
Business
Manufacturer and
exporter of diagnostic
instruments
Start-up Year: 1979
Address: Transasia House, 8
Chandivali Studio Road,
Mumbai - 400072
Tel: +91-22-40309000
Fax: +91-22-28573030
Website: www.transasia.co.in
Rank
`350 crore
10
Transasia
Bio-Medicals
BS
R
e
v
e
n
u
e
Revenue in ` crore
2
0
1
0
-
1
1
2
0
0
9
-
1
0
3
5
0
1
8
6
Creates Bt cotton
sales record
The company sold 15 lakh packets of BG-I and 9.50
lakh packets of BG-II in almost all the cotton growing
states of India during the fiscal.
A
nkur Seeds Private Limited,
a forerunner in market-
ing of insect resistant cot-
ton hybrids in the country,
increased its market share in Bt cot-
ton substantially. The total revenue of
Ankur Seeds for FY 2010-11 was `325
crore.
The company sold 15 lakh packets of
BG-I and 9.50 lakh packets of BG-II in
almost all the cotton growing states of
India during the scal. For distribu-
tion of its products, the rm has a well
spread marketing network in 16 states
of the country, head ofce in Nagpur, 11
regional ofces and six area ofces.
The company organizes several re-
gional demonstrations across the
country which is attended by 100,000
farmers every year. The company has
organized seven regional demonstra-
tions in the previous year and invited
over 50,000 farmers to its programs.
It started its research activities in cot-
ton, okra, brinjal and chillies and has
expanded to more than 15 crops. The
R&D of the company is recognized by
the Department of Scientic & Indus-
trial Research (DSIR) and the company
also received the National Award for
excellent R&D achievement from Gov-
ernment of India in 1996.
Ankur Seeds has production and
processing facilities spread across the
various potential production areas of
the country.
The company has 11 state-of-the-art
processing plants, with production ca-
pacity of over 16,000 tons; a dehumidi-
ed storage capacity of 5,000 sq m for
medium term storage and 10,000 sq m
of warehouses. Its products like Akka-
Bt, Jai-Bt in cotton; Sonam & Rupali in
paddy; Ankur 40 in okra; Ankur 32 in
chilly; tomato 1001; Ajay, Kirti, Utkarsh
in brinjal; Latika in ridge gourd; Shreya
and Karishma in bitter gourd have
become extremely popular with the
farmers.
In the year 2010-11, Ankur Seeds
applied for registration of 14 varieties
in PPV and FRA and it also released
more than 20 varieties of commercial
crops.
Ankur Seeds has invested signicant-
ly in marker-assisted breeding projects
for developing drought and disease re-
sistant varieties in vegetable and rice.
To achieve this it has collaborated with
national and international institutes.
Screening of drought resistant cot-
ton transgenics is under process as per
the guidelines of DBT and will also ap-
ply for the event selection trials for Bt
brinjal that has been developed by the
company.
In brinjal, the company has success-
fully developed cytoplasmic genetic
male sterility, which will have long
term benets in hybrid seed produc-
tion technology in brinjal.
The company has also procured a
gene for insect resistance from the In-
dian Agricultural Research Institute in
2009, work on which is presently un-
derway.
Ankur Seeds also signed a memoran-
dum of understanding (MoU) with the
International Centre for Genetic En-
gineering & Biotechnology to work on
a research project on development of
virus resistance in okra.
MD
Mr MG Shembekar
Business
Agri-business in field
crops, vegetables &
transgenic crops (cotton)
Start-up Year: 1976
Address: 27, New Cotton
Market Layout,
Nagpur - 440018
Tel: +91-712-2726148; 2725117
Fax: +91-712-2723455
Website: www.ankurseeds.com
A
nkur Seeds
Rank
`325 crore
R
e
v
e
n
u
e
CompanyRanking
11
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
3
2
5
1
0
9
.
5
5
5
.
7
3
6
9
.
5
0
Revenue in ` crore
8
0
.
3
5
BS
Syngene battles market
pressure, grows 26%
Syngenes highly competitive discovery platform
and the growth of long term R&D collaboration with
Bristol Myers Squibb has yielded in the firms growth
S
yngene International, a
subsidiary of Biocon, is an
internationally reputed cus-
tom research company with
multi-disciplinary skills in synthetic
chemistry and molecular biology. The
company has posted another strong
year of financial performance, deliv-
ering topline growth of 26 percent.
The company reported sales revenue
of `318 crore in FY 2010-11 as com-
pared to `252 crore in FY 2009-10.
These results are all the more en-
couraging for the company when set
against the background of macro
market pressures such as reduc-
tion in the global R&D expenditure
and consolidation of market players.
Key drivers of this growth have been
Syngenes highly competitive plat-
form in discovery chemistry, where
they have strong customer retention;
accelerating new customer traction;
and the growth of Syngenes long
term discovery and development col-
laboration with Bristol Myers Squibb,
where Syngene is contributing over
400 scientists.
Syngenes pioneering platform in
biologics has supported discovery
and development in the fast grow-
ing monoclonal antibody and protein
therapeutics arena.
According to Mr Peter Bains, direc-
tor, Syngene International, much of
the growth is coming from programs
where its clients are utilizing Syn-
genes discovery and development
platforms together in discreet inte-
grated programs and where Syngene
is able to make higher, value contri-
butions to its clients work.
Syngene conducts high value re-
search in early stage drug discovery
and development for a diverse range
of global clients. From early stage
discovery and process development
to cGMP manufacturing, Syngene
provides customized R&D services
to pharmaceutical and biotechnology
companies on a strong platform of
confidentiality and intellectual prop-
erty protection.
Established in 1994, Syngene was
Indias CRO to receive special export
status from the Government of India.
Over the past 16 years, the company
has successfully partnered with lead-
ing players in the global pharma in-
dustry across a range of challenging
programs.
During 2007, the company entered
into a research partnership with Bris-
tol-Myers Squibb (BMS). With the
help of this partnership, Syngene is
providing R&D services for discovery
and early drug development to BMS.
In 2008, Syngene International part-
nered with Sapient Discovery, a US-
based biotech company, offering fully-
integrated drug discovery services.
The changing dynamics of the glo-
bal pharmaceutical industry makes
a compelling case for risk and cost
mitigation strategies that rely on out-
sourced R&D services. Data already
indicates that 21 percent of global
R&D spends in 2009 were outsourced
which was less than one percent a
decade ago. This trend augers well
for Syngene, which sees itself as a
key player in this space with the po-
tential of building niche capabilities
for global leadership, says Ms Kiran
Mazumdar-Shaw, CMD of Biocon, the
parent company.
R
e
v
e
n
u
e
CompanyRanking
COO
Mr Gautam Das
Business
Custom research
and manufacturing of
biopharmaceuticals
Start-up Year: 1994
Address: Biocon Park, Plot No.
2-3, Bomasandra IV phase,
Jigini link road,
Bangalore-560099
Tel: +91-80-28082808
Fax: +91-80-28083150
Website: www.syngeneintl.com
Rank
`318 crore
12
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
3
1
8
2
5
2
1
7
5
.
5
0
1
3
2
Syngene
International
Revenue in ` crore
R
e
v
e
n
u
e
2
2
4
.
6
0
BS
Bharat Biotech surges
ahead on H1N1 vaccine
While maintaing its average growth rate, Bharat
Biotech strengthened its position as the producer of
quality indigenous vaccines
B
harat Biotech Internation-
al Limited (BBIL) special-
izes in product-oriented
research, development and
manufacturing of vaccines and bio-
therapeutics. The company regis-
tered an annual turnover of `298.34
crore in FY 2010-11 as compared to
`271.66 crore in FY 2009-10.
Established in 1996 by Dr Krishna
M Ella and Ms Suchitra K Ella, the
company is one of the largest man-
ufacturers of Indirab (anti-rabies
vaccine) in India. It is a WHO pre-
qualified manufacturer of Revac-B
(hepatitis-B vaccine) for supply to
UNICEF and the only vaccine com-
pany in India to manufacture and
supply the preservative (thiomersol)
free vaccine, Revac-Bmcf.
The company has the largest
manufacturing capacity for making
hepatitis-B (10 crore doses), typhoid
vaccine (five crore doses) and rabies
(80 lakh doses). It has product devel-
opment projects in varying stages for
vaccines and therapeutics of several
diseases including, malaria, rotavi-
rus, typhoid, Japanese encephalitis,
pandemic influenza, chikungunya,
and staphylococcus aureus.
On October 18, 2010, the company
launched Indias first indigenously
developed cell culture H1N1 swine
flu vaccine under the brand name,
HNVAC. This is the only develop-
ing world flu vaccine that has been
manufactured in cell culture instead
of eggs. HNVAC places Bharat Bio-
techs superior, clean, safe and con-
trolled mammalian cell culture tech-
nology ahead of several multinational
and Indian vaccine manufacturers,
all of whom still use eggs for manu-
facturing. USFDA has discouraged
the use of egg-based vaccines due to
the adverse reactions generated by
egg based proteins, particularly in
children.
On February 4, 2011, Bharat Bio-
tech initiated a phase III trial in
India with THR-100 in patients suf-
fering from acute myocardial infarc-
tion. The trial is expected to recruit
approximately 120 patients and the
company anticipates that the phase
III trial with THR-100 will be com-
pleted in the second half of 2011.
In December 2006, Bharat Biotech
entered into a license agreement with
ThromboGenics for the manufacture,
clinical development and commercial-
ization of THR-100 with the objective
of potentially commercializing THR-
100 as a replacement for established
thrombolytics, such as streptokinase
and urokinase in the developing
markets. THR-100, a novel variant
of recombinant staphylokinase, is
a thrombolytic agent developed by
ThromboGenics for the treatment of
acute myocardial infarction (AMI)
and other vascular diseases.
Rotavac, the first oral rotavirus vac-
cine developed by Bharat Biotech, is
currently under phase III clinical tri-
als. This is one of the largest phase III
clinical trial in Indian history, encom-
passing 10,000 infants. The company
has invested `200 crore to `250 crore
in the clinical trials and has received
funding from the Gates Foundation
and the Department of Biotechnology,
Government of India (`30 crore). The
vaccine is expected to hit the market
by the end of 2011.
CMD
Dr Krishna M Ella
Business
Manufacturer of
human vaccines and
biopharmaceuticals
Start-up Year: 1996
Address: Road No. 65, Jubilee
Hills, Hyderabad-500033
Tel: +91-40-23480567,
55510150
Fax: +91-40-23480560
Website: www.bharatbiotech.com
Rank
`298.34 crore*
R
e
v
e
n
u
e
CompanyRanking
13
Bharat Biotech
Revenue in ` crore
BS
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
2
9
8
.
3
4
2
7
1
.
6
6
8
3
.
4
4
5
6
.
8
4
2
4
1
.
0
5
Aim: Affordable immunity
for animals, humans
The company also has a R&D center in India that
conducts research in rabies, hepatitis b and measles
among others
C
locking an estimated rev-
enue of `283 crore, Indian
Immunologicals has shown
improvement from 2009-
10 revenue of `272.87 crore. With an
aim to make immunity affordable to
both animal and humans alike, Indian
Immunologicals, has grown to be one
of the largest biologicals company in
India since its inception in 1983.
In 2010, the company introduced
Folyson, a dairy cattle hormone,
which indirectly enhances the milk
production capacity of a dairy cow or
buffalo.
Furthermore, motivated by the suc-
cess of the foot and mouth disease vac-
cine, Raksha, the company went on to
launch its tissue culture vaccine, Rak-
sharab, and also successfully produced
and marketed its human anti-rabies
vaccine, called Abhayrab.
With a 213-acre complex in Hydera-
bad, which has the distinction of being
WHO-GMP and ISO-9002 certied,
Indian Immunologicals has one of the
worlds largest veterinary vaccine plants
in the world, equipped with state-of-
the-art technology to manufacture and
market vaccines to the masses.
In the animal health sector, Indian
Immunologicals manufactures vaccines
for foot and mouth diseases, clostrid-
ium perfringens, sheep pox, brucella
abortus, theileriosis and bacillus an-
thracis among others. It is also actively
engaged in the production of other ani-
mal health products.
In the human health sector, Indian
Immunologicals has made a signicant
progress through its cell culture rabies
vaccine, Abhayrab. This vaccine is sold
by Abhay Clinics, which belong to the
marketing network of Indian Immuno-
logicals. The success of this anti-rabies
vaccine has inuenced the company to
venture deeper into this domain by es-
tablishing two manufacturing facilities,
one in Ooty and another in Hyderabad,
India.
The manufacturing facility of the
company that is located in Hyderabad
is equipped to produce vaccines such as
hepatitis-b, diphtheria, pertussis, teta-
nus and measles.
The company has another R&D
center in India that conducts research
in rabies, hepatitis b and measles
among others.
The companys marketing network
is widespread with over 19 marketing
outlets spread across India. In addition
to the domestic network, the company
also has signicant export connections,
supplying animal health vaccines to
over 20 countries apart from the Food
and Agriculture Organization (FAO)
of the US. More than 12 countries
across the world are receivers of Indian
Immunologicals human anti-rabies
vaccine, Abhayrab. The export market
of the company is extremely diversied.
It is spread across several countries in-
cluding, the Gulf, Asia, Africa, Europe,
Russia and other CIS nations.
The company has research collabo-
rations with several renowned institu-
tions like Thomas Jefferson Medical
School, Onderstepoort Veterinary In-
stitute and Institute of Animal Health
among others.
Indian Immunologicals aims to com-
bat infectious diseases in animals and
human beings by producing afford-
able products for the betterment of
mankind.
MD
Mr KV Balasubramaniam
Business
Animal and human
biologicals manufacturer
Start-up Year: 1983
Address: Road # 44, Jubilee
Hills, Hyderabad 500033,
Tel: +91-40-23544585
Fax: +91-40-23544007
Website: www.indimmune.com
Rank
`283 crore
R
e
v
e
n
u
e
CompanyRanking
14
Indian
Immunologicals
Revenue in ` crore
BS
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
2
8
3
1
7
2
.
7
0
1
4
1
.
5
4
2
7
2
.
7
5
2
2
4
.
7
5
`276.13 crore
R
e
v
e
n
u
e
Krishidhan expands
footprint in Europe
During early 2010, KSL announced the opening of its
first European subsidiary under the name of Krishidhan
Seeds Europe, with HQ at Enkhuizen, Holland
K
rishidhan Seeds Limited
(KSL) clocked biotech rev-
enue of `276.13 crore for
FY 2010-11 as compared to
`133.23 crore in the previous year.
The companys revenue increased
signicantly because it was able to sell
more Bt cotton seeds to farmers during
the last year. The company made con-
siderable progress in biotechnology in
terms of offering the best solutions to
farmers by providing Bt cotton seeds
from 2007-08.
The company develops, produces and
distributes proprietary hybrid seeds to
Indian farmers. Krishidhan Seeds was
founded in the early 1980s and in 1996
got incorporated with Mr Sushil Karwa
taking charge as its managing director.
Today, the company has a pan India
presence and has a product portfolio
of more than 120 products to offer to
farmers including eld crops, vegetable
seeds and crop nutrition.
Some of the prominent products of
the company include cotton BG I & BG
II, soyabean, paddy, maize, wheat, sun-
ower, pearl millet, sorghum, pulses. It
has a strong presence in 15 states with
over 1,300 distributors in the country.
The company today has a headcount
of 250 marketing professionals and has
a registered ofce in Indore (Madhya
Pradesh), corporate ofce in Pune and
the operational ofce spread across 16
acres in Jalna.
Having consolidated its position
in the domestic market, KSL took the
leap last year in extending its footing
to international markets. During early
2010, KSL announced the opening of
its rst European subsidiary under the
name of Krishidhan Seeds Europe BV,
with headquarters at Enkhuizen, Hol-
land. Mr J H A Tamboer was appointed
as the CEO of the subsidary.
In April 2011, Krishidhan Seeds Eu-
rope B V and Axia Vegetable Seeds BV
(a new venture of Sandor van Vliet) an-
nounced that they had entered into a
strategic alliance agreement in the eld
of breeding, seed technology and sales.
The new alliance will enable Krishid-
han Seeds Europe to access the top Eu-
ropean vegetable seed industry as well
as large growers of produce.
In India, the company has been in-
vesting heavily in R&D activities. Dur-
ing FY 2010-11, KSL invested a total
amount of `2.3 crore in R&D and also
invested around `8 crore in developing
its infrastructure.
The company today has 10 regional
research stations in India and a state-
of-the-art research center at Jalna,
Aurangabad. It has a signicant size of
products, based on its own R&D and
has successfully harnessed biotech-
nology to develop products using both
GMO & non-GMO approaches.
The R&D units of KSL and its sub-
sidiaries (Krishidhan Research Foun-
dation, Krishidhan Vegetable Seeds
and Subhash Fertilizers) have been
recognized by the Department of Sci-
entic and Industrial Research(DSIR),
Government of India.
KSL is managed by a board com-
prising 12 directors. Under the expert
guidance and supervision of these top
managers, a group of committed, high-
ly qualied, experienced professionals
continuously carry out innovation in
every eld of activity like research, pro-
duction, processing, quality assurance
and marketing.
BS
MD
Mr Sushil Karwa
Business
Production and distribution
of hybrid seeds
Start-up Year: 1996
Address: Krishidhan Bhavan,
D3-D6, Additional MIDC Area,
Aurangabad Road, Jalna-431203
Tel: +91-2482-222750
Fax: +91-2482-222600
Website: www.krishidhanseeds.com
Rank
15
Krishidhan
Seeds
CompanyRanking
Revenue in ` crore
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
2
7
6
.
1
3
4
7
.
7
0
1
8 1
3
3
.
2
3
6
3
.
2
5
At West, we deliver innovative solutions that can help you overcome
the challenges of doing business on a global scale.
West Makes the Dierence.
West Pharmaceutical Services
India: +91 40 40021790,
Singapore: +65 6 862-3400,
Email : [email protected]
www.westpharma.com
Westar is a registered trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
West
TM
and the diamond logo is a trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
On aGlobal Scale
Are you looking for a partner who can provide best-in-class solutions to your global production, sales and distribution needs?
A partner who has invested in world-class quality systems to provide you with the best possible products?
Look no further than West.
Innovation
You can transformyour lling
operation into a lean, ecient
process with Wests innovative
solutions for your drug
packaging, delivery and
administration needs.
#5426 B
High Quality
Quality
You can ensure consistency of
component preparation and
compliance with regulatory
standards by choosing Westar
ready-to-sterilize components.
Compliance
You can mitigate compliance
risks for your drug product
by tapping into Wests vast
knowledge of pharmaceutical
container closure and drug
delivery regulations.
Shan5 product recall hits
Shanthas revenue by 19%
Shantha Biotech is undeterred by the setback faced
on account of its Shan5 vaccine and is gearing to
launch four new vaccines between 2011-16
S
hantha Biotech, the rst Indian
company to launch an r-DNA
vaccine in 1997, witnessed a
considerable 19 percent drop
in its revenue from `334.23 crore
in 2009-10 to `272 crore in 2010-11.
The drop in revenue is mainly because
Shantha Biotech recalled its ve-in-
one vaccine, Shan5, from across the
global markets following emergence of
safety concerns.
The WHO, which was procuring the
Shan5 vaccine from Shantha Biotech
under a long-time contract worth $340
million, called for recall and destruc-
tion of all the batches of the vaccine af-
ter a white sediment was discovered
in some of the vials. Shantha Biotech
supplied 24 million doses of Shan5
vaccines between November 2008 and
February 2010.
However, it is difcult to ascertain
how much portion of this supply has
been used. The cost of the 24 million
vaccines would be around $72 million,
assuming that the WHO pays $3 for a
single dose of vaccine.
The WHO, in its July 28, 2010, state-
ment noted that it will maintain the
tetanus toxoid, Shan TT, and hepatitis
B vaccine, Shanvac, on the list of its
prequalied products. Also, the pre-
qualication for evaluation of cholera
vaccine, Shancol, will continue. Since
the potential root cause of the appear-
ance of the sediment is linked with the
manufacture of the pertussis compo-
nent, the WHO has decided to remove
the tetravalent vaccine (DTwP-hepa-
titis B) from the list of prequalied
products.
The WHO has also decided to ter-
minate the ongoing prequalication
evaluation process for a DtwP vaccine,
Shantrip.
Shantha Biotech, 80 percent of
which is now owned by Sano Aventis,
is one of the leading players in the eld
of modern biotechnology in India.
Since the development of the recom-
binant hepatitis B vaccine, the com-
pany has launched a tetravalent DPT
hepatitis vaccine and has also com-
mercialized three therapeutic proteins,
including interferon alpha 2b, strep-
tokinase and erythropoietin.
Along with its subsidiary, Shantha
West at San Diego, Shantha Biotech is
engaged in the development of mono-
clonal antibodies using the human
bodys own defense mechanisms.
Realizing the potential of collabora-
tive research, the company established
collaborations with leading institutes
like the Center for Cellular and Mo-
lecular Biology, the Indian Institute of
Sciences and the International Vaccine
Institute, Korea. Vaccines, therapeutic
proteins and therapeutic monoclonals
are the main focus areas of the rm for
R&D in the product segment.
Channeling almost 25 percent of its
revenue into research, equipped with
50,000 sq ft of laboratory area and
having facilities for animal cell culture,
hybridoma technology, virus handling,
and upstream and downstream process
development, Shantha Biotech boasts
of state-of-the-art R&D infrastructure
to engage in research of infectious dis-
eases and oncology. The company has
four vaccines, including a typhoid vac-
cine, a measles-rubella vaccine, a rota-
virus vaccine and an HPV vaccine, in
its product pipeline for the period of
2011-16.
Rank
`272 crore*
R
e
v
e
n
u
e
CompanyRanking
16
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
2
7
2
3
3
4
.
2
3
2
4
7
1
5
0
1
1
5
Shantha
Biotech
MD
Dr KI Varaprasad Reddy
Business
R&D and manufacture of
human therapeutics
Start-up Year: 1993
Address: H.No.5-10-173, 3rd &
4th Floors, Vasantha Chambers,
Fateh Maidan Road, Basheerbagh,
Hyderabad - 500 004.
Tel: +91 40 23234136
Fax: +91 40 2323410
Website: www.shanthabiotech.com
BS
Revenue in ` crore
Aims to create a million
jobs by 2020
Novozymes is trying to tap the huge potential of
the vast Indian biomass resources and is looking to
generate a million jobs by 2020
N
ovozymes, which is a group
company of Novo Nordisk,
Denmark, is represented in
India by Novozymes South
Asia and is headquartered at Bangalore.
Novozymes, a leader in bioinnovation,
has businesses in industrial enzymes,
microorganisms and biopharmaceuti-
cal ingredients. Its biological solutions
save energy and raw materials and also
reduce waste, thus resulting in higher
quality, lower costs, lower CO2 emis-
sions and a better environment.
Novozymes South Asia, the larg-
est supplier of industrial enzymes and
microorganisms in India, is catering
to the requirements in the detergent,
food, feed, textile, leather, oils and fats,
beverage and biofuel industries. The
rm registered a growth of about nine
percent in 2010-11 with sales revenue
of `242 crore as compared to the previ-
ous years revenue of `224 crore.
Detergent and technical enzyme sales
were the strongest growth drivers for
the company in absolute terms. While
the sales of microorganisms performed
well during the year, the divestment of
noncore ingredient activities in India in
the year 2009 impacted the growth of
the company in a negative manner.
In November, last year, the com-
pany opened its new state-of-the art
R&D center and ofce at Whiteeld in
Bangalore, India. The R&D center will
undertake protein engineering work
for Novozymes global requirements
and will act as a resource base for the
companys global discovery projects.
The center will also serve as an appli-
cation technology excellence center
for Novozymes global juice and wine
industry requirements. The center is
actively innovating food applications
for the Indian market by undertaking
research to understand the local needs
in India.
Novozymes India began its opera-
tions in 1983 and has grown into an
organization that is spread across three
sites in India, covering manufacturing,
business functions, a shared service
center and R&D.
Novozymes is focusing on biofuel in a
big way in India and it aims to produce
second generation bioethanol mainly
from agricultural residues and waste.
The company is trying to tap the huge
potential of the vast Indian biomass re-
sources and is looking to create around
a million aggregated jobs between 2010
and 2020, thus providing the much-re-
quired impetus for inclusive growth by
providing employment in rural India.
Novozymes entered into an agree-
ment with Praj Industries, a diversied
biofuel and brewery technology solu-
tions provider.
Together, Praj and Novozymes will
optimize the enzymatic hydrolysis
processes and the use of enzymes in
the production of advanced biofuels.
Novozymes believes that this collabo-
ration with Praj will be instrumental in
ensuring rapid deployment of cellulosic
biofuel in India as well as in other parts
of the world.
Globally, Novozymes is organized
into two business areas including, en-
zyme business and biobusiness. The
development, production, distribu-
tion, and sale of enzymes form the
major part of its business, currently
accounting for 94 percent of sales. Bio-
business accounts for the remaining
six percent.
Rank
`242 crore*
R
e
v
e
n
u
e
CompanyRanking
17
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
2
4
2
2
2
4
2
0
5
.
5
0
1
8
6
.
8
2
1
6
0
.
6
3
Novozymes
South Asia
Regional President, India
Mr Krishnan GS
Business
Industrial enzymes
Start-up Year: 2000
Address: Genisys Building, Plot No.
32, 47-50, EPIP Area, Whitefield,
Bangalore-560066
Tel: +91-80-30593500
Fax: +91-80-30593620
Website: www.novozymes.com
BS
Revenue in ` crore
BSV seeks partners to
enter regulated markets
Bharat Serums is extremely focussed on research and
has invested seven percent of its turnover in research
and development in 2010-11
B
harat Serums and Vaccines
(BSV) recorded total biotech
revenues worth `226 crore
for FY 2010-11 as compared
to `175 crore in 2009-10. The company
manufactures and markets biologi-
cal, pharmaceutical and biotechnology
products and has a portfolio of over 25
brands, including plasma derivatives,
monoclonals, equine antitoxins and
serums cardiovascular, antimicrobi-
als, antifungals, anaesthetics and hor-
mones. Over the years, BSV has put a
lot of emphasis on its R&D operations,
both in India and overseas. BSV has
also undertaken signicant R&D activi-
ties with focus on biopharmaceuticals,
novel drug delivery systems and equine
products.
The company invested around seven
percent of its turnover in R&D, which is
at par with international rms R&D ex-
penditure. The research activities of the
company have been recognized by the
Department of Scientic and Industrial
Research, Government of India.
BSV holds a signicant market share
in India for plasma derivatives. The
product portfolio of the rm includes
Tetglob (human tetanus hyper im-
mune globulin, Vinobulin (anti-Rho
immuneglobulin gamma IV), Bharglob
(intravenous immune serum globulin),
Histoglob (histamine plus normal se-
rum immunglobulin), Rhoclone (anti
Rho-D immunoglobulin injection),
equine antitoxins/antisera ASVS-Asia
(polyvalent snake antitoxin Asia),
ASVS-Africa, polyvalent snake anti-
toxin Africa equirab, rabies immu-
noserum 1000 I U, AGGS, mixed gas
gangerene antitoxin and thymogam
anti-thymocyte globulin.
BSV is targeting the regulated mar-
kets for its products through technol-
ogy licensing, in order to secure growth
in the future. Since the company has
quite a few potential products in its
portfolio, it is now looking for alliances
with partners for marketing and distri-
bution of similar products. By follow-
ing this model of business alliances and
strategic partnerships, it can signi-
cantly reduce the time required to com-
mercialize these products globally.
BSV is presently looking for partners
who can complement its product de-
velopment skills with the expertise and
resources in getting the products regis-
tered in regulated markets.
In April 2010, Piramal Healthcare
Limited, acquired BSVs injectible
anaesthetic products business. The
former signed a denitive agreement to
acquire Bharat Serums injectible an-
aesthetic products business including,
Propofol, bupivacaine and atracurium
besylate. The acquisition provides Pi-
ramal an immediate entry into the Pro-
pofol market, the worlds largest selling
injectible anaesthetic. As per IMS, the
total market size of Propofol is approxi-
mately $825 million. The market for the
product excluding the European, US
and Japanese region is approximately
$250 million. BSV also received fund-
ing from Malaysian investment rm,
OrbiMed, which would help facilitate
the next stage of growth.
Recently, BSV entered into a licens-
ing agreement with a large European
company for an anti-infective product.
BSV is in exploratory discussions with
pharmaceutical companies for collabo-
ration in commercializing Docetaxel in
markets throughout the world.
CMD
Mr Bharat Daftary
Business
R&D, manufacturing and
marketing of biologicals
Start-up Year: 1971
Address: Hoechst House,
16th Floor, Nariman Point,
Mumbai-400021
Tel: +91-22-66560900
Fax: +91-22-66560901
Website: www.bharatserums.com
Rank
`226 crore
R
e
v
e
n
u
e
CompanyRanking
18
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
2
2
6
1
7
5
1
4
0
1
4
0
1
0
8
.
4
9
Bharat Serums
& Vaccines
Revenue in ` crore
BS
Rank
`210 crore
R
e
v
e
n
u
e
19
Jubilant Life
Sciences
CompanyRanking
Jubilant looks ahead to
robust sales growth
Jubiliant is expecting a huge positive turnaround in
its growth on the back of its life science products,
services and business
J
ubilant Life Sciences Limited
(formerly Jubilant Organosys)
is an integrated pharmaceutical
industry player that provides
custom research and manufacturing
services (CRAMS) and drug discovery
and development services to 60 coun-
tries. The rm boasts of 10 world-class
manufacturing facilities and a team
of around 5,700 personnel across the
globe.
In FY 2010-11 the company recorded
revenue of `3,433 crore in its prod-
ucts business, fueled by a robust vol-
ume growth of 16 percent across all
products. However, the growth in drug
discovery and development solutions
(DDDS) business remained muted.
The business clocked only `210 crore
for FY 2010-11 from the drug discovery
and development services business,
Jubilant reported a decrease of 15.76
percent as compared to `249.3 crore
in FY 2009-10. The company attrib-
uted the decline to delays on boarding
of new integrated programs from key
customers, postponement of milestone
payments and slowdown in clinical re-
search business due to global pharma
consolidation.
The DDDS group within Jubilant
constitutes three of its subsidiaries,
Jubilant Biosys, Chemsys and Clinsys
Clinical Research. The DDDS group
leverages its capabilities in emerging
markets for a global outcome thus ac-
celerating global drug development
efforts. The group employs over 1,000
highly skilled and experienced scientif-
ic and medical personnel spread across
Bangalore and Noida in India, Europe
and the US.
Jubilants therapeutically aligned
clinical development capabilities pro-
vide collaborators a seamless transi-
tion from preclinical, translational and
early stage development. This is further
augmented by Jubilants ability to pro-
vide global access to late stage develop-
ment (phase II-IV) across Europe, US
and India.
Jubilant is highly optimistic regard-
ing its future as its services business is
likely to witness substantial turnaround
in margins and sales growth due to on-
boarding of new projects and strong
order book for products.
In August 2010, the company signed
a long term contract, valued at $51 mil-
lion, in its CRAMS business with a lead-
ing US life science company. Jubilant
also signed a long term contract in its
CRAMS business with another US-based
rm in the same month, with the expect-
ed contract valued at $33 million for the
initial term of four-and-a-half years.
To focus completely on its life sci-
ences business, the company changed
its name from Jubilant Organosys to
Jubilant Life Sciences in Oct 2010 and
subsequently in Dec 2010, the com-
pany went for the demerger of its agri
and performance polymers business.
According to Mr Shyam S Bhartia,
chairman & managing director and Mr
Hari S Bhartia, co chairman & manag-
ing director, Jubilant Life Sciences,
In FY2012, we expect to deliver a ro-
bust sales growth and better margins
across all the businesses on account of
increased capacity utilization, commis-
sioning of new plants, innovation led
new launches and expansion of market
geographies.
MD
Mr Shyam S Bhartia
Business
CRAMS, drug discovery
and development services
Start-up Year: 1978
Address: 1A, Sector 16A,
Noida-201301
Tel: +91-120-2516601-11
Fax: +91-120-2516628-30
Website: www.jubl.com
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
2
1
0
2
4
9
.
3
2
4
2
1
5
9
1
5
4
.
1
0
Revenue in ` crore
BS
Rides on innovation to
maintain steady growth
Eli Lilly sustained a consistent growth in the past year
and has doubled its Indian business operations during
the last five years
E
li Lilly, which established its
Indian operations in 1993 as
a joint venture with Ranbaxy
Laboratories, clocked rev-
enue of `204 crore for the year 2010.
Since its divestiture in 2001, the com-
pany emerged as one of the most ad-
mired organizations in terms of its fo-
cus on scientic selling, unique bouquet
of products and services, professional
working environment and relentless
focus on ethics and compliance.
With the help of a well established
marketing set up at Gurgaon, India,
Lilly provides innovative answers to
the needs of patients of diabetes, can-
cer, sepsis, osteoporosis, cardiovas-
cular disorders and growth hormone
deciency.
Lilly has won numerous accolades in
the past. It was ranked among top 25
companies in the Best Employers in In-
dia survey by Hewitt Associates in 2003.
Eli Lilly also made it to the top 10 Best
Companies to Work for in India in Busi-
ness Today-Mercer-TNS survey 2008.
Lilly was was also ranked the 2nd
best company to work for under Bio-
tech & Pharmaceutical category in
2008: survey by Great Places to Work
Institute, US. Lilly has an unique dis-
tinction of being the only pharmaceuti-
cal company in this list.
Lilly was also recognized for its work
in the eld of pharma ad biotechnology
by the Delhi Government, which felici-
tated Lilly India with a special Award
for Excellence in 2010.
Lilly has seven products in its biotech
stable, including Human Insulin (Hu-
minsulin); human insulin analogues
(Humalog), Human Growth Hormone
(Humatrope), Teriparatide (Forteo);
drotrecogin alfa (Xigris), reopro (Ab-
ciximab-monoclonal antibody) and ex-
enatide (Byetta).
Overall, the rms anti-diabetes
product range contributes roughly 60
percent of the Lilly India revenue. In
October, 2010, Eli Lilly and Company
launched a cardiovascular product
called Efent (Prasugrel) in India.
Efent is an oral antiplatelet (OAP)
agent that has been approved for pa-
tients with acute coronary syndrome
(ACS), who have undergone angi-
oplasty procedures.
The company also launched Huma-
log KwikPen, a pre-lled pen that con-
tains Humalog (Insulin Lispro, rDNA
origin) brand of insulins in April 2010.
Humalog KwikPen requires less force
to administer the injection, provides
users with a smoother injection expe-
rience and is conveniently lighter and
shorter than other pre-lled pens.
On the corporate social responsibility
(CSR) front, the company continues to
work on the global Lilly MDR-TB Part-
nership, which was rst announced in
2003 to confront multidrug-resistant
(MDR) tuberculosis.
Since then, this unique public-pri-
vate partnership, with a total expendi-
ture of nearly $135 million, has mobi-
lized 25 partners on the ve continents
to tackle the scourge of TB and multi-
drug-resistant (MDR) tuberculosis.
The partnership has adopted a multi-
pronged approach in India and works
in close coordination with the National
TB Control Program in India.
CMD
Sandeep Gupta
Business
Solutions in diabetes, on-
cology, osteoporosis and
growth hormones
Start-up Year: 1993
Address: Plot No-92, Sector 32,
Institutional Area,
Gurgaon-122001
Tel: +91-124-2823000
Fax: +91-124-2823012
Website: www.lillyindia.co.in
E
li Lilly
Rank
`204 crore
R
e
v
e
n
u
e
CompanyRanking
20
Revenue in ` crore
BS
2
0
1
0
-
1
1
2
0
0
9
-
1
0
2
0
0
8
-
0
9
2
0
0
7
-
0
8
2
0
0
6
-
0
7
2
0
4
1
8
7
1
6
4
1
4
9
1
1
4
CompanyRanking
Revenue
`202 crore*
Rank
21
Founder & Chairman
Dr Gautam Daftary
Business
Offers clinical Trials
services
Start-up Year: 1996
Address: DIL Premises, Ground
Floor, Swami Vivekanand Rd, Near
Tatwagyan Vidyapeeth, Ghodbhunder
Rd, Thane (W)- 400607
Tel: +91-22-25848000
Fax: +91-22-25848475
Website: www.siroclinpharm.com
Siro Clinpharm
S
IRO Clinpharm Private Limited (SIRO), clocked an esti-
mated sales revenue of `202 crore for FY 2010-11 when
compared with `150 crore in 2009-10. During early 2011, the
CRO announced the launch of its operations in Malaysia and
also announced strategic alliances with CROs in South Korea
and Taiwan in 2010. The company is in the process of evaluat-
ing Philippines and Thailand amongst other Asian countries for
expanding its clinical operations. SIRO has strategic alliances
and partnerships with several rms such as Clingene, Pzer and
with Fisher Clinical services. SIRO is a member of Bundesver-
band Medizinischer Auftragsinstitute, the German Federal As-
sociation of Contract Research Organizations. SIROs laurels in-
clude, conducting over 130 clinical trails, recruiting over 20,000
clincial trial subjects, passing over 240 audits by sponsor QA
teams and working on USFDA, EMEA, UK MHRA, Korean FDA
WHO Health Canada and DCGI submissions.
C
adila Healthcare clocked biotech revenues worth `190.59
crore for FY 2010-11 as compared to the previous scals
revenue of `147.48 crore. Presently, the rm has 15 biosimilars
and two novel products in its pipeline. The company is also look-
ing at biobetters for the future growth and has dedicated 120
scientists for this purpose. Zydus Cadila acquired Italy-based,
Etna Biotech, and the rms Zydus Research Center (ZRC), has
been working on strategic research collaboration with Prolong
Pharmaceuticals, US, and Karo Bio, Sweden and Eli Lilly.
Zydus Cadila has made swift progress on NME research and
has 12 INDs in various stages of clinical trials and several more
INDs in pre-clinical evaluation. The company also signed an
agreement with Bayer HealthCare, in January 2011, to set up a
joint venture company, Bayer Zydus Pharma, for the sales and
marketing of pharmaceutical products in India.
Revenue
`190.59 crore*
Rank
22
CMD
Mr Pankaj R Patel
Business
Biologics & diagnostics
Start-up Year: 1995
Address: Cadila Healthcare Ltd.,
Zydus Tower, Satellite Cross Roads,
Ahmedabad380015
Tel: +91-79-26868100
Fax: +91-79-26862365
Website: www.zyduscadila.com
Cadila Healthcare
Rank
23
T
ulip Group of companies clocked a total revenue of `185.63
crore for FY 2010-11 as against `182.48 crore in FY 2009-
10. Revenues from domestic sales for FY 2010-11 were `128.23
crore, while the rm reported exports worth `57.40 crore. Dur-
ing the scal, the company made investments worth `89.25
crore, including `1.67 crore in R&D, `20.25 crore in infra-
structure and `30.01 crore on manpower. The group has on
its rolls a total staff of 1,033 people and consists of several
individual companies such as Tulip Diagnostics, Microxpress,
Orchid Biomedical Systems, Qualpro Diagnostics, Zephyr Bio-
medicals, Coral Clinical Systems, BioShields, Tulip Marketing,
Crest Biosystems and Lilac Medicare. It also has marketing alli-
ances with companies like Monobind, US; Orgentec, Germany
and TOSOH, Japan. The companys products are distributed
across 55 countries, it has a sales team of 325 personnel, has a
customer base of over 15,000 and has 300 distributors.
Revenue
`185.63 crore
CEO
Dr DG Tripathi
Business
Manufacture &
marketing of in vitro
diagnostic kits
Start-up Year: 1988
Address: Gitanjali, Tulip Block, Dr
Antonio Do Rego Bagh, Alto Santacruz,
Bambolim Complex Post Office, Goa
-403202
Tel: +91-832+2458546-51
Fax: +91-832-2458544
Website: www.tulipgroup.com
Tulip Group
X - GAL - IPTG SPRAY X - GAL - IPTG SPRAY
Bhat BioScan
X - GAL - IPTG
BLUE-WHITE SPRAY
KEY FEATURES
BHAT BIOSCAN (X-GAL-IPTG ) BLUE WHITE SPRAY CONVENTIONAL METHOD

Reagent Single Reagent Spray type
Both X-Gal and PTG has to be weighed
separately, reconstituted and stored @ -20C.
Blue - white Detection
Time
Rapid screening time (15 min) @ 37C after spraying
on to the already streaked plate (16 h).Can also be added
onto LB plates prior to streaking the test organisms.
Should be added to the LB plate prior
to inoculation and incubation.
Cost Effective
Economical, since the reagent is highly sensitive [single
spray (140 l)] is sufficient for screening. More than 75
plates (90 mm) can be screened using this 10 ml reagent.
More expensive/test
Shelf Life Liquid stabilized reagent having a shelf-life of 1 year @ 2-8C Suggested storage at - 20C
BHAT
BIO-TECH
INDIA (P} LTD.
NORGEN,
CANADA
NRL, USA GENEKAM,
GERMANY
TEACHING KIT
TRAINING &
PRO1ECTS
MEDIA
STAINS
MOLECULAR
DIAGNOSTIC
KIT &
REAGENTS
ELETROPHORESIS
SYSTEM
POWER SUPPLY
TRANSILLUMINAOR
SPECTROPHOTO-
METER
ELISA READDER
ELISAWASHER
MICROPIPETTES
LIFE SCIENCE DIVISION
INSTRU-
MENTS (BBI}
micro RNA
RNA
DNA &
PROTEIN
SAMPLE
PREPARATION
PRODUCTS
ULTRA FAST
SILAER STAING
KIT
ULTRA FAST
COOMASSIE
STAINING KIT
GEL DRYING
SYSTEMS &
COMPONENTS
CHEMILUMINES
CENT WESTERN
BLOT KIT
REVERSIBLE
STAIN KIT FOR
WESTERN BLOT
SNCE 1994
Au |SO 9001: 2008,1(48s: 200( o GMP tompauy
CompanyRanking
Rank
G
laxoSmithKline (GSK) Pharmaceuticals, an afliate of
GlaxoSmithKline Biologicals, headquartered in Rixensart,
Belgium, clocked an estimated sales of `163 crore in 2010-11 as
compared to `123.34 crore in 2009-10. Today, GSK has a market
share of 20 percent in the total Indian private vaccine segment.
Vaccines contributed to nine to 10 percent of its total sales in the
current year and in the coming years the company is looking at a
growth of around 15 percent from its vaccines product portfolio.
GSK India has 14 vaccines in its product basket, including Boos-
trix (tetanus toxoid, reduced diphtheria toxoid and acellular
pertussis vaccine, adsorbed) and Cervarix, (human papilloma-
virus vaccine (types 16 and 18)) among others. The companys
vaccine facility in Nasik, Maharashtra, is expected to witness an
overhaul of `100 crore in the next three years. The Nashik facil-
ity also accounts for half of GSKs annual manufacturing capac-
ity for its lymphatic lariasis (LF) programme.
Rank
A
dvanced Enzyme Technologies (AETL) clocked total sales
revenue of `154 crore for FY 2010-11 as compared to `121
crore in 2009-10. The revenue is expected to increase 30 to 35
percent on a year-on-year basis for the next ve to eight years.
The company operates primarily in four segments, including
human health & nutrition, animal nutrition, food processing,
and industrial processing. The company is expected to start its
European and Chinese subsidiaries soon. More than 50 per-
cent of the companys sales come from its exports to 53 coun-
tries. AETL, which had a overhaul in 2009, developed more
than 400 unique enzyme products like luicine amino peptidase
(exo-peptidase), candida antarctica lipase b immobilized, a full
range of hemicellulase and pectinase enzymes and a full range
of grain ethenol enzymes. AETL is also the largest manufac-
turer of serratiopeptidase, having perfected the art of manu-
facturing the enzyme over the past 15 years.
M
onsanto India clocked revenue sales of `161 crore in FY
2010-11 as against `142.4 crore in 2009-10. Monsanto
has been selling Bt cotton hybrids in India for the last ve years
under Monsanto Holdings Private Limited (MHPL). MHPL is
focused on marketing Paras cotton hybrid seeds with Bollgard
and Bollgard Bt cotton technologies and Seminis vegetable hy-
brid seeds. It was estimated that the company sold about 18
lakh packets of Bollgard during the 2010 kharif season, which
is an increase of two lakh as comapred to the same period in
the last year. Monsanto has launched Project SHARE (Sustain-
able Harvest Agriculture, Resources, Environment), a sustain-
able yield initiative with an NGO called the Indian Society of
Agribusiness Professionals (ISAP), to improve the socio-eco-
nomic conditions of 10,000 small-marginal corn and cotton
farmers in 1,100 villages in Andhra Pradesh, Maharashtra and
Rajasthan within four years.
Rank
Monsanto India
Revenue
`163 crore*
24
CEO
Dr Hasit Joshipura
Business
Sales of vaccines and
biologicals
Start-up Year: 2001
Address: Dr Annie Besant Road,
Worli, Mumbai-40030
Tel: +91-22-24959205
Fax: +91-22-24914863
Website: www.gsk-india.com
GlaxoSmithKline Pharmaceuticals
Revenue
`154 crore
26
CEO
Dr CL Rathi
Business
Manufacturing, R&D
and marketing of
enzymes
Start-up Year: 1989
Address: Sun Magnetica, A wing,
5th Floor, LIC Service Road, Louiswadi,
Thane (W)- 400 604
Tel: +91-22-41703200
Fax: +91-22-25835159
Website: www.enzyme.com/
Advanced Enzyme Technologies
Revenue
`161 crore*
Managing Director
Mr Amitabh Jaipuria
Business
Production and sale
of herbicides, hybrid
seeds and pesticides
Start-up Year: 1949
Address: Ahura Centre, 5th Floor,
96, Mahakali Caves Road, Andheri
(East), Mumbai -400 093
Tel: +91-22-28246450
Fax: +91-22-26902121
Website: www.monsantoindia.com
25
Rank
L
ambda Therapeutic Research recorded an estimated sales
revenue of `128 crore for 2010-11. The company offers
services such as clinical trials implementation, laboratory and
data management, information technology support, medical
affairs assistance, quality assurance and bio analysis. The CRO
has more than 640 clinical beds globally, including a 16-bed
phase I unit in Ahmedabad, a 12-bed phase I unit in Toronto,
Canada, a six-bed phase I unit in Warsaw, Poland.
The company also has more than 40 LC-MS/MS systems, a
CAP/NGSP accredited clinical laboratory, molecular and mi-
crobiological laboratory and a low temperature (2-8 C, -20 C
and -80 C) controlled storage facility, to store over 4.0 million
samples. Lambda Therapeutic Research has additional facili-
ties in Mumbai, India and Erwitte, Germany and has acquired
a pharmacovigilance CRO in UK, named Pharm V Solutions.
Rank
E
cron Acunova is a Bangalore-based CRO with ofces across
India and operations in 14 European countries. The com-
pany recorded revenue worth `125 crore in the FY 2010-11 as
compared to `97 crore in FY 2009-10. In January 2011, Ecron
Acunova expanded its clinical research center for drug devel-
opment by 80 beds. The company also announced a joint ven-
ture with Jamjuree Innovations(JJI), Thailand and will con-
duct clinical research in key South East Asian countries under
the name, Ecron Acunova Company Limited (EACL).
In April 2011, Ecron Acunova acquired a majority stake in aC-
ROnordic, a Danish CRO specializing in clinical research in
Sweden, Finland and Norway. Since its inception ve years ago
Ecron has conducted over 250 phase I one studies and over 70
late phase studies, which has helped the company reach the
third position amongst nearly 100 CROs in India.
CompanyRanking
C
oncord Biotech, a R&D-based company that focuses on fer-
mentation and semi-synthetic based products, achieved a to-
tal income of `126.17 crore in FY 2010-11 as compared to `111.07
crore in the previous year. It is the largest producer of penicil-
lin-G amidase enzyme, with a market share of 90 percent. It ex-
ports this enzyme to a number of companies in China, Europe
and the US. Concord also produces and exports lovastatin and
tacrolimus and is also starting the production of simvastatin and
pravastatin in its new US-FDA approved facility. It now boasts
of having one of the largest numbers of bioreactors in India and
has setup a lyophilization facility for sterile bulk biopharmaceu-
tical. It also has a manufacturing facility, spread across 28 acres
of land, located at Ahmedabad, Gujarat. In FY2010-11, Concord
initiated its CRAM business by setting up of its new R&D facility.
The company received award for its outstanding contribution to
the healthcare sector at Bangalore India Bio 2011.
Rank
Revenue
`128 crore*
27
MD
Ms Bindi Chudgar
Business
Clinical trials
implementation,
laboratory and data
management
Start-up Year: 1999
Address: Near Gujarat High
Court, S. G. Highway, Gota,
Ahmedabad-380061
Tel: +91-79-40202020
Fax: +91-79-40202021
Website: www.lambda-cro.com
Lambda Therapeutic Research
Revenue
`126.17 crore
28
MD and CEO
Mr Sudhir Vaid
Business
Manufacturing of bulk
drugs
Start-up Year: 2000
Address: 302, Sakar-III, Opp:
Gujarat High Court, Off ITO Circle,
Ashram Road, Ahmedabad-380014
Tel: +91-79-27544998, 27543557
Fax: +91-79-27540802
Website: www.concordbiotech.com
Concord Biotech
Revenue
`125 crore
29
Founder & Chairman
Mr DA Prasanna
Business
Clinical research
services
Start-up Year: 1986
Address: Manipal Acunova Limited,
Mobius Towers, SJR i-Park, EPIP,
Whitefield, Bangalore-560066
Tel: +91-80-66915700
Fax: +91-80-66915719
Website: www.ecronacunova.com
Ecron Acunova
Rank
T
hemis Medicare (TML) achieved a total turnover of `124
crore as against `90 crore for the year ending March 31,
2010.
TML has a plant located in Hyderabad where lovastatin, simv-
astatin and other fermentation-based actives are produced.
TML boasts of four state-of-the-art manufacturing facili-
ties at three locations, in Vapi (Gujarat), Hyderabad (Andhra
Pradesh) and Haridwar (Uttaranchal). The company has a
joint venture partnership with Gedeon Richter (Budapest,
Hungary), named Richter-Themis Medicare (India) Private
Limited and also has signed a long-term business agreement
with Schering-Plough Animal Health Corporation, US (SPAH).
Although its rst breakthrough product was vitamin B12, TML
moved on to manufacture several synthetic API and numerous
therapeutics.
Rank
V
eeda Clinical Research, is a full service global CRO special-
izing in early clinical development of drugs (phase I and
IIa) with state-of-the-art facilities in the UK, India and Bel-
gium. It recorded revenues of `120 crore during the FY 2010-
11 as against last years revenue of `112 crore, with a growth
of about 7.14 percent. Veeda has been growing at a rate of 70
percent since its inception and aims to achieve a turnover of
`325 crore in the next three years. The rm has acquired four
CROs in Europe and presently houses state-of-the-art phase
I facilities in Plymouth, UK; Ahmedabad, India and Grlitz,
Germany. In October 2010, Veeda announced the opening of
its facility at Ahmedabad, spread across three oors with an
area of 25,000 sq ft. In May 2011, Veeda announced that the
nal steps have been put in place for the commissioning of its
CRC Veeda (Malaysia) phase I unit in the Ampang Hospital in
Kuala Lumpur, Malaysia.
CompanyRanking
D
iagnoSearch Life Sciences, formerly iGate Clinical Re-
search, recorded revenues of `121 crore for 2010-11 as
against previous years revenue of `97 crore. DiagnoSearch has
passed over 100 CQA audits by North American and European
biopharmaceutical companies and offers a complete range of
phase I to IV clinical trials support services. Over the past 12
years, DiagnoSearch managed over 100 clinical trials for global
sponsors in a broad range of therapeutic areas. The company
has a headcount of more than 100 staff and is going to come up
with a new 30,000 sq ft ofce facility. The rms mainly oper-
ates using three divisions, namely, clinical operations, moni-
toring and the project management division. The rm has a
central laboratory that offers comprehensive solutions includ-
ing, production of bar-coded, visit-specic kits, investigator
team training, state-of-the-art analytical methods, efcient
specimen shipment and automated data reporting.
Rank
Revenue
`124 crore*
30
MD and CEO
Dr Dinesh Patel
Business
Formulations and API
of synthetic origin
Start-up Year: 1969
Address: 11/12, Udyog Nagar,
S.V.Road, Goregaon (West),
Mumbai-400 104.
Tel: +91-22-67607080, 28757836
Fax: +91-22-28746621
Website: www.themismedicare.com
Themis Medicare
Revenue
`121 crore*
31
Founder and MD
Dr Vasudeo Ginde
Business
Offering a complete
range clinical trials
support services
Start-up Year: 1975
Address: 101, First Floor, B G
House, Orchard Avenue, Hiranandani,
Business Park, Mumbai-400076
Tel: +91-22-66976300
Fax: +91-22-66754090
Website: www.diagnosearch.com
DiagnoSearch Life Sciences
Revenue
`120 crore
32
Founders & MDs
Mr Apurva Shah
& Mr Binoy Gardi
Business
Specializes in
early clinical
development
Start-up Year: 2005
Address: Veeda Clinical
Research India, Shivalik
Plaza-A, Near IIM, Ambawadi,
Ahmedabad- 380015
Tel: +91-79-30013000
Fax: +91-79-30013010
Website: www.veedacr.com
Veeda Clinical Research
(formerly iGATE Clinical Research)
Rank
I
ntas Biopharmaceutical (IBPL) clocked revenue of `110 crore
in FY 2010-11 as compared to `115 crore in the previous FY.
Intas Pharmaceuticals, IBPLs parent compnay has led its red
herring prospectus (DRHP) with SEBI and is looking to raise
`425 crore. The rm has presently developed and commercial-
ized ve products in India and other semi-regulated markets
in Africa, Latin America and Asia Pacic and has an additional
11 projects at advanced stages of development, out of which,
nine projects are for the Indian market and two are for regu-
lated markets. IBPL also intends to invest `15.33 crore at the
Moraiya facility. The company launched bortezomib injection,
under the brand name Borviz, which is expected to offer an ef-
fective treatment for multiple myeloma. The company will also
invest `160 crore towards setting up a manufacturing facility
at Sanand, near Ahmedabad, to produce monoclonal antibod-
ies with a capacity of 5,000 liter in phases.
Rank
V
imta Labs, one of Indias leading contract research and
testing organization, reported a revenue of `96.5 crore in
FY 2010-11 as compared to `88.42 crore in 2009-10.
The company employs 756 personnel, including 479 scientists,
and boasts of more than 300,000 sq ft of world class labora-
tory facilities. Vimta Labs achieved AAALAC International full
accreditation in February, 2011, and the company conducts its
operations in compliance with ICH-GCP and GLP. The com-
pany has a large bioanalytical group, equipped with 26 mass
spectrometers across two sites, operational round the clock.
Over 200 bioanalytical methods have been developed and vali-
dated at Vimta Labs and the rm conducted over 1,100 BA/BE
studies on various dosage forms such as tablets, capsules, ex-
tended release preparations, gels, jellys, solutions, transder-
mal patches and injectibles among others.
CompanyRanking
D
iagnova is the diagnostic division of RFCL, which is now part
of US-based Avantor Performance Materials. In FY 2010-
11, Diagnova recorded a sluggish growth with revenues of `103
crore as compared to `100 crore in the FY 2009-10. This rms
manufacturing plant is situated in Dehradun, Uttarakhand, and
the company offers quality products and services to over 6,000
customers. The business of Diagnova is divided into three stra-
tegic units: In Vitro Diagnostics (IVD), Medical Sciences Group
(MSG) and Life Sciences Group (LSG). Diagnova has an ISO cer-
tied manufacturing setup for IVD products based at Haridwar,
Uttaranchal. The MSG Group of Diagnova markets medical de-
vices in the eld of gastroenterology with a product prole that
covers ph & motility systems, breath test analyzer, cardiac sur-
veyor and surgical staplers among others. The LSG group offers
solutions for the molecular biology segment and emerging areas
like protein crystallography & drug discovery.
Rank
Revenue
`110 crore*
33
CEO (MD)
Dr Urmish Chudgar
Business
R&D, manufacturing
& marketing of
recombinant products
and oncology drugs
Start-up Year: 2006
Address: Plot No 423/P/A/GIDC,
Moraiya, Sarkhej-Bavla highway, Tal:
Sanand, Ahmedabad-382210
Tel: +91-2717-660101
Fax: +91-2717-251189
Website: www.intasbiopharma.co.in
Intas Biopharmaceuticals
Revenue
`103 crore
34
MD
Mr Sushil Mehta
Business
Diagnostics
Start-up Year: 2005
Address: A-3, Okhla Industrial Area
Phase-I, New Delhi-110 020
Tel: +91-11-42395700
Fax: +91-11-41609189
Website: www.rfcl.in/dignova,
www.diagnova.in
Diagnova (A division of RFCL)
Revenue
`96.5 crore*
35
CMD
Dr S P Vasireddi
Business
Contract research
Start-up Year: 1984
Address: 142, IDA,Phase II,
Cherlapally, Hyderabad-500 051
Tel: +91-40-27264141
Fax: +91-40-27263657
Website: www.vimta.com
Vimta Labs
For more details, contact
Rank
S
pan Diagnostics clocked an estimated revenue of `92.53
crore for FY 2010-2011, as against `78.98 crore for 2009-
10. The company, which has been supplying to Indias national
programmes for AIDS and malaria since the past eight years,
achieved tender sales worth `28 crore from the Indian gov-
ernment during the past year. Span currently houses three
businesses namely, the diagnostic reagent business, the in-
struments business and exports, and boasts of a joint venture
with Japan-based, Nihon Kohden corporation. The company
is looking to modernize its plant by investing `12 crore over a
period of one-and-half years. The company expects to grow at
a rate of 17 to 20 percent in 2011, following which, Span antici-
pates hitting a growth rate of 25 to 30 percent. This condence
is due to the launch of a number of products by 2012 along
with an increase in export sales. Span is looking to achieve a
turnover of `1,000 crore by 2020.
Rank
I
n the FY 2010-2011, the vaccine business of Novartis in
India clocked `89.65 crore. In India, Novartis and Aventis
Pharma had a 51:49 joint venture in Chiron Behring Vaccines,
in which the former had marketing rights of the laters anti-
rabies vaccine, Rabipur, in India.
However in December 2010, Aventis Pharma sold off its 49
percent stake in the joint venture to Novartis Vaccines and
Diagnostics (NV&D) for around `100 crore. Novartis Vaccines
and Diagnostics division s portfolio includes some prominent
inuenza and meningitis vaccines and travel vaccines.
In the rst half of 2010, the division globally completed the
distribution of A(H1N1) vaccine.
Now, work has started for developing pre-pandemic vaccines
that would provide protection to the global population against
possible future pandemics.
CompanyRanking
A
ventis Pharma clocked an estimated sales of `90 crore in FY
2010-11 when compared with `68.34 crore in FY 2009-10.
The company has consolidated its position in the growing insulin
market with its star product Lantus, which has a market share
of 10.24 percent, showing a growth of nearly 30 percent. Other
insulin brands including Amaryl and Apidra witnessed a growth
of 29 percent and 100 percent respectively. During the FY, the
company sold off its entire shareholding in the joint venture
company, Chiron Behring Vaccines Private to Novartis Pharma
for `100.7 crore. The company reduced the price for its mono-
component insulin, Lantus, by 2.8 percent as per the direction
from the National Pharmaceutical Pricing Authority (NPPA)
from `2,439.27 for a 10 ml vial of Lantus 100 IU/ml to `2,370.49.
The company also has several community service initiatives like
the SOS Childrens villages, Childline, the Akansha Foundation,
Voluntary Health Association of Goa and the Joy of Giving.
Rank
Revenue
`92.53 crore*
36
Founder and Chairman
Dr Pradip Desai
Business
Provider of diagnostic,
instruments & clinical
chemistry products
Start-up Year: 1976
Address: 173- B ,New industrial
Estate, Udhna, Surat 394210,
Gujarat
Tel: +91-261-2277211
Fax: +91-261-2279319, 2665757
Website: www.span.co.in
Span Diagnostics
Revenue
`90 crore*
37
MD
Dr Shailesh Ayyangar
Business
Marketing of biotech
products
Start-up Year: 1956
Address: Aventis House, 54/A, Sir
Mathuradas, Vasanji Road, Andheri
East, Mumbai-400093
Tel: +91-22-28278000
Fax: +91-22-28370939
Website: www.aventispharmaindia.
com
Aventis Pharma India
Revenue
`89.65 crore*
38
Country Head, India
Mr Masood Alam
Business
Healthcare, vaccines
and diagnostics
Start-up Year: 2006
Address: Novartis India Limited,
Sandoz House, 8th floor, Shivsagar
Estate, Dr Annie Besant Road, Worli,
Mumbai - 400 018, India
Tel: +91-22-24958804, 24951074
Fax: +91-22-2495 2624
Website: www.novartis.in
Novartis Vaccines (India)
Rank
A
jeet Seeds, a producer and processor of hybrid cottonseeds
in India, generated a revenue of `87.5 crore in 2010-11. The
company received approval from the Genetic Engineering Ap-
proval Committee (GEAC), Government of India, for the sale
of Bollgard I (Ajeet 33, Ajeet 155, Ajeet 177), Ajeet 901 (HxB),
ACH 21 (Arya 21 Bt) and Bollgard II (Ajeet-11, Ajeet 155, Ajeet
33), ACH 177 (Arya 177 BG II, Ajeet 111), ACH 5 (Arya 21 BG II)
cotton hybrids in Central, South and North zones in 2006.
The company has developed its own genetic resources of
hybrid seeds in cotton, jowar, bajra, maize, chilli, okra and
pigeon pea. The company has established a wide network of
400 distributors, 3,000 dealers and more than 30,000 seed
growers all over India. The company is gearing up to launch
its indigenous transgenics in okra & cotton that would offer
resistance to biotic and abiotic stress.
Rank
T
he total biotech revenue of Dr Reddys Laboratories in FY
2010-11 has grown to `82.5 crore from `62.5 crore in FY
2009-10. The company sells three biologic products, including
Grafeel, Peg-grafeel (generic Filgrastim) and Reditux (generic
Rituximab) and has 11 biosimilars in various stages of develop-
ment and commercialization. Peg-grafeel, which was launched in
May 2011, is priced at `8,865, thus representing a breakthrough
in the pricing of this complex molecule. The company has a fully
integrated biosimilar development team including R&D, clinical
operations, medical affairs and global pharmacovigilance and
has a WHO certied cGMP manufacturing facility. Its core busi-
nesses are pharmaceutical services and active ingredients, ge-
nerics and proprietary products. Dr Reddys completed the ac-
quisition of GlaxoSmithKlines (GSK) US-based oral penicillin
facility in Bristol, Tennessee on Nov 23, 2010 and has got rights
for the sale of Augmentin and Amoxil brands in the US.
CompanyRanking
H
affkine Bio-Pharmaceutical Corporation (HBPCL) is en-
gaged in the manufacture and supply of a wide range of
products comprising bacterial and viral vaccines, antisera,
toxoids injectables, disinfectants, ointments, injectables, syr-
ups and mixtures. The rm clocked an annual sales revenue
of `86 crore for 2010-11 against last years `168.98 crore. The
rms total group turnover, comprising Haffkine Ajintha Phar-
maceuticals and Antitoxin and Sera is over `100 crore. The
Antitoxin and Sera (ATS) department of HBPCL is located at
Pimpri, near Pune, and it is engaged in the manufacture of an-
tiserum against tetanus, diphtheria, gas gangrene, snake and
scorpion venoms. The ATS operates on 75 acres of land with a
total strength of 400 equines. HBPCL has supplied oral polio
vaccines to UNICEF and the Government of India. The compa-
ny is also planning to build manufacturing facilities complying
with the WHOs GMP standards for DTP/pentavalent vaccine.
Rank
Revenue
`87.5 crore*
39
MD
Mr Sameer Mulay
Business
Research, production,
processing and
marketing of hybrid
seeds
Start-up Year: 1986
Address: Tapadia Terraces, 2nd
Floor, Adalat Rd, Aurangabad- 43100
Tel: +91-240-2333933
Fax: +91-240-2333335
Website: www.ajeetseed.co.in
Ajeet Seeds
Revenue
`86 crore
40
MD
Mr P R Sabde
Business
Production and supply
of biopharmaceutical
products
Start-up Year: 1975
Address: Acharya Donde Marg,
Parel, Mumbai - 400012
Tel: +91-22-24129320
Fax: +91-22-24168578
Website: www.vaccinehaffkine.org
Haffkine Bio-Pharmaceutical
Corporation
Revenue
`82.5 crore*
41
Vice Chairman and CEO
Mr G V Prasad
Business
Biopharmaceuticals
Start-up Year: 1984
Address: 7-1-27, Ameerpet,
Hyderabad-500016
Tel: +91-40-23731946
Fax: +91-40-23731955
Website: www.drreddys.com
Dr Reddys Laboratories
Rank
A
nthem Biosciences, a Bangalore-based discovery research
alliance partner (DRAP ) dedicated to supporting research
efforts in the discovery of new compounds by pharmaceuti-
cal, biotechnology, specialty chemicals, agriculture chemicals
and material science companies, registered a growth of 47.17
percent in 2010-11 as its revenue touched `78 crore. In 2009-
10, the company reported revenue worth `53 crore. Anthem
Biosciences has adopted several business models like full time
equivalent (FTE) and project basis, depending on the complex-
ity of the task and project. This has helped the company wit-
ness a signicant growth since its inception in 2007. Presently,
Anthem employs more than 200 people. Apart from modern,
well equipped laboratories, the company has a cGMP kilo lab
and a versatile GMP pilot plant. In the eld of discovery re-
search, the rm provides services for generation of hits, trans-
forming hits to leads and optimization of leads.
Rank
R
ossari Biotech clocked an estimated total revenue sales of
`72 crore in FY 2010-11 as compared to `55.38 crore in
2009-10. It is an ISO 9001: 2000 company and manufactures
enzymes for textile processing, high concentrates and standard
formulations of neutral cellulose, acid cellulose, engineered acid
cellulose amylases, high temperature stable amylases and mul-
tizyme formulations for bioscouring, wool and silk processing
and print washing. It exports its products to several countries
including, Sri Lanka, Bangladesh, UAE, Australia, Malaysia,
Kenya, New Zealand, Jordan, China, Venezuela and Nepal. Ros-
saris new product range includes Flameshield, Fragma, Hydro-
gard, Snocool and Fabshield. Rossari set up an R&D center for
biotechnology at Navi Mumbai to explore the potential of new
molecules and manufacture new products as well as to optimize
the processes. It has entered into collaborations with rms and
is looking at nutraceuticals as a potential growth area.
CompanyRanking
W
yeth India, a subsidiary of Pzer India, clocked an estimat-
ed revenue of `73.35 crore. In 2010, Prevenar 13 (manu-
factured by Wyeth and marketed by Pzer) was launched in In-
dia, as advanced pneumococcal conjugate vaccine for infants and
young children. However, the price of this advanced product is
the same as its predecessor, Prevenar 7-`3,800 for a single dose.
Presently, Prevenar 13, has been launched in 30 countries and
registered in 98 countries. Wyeth has been in talks with the In-
dian Government to include the vaccine in the National Immu-
nization Programme. It has a strong presence in oral contracep-
tives, folic acid, depilatory cream, hormone therapy and invasive
pneumococcal vaccines. Enbrel, a breakthrough treatment for
rheumatoid arthritis; Rapamune, an immuno suppressant for
the prevention of rejection after renal transplant, and Tygacil,
the worlds rst glycilcycline antibiotic, are among internation-
ally known products launched by Wyeth in India.
Rank
Revenue
`78 crore
42
CEO
Mr Ajay Bharadwaj
Business
Discovery services,
nutritional products,
enzymes
Start-up Year: 2007
Address: 49, Canara Bank Road,
Bommasandra Industrial Area Phase I,
Hosur Road, Hebbagodi,
Bangalore 560037
Tel: +91-80-66724000
Fax: +91-80-266724020
Website: www.anthembio.com
Anthem Biosciences
Revenue
`73.35 crore*
43
MD
Mr Kewal Handa
Business
Biologics, animal
healthcare products &
consumer healthcare
Start-up Year: 2003
Address: Level 6&7, Platina, Plot
no C-59, G Block, Bandra-Kurla
Complex, Bandra East, Mumbai
-400098
Tel: +91-22-24935211
Website: www.wyethindia.com
Wyeth India (now a subsidiary of Pfizer India)
Revenue
`72 crore*
44
Director
Mr Sunil Chari
Business
Production and
marketing of industrial
enzymes
Start-up Year: 1997
Address: 401 Omega, Main St,
Hiranandani Gardens, Powai, Mumbai
- 400076
Tel: +91-22-25709200 / 01
Fax: +91-22-25709210
Website: www.rossari.com
Rossari Biotech
Rank
O
cimum Biosolutions witnessed a decline in its revenue
from `76 crore in 2009-10 to `65 crore in 2010-11.
Ocimum offers solutions spanning bioresearch design and
execution data analytics and insights; laboratory, sample and
data management; and integrated solutions. Ocimum received
funds worth `36.12 crore from its existing shareholders, in
order to cater to the growing demand for its integrated ge-
nomic services and to enhance its Research as a Service (RaaS)
platform. Part of the funds would be utilized for completing a
state-ofthe art integrated campus in Patancheru, Hyderabad,
a 360,000 sq ft facility spread across four blocks. Last year,
Ocimum also started providing BioIT Consulting Services to
help life science organizations in their R&D. It also launched
its quantitative real-time polymerase chain reaction (qRT-
PCR) services in India. This technology is already in use at
Gene Logic, an Ocimum Biosolutions company.
Rank
J
K Agri Genetics Limited (JKAL), an erstwhile division of JK
Tyre & Industries, clocked a total turnover of `50.66 crore in
2010-11 when compared with the last years revenue of `32.50
crore. The company is focused on R&D, production, processing
and marketing of hybrid seeds of sorghum, pearl millet, maize,
cotton, rice, sunower, tomato, okra and hot pepper. There are
many hybrids marketed by the company, including fast-mov-
ing hybrids such as JK 99, JK Durga, JK 666, JK Indra, JK Va-
run (555), JK Chamundi. The rm has a team of 15 committed
scientists working on different areas of biotechnology. JKAL is
planning to diversify its research into medicinal and aromatic
plants in core activities such as cultivation, contract farming,
varietal development, quality extract production and chemical
& DNA nger printing. JKAL is building up its R&D as well
as marker-assisted selection with novel traits with the help of
biotechnology tools.
CompanyRanking
S
ynchron Research Services reported an estimated revenue
of `63 crore in 2010-11 as compared to previous years
estimated revenue of `57 crore. It is a leading CRO in India,
which provides a broad range of clinical research services from
phase I to phase IV, including bioavailability, bioequivalence,
pharmacokinetic, pharmacodynamic studies, dermato-phar-
macokinetics, bioanalysis, statistical analysis, data manage-
ment and pharmacovigilance. It has a 30-bed facility in Bangkok
called Bio-Innova Synchron Research to serve the Asia Pacic
region, which was formed by a joint venture between Bio-inno-
va and Synchron Research. Synchron also acquired Innovance,
an Ahmedabad-based start-up CRO having a clinical research
facility. The new clinical facility is spread across 18,000 sq ft on
a single oor, with three different volunteer housing areas. The
new 80 beds will be an addition to the already existing 90 beds
in the existing facility, thus totaling to 200 beds across Asia.
Rank
Revenue
`65 crore
45
CEO
Ms Anu Acharya
Business
Bioinformatics tools
and services
Start-up Year: 2000
Address: 6th Floor, Reliance
Classic Road No. 1, Banjara Hills,
Hyderabad - 500 034.
Tel: +91-40-66986700
Fax: +91-40-66627205
Website: www.ocimumbio.com
Ocimum Biosolutions
Revenue
`63 crore*
46
CMD
Dr Shivprakash
Business
Provides clinical
research services from
phase I to phase IV
Start-up Year: 1998
Address: The Chambers, 3rd
Floor, Sarkhej-Gandhinagar Highway,
Bodakdev, Ahmedabad - 380 054
Tel: +91-79-26853419, 26840427
Fax: +91-79-26853415
Website: www.synchronresearch.
com
Synchron Research Services
Revenue
`50.66 crore
47
President
Mr P S Dravid
Business
Involved in R&D and
marketing of agri
biotech products
Start-up Year: 1989
Address: 1-20-177, 4th Floor,
Varun Towers, Begumpet, Hyderabad-
500016
Tel: +91-40-66316858
Fax: +91-40-27764943
Website: www.jkseeds.net
JK Agri Genetics
W
ockhardt, the rst company in Asia to launch its recombi-
nant human insulin product, Wosulin, in 2003, recorded
an estimated biotech revenue of `50 crore for 2010-11. In Feb
2011, Wockhardt entered into a strategic global alliance with
Shefeld Bio-Science, a Kerry Group Business from the US,
under which the latter will have exclusive sales and distribu-
tion rights to supply the recombinant insulin to the cell culture
markets worldwide. Wockhardt announced in 2009 that it was
experiencing liquidity crisis and was reportedly facing a debt
burden of more than `3,000 crore. Following this, there were
talks that the company would sell its biotech division. Compa-
nies like Pzer and Sano Aventis were on the run to acquire
this unit, and its valuations reached a whopping `250 crore.
Presently, the rms R&D is based in Aurangabad & Mumbai;
Negma Laboratories in France; Morton Grove Pharmaceuti-
cals in Illinois, US; Pinewood, Ireland and in UK.
Rank
Rank
C
linigene International, the full service clinical research
arm of biotech major, Biocon, registered a turnover of `43
crore in FY 2010-11 as compared to `39 crore in the FY 2009-
10. In the year 2010, studies conducted by Clinigene were suc-
cessfully audited by the USFDA and EMA without Form 483 or
critical ndings. In addition to the standard service platforms,
the company has identied several more specialized areas,
such as patient-based early studies, complex BA/BE studies
and bio-analytical services, where customers are now seek-
ing CRO support. The new areas of focus for Clinigene include
biomarker development, data management and pharmacovigi-
lance. Clinigene is Indias rst CAP accredited central labora-
tory and has also received NABL accreditation. The company
has evolved and adapted its capability platforms and service
offerings against a background of continued macro market
pressures.
CompanyRanking
Rank
M
ax Neeman International, a subsidiary of the Max India
Group, registered a growth of 21 percent from `40 crore
in FY 2009-10 to `48.4 crore in FY 2010-11. The rm offers
a full range of clinical research services with focus on phase
I-IV trials for drugs, devices, nutraceuticals and cosmetics in
compliance with ICH GCP standards. It is based out of six re-
gional ofces and has 175 active sites in 22 cities, with access
to over 900 GCP trained investigators. Max Neeman is a ISO
9001:2008 and ISO 27001 certied organization. The number
of trials of the rms reached 200 and the CRO has a total cli-
ent base of 65 companies across the globe. Max Neeman has
consistently maintained a patient retention rate of above 98
percent across multiple therapeutic areas for all its studies.
Max Neeman successfully completed four FDA audits for the
highest enrollment globally and has been successfully audited
around 40 times by the sponsor companies.
Revenue
`50 crore*
48
Chairman
Mr Habil F Khorakiwala
Business
Pharmaceutical and
biotechnology business
Start-up Year: 1960
Address: Wockhardt Towers,
Bandra Kurala Complex, Bandra (East),
Mumbai-400051
Tel: +91-22-26596258
Fax: +91-22-26596801
Website: www.wockhardt.in
Wockhardt
Revenue
`48.4 crore
49
CEO
Dr Ajoy Kumar
Business
Clinical research
services
Start-up Year: 2001
Address: Max House, 1 Dr Jha
Marg, Okhla III, New Delhi-110020
Tel: +91-11-40772100
Fax: +91-11-28322846
Website: www.neeman-medical.
com
Max Neeman International
Revenue
`43 crore
50
COO
Dr Abhijit Barve
Business
Clinical research
Start-up Year: 2000
Address: Clinigene House, Tower 1,
Semicon Park, Electronic City, Phase II,
Bangalore-560100
Tel: +91-80-28082808
Fax: +91-80-28083150
Website: www.clinigeneintl.com
Clinigene International
* BioSpectrum estimates
Top 50 Life Science Companies by Revenue (Overall)
Rank Company
Revenue in
`Crore
Change
over
2009-10 (%)
2010-11 2009-10 2011 (%)
1 Biocon 1483.00 1180.00 25.68
2 Serum Institute of India 1041.00 850.00 22.47
3 Panacea Biotec 928.41 703.10 32.05
4 Nuziveedu Seeds 610.00 476.86 27.92
6 Quintiles India* 476.25 375.00 27.00
7 NovoNordisk 462.00 362.00 27.62
8 Rasi Seeds 371.88 358.78 3.65
9 Mahyco* 364.90 312.00 16.96
10 Transasia 350.00 186.00 88.17
11 Ankur Seeds 325.00 109.50 196.80
12 Syngene International 318.00 252.00 26.19
13 Bharat Biotech * 298.34 271.66 9.82
14 Indian Immunologicals 283.00 272.75 18.65
15 Krishidhan Seeds 276.13 133.23 107.26
16 Shantha Biotech* 272.00 334.23 -18.62
17 Novozymes South Asia * 242.00 224.00 8.04
18 Bharat Serums 226.00 175.00 29.14
19 Jubilant Life Sciences 210.00 249.30 -15.76
20 EliLilly 204.00 186.72 9.25
21 Siro Clinpharm* 202.00 150.00 34.67
22 Cadila Healthcare* 190.59 147.48 29.23
23 Tulip Group 185.63 182.48 1.73
24 GlaxoSimtheKline * 163.00 123.34 32.16
25 Monsanto* 161.00 142.00 13.38
26 Advanced Enzymes 154.00 121.00 27.27
27
Lambda Therapeutic
Research *
128.00 145.00 -11.72
28 Concord Biotech 126.17 111.07 13.60
29 Ecron Acunova 125.00 97.00 28.87
30 Themis Medicare* 124.00 90.00 37.78
31
Diagnosearch Life
Sciences *
121.00 97.00 24.74
32 Veeda Clinical Research 120.00 112.00 7.14
33 Intas Biopharma* 110.00 115.00 -4.35
34 RFCL (Diagnova) 103.00 100.00 3.00
35 Vimta Labs* 96.50 88.42 9.14
36 Span Diagnostics* 92.53 78.98 17.16
37 Aventis Pharma* 90.00 68.34 31.69
38 Novartis* 89.65
39 Ajeet Seeds* 87.50 103.00 -15.05
Rank Company
Revenue in
`Crore
Change
over
2009-10 (%)
2010-11 2009-10 2011 (%)
40 Haffkine Biopharma 86.00 168.98 -49.11
41 Dr Reddys Laboratories* 82.50 62.50 32.00
42 Anthem Biosciences 78.00 53.00 47.17
43 Pfizer (Wyeth India)* 73.35 53.00 38.40
44 Rossari Biotech* 72.00 55.38 30.01
45 Ocimum Biosolutions 65.00 76.00 -14.47
46
Synchron Research
Services*
63.00 57.00 10.53
47 JK Agrigenetics 50.66 32.50 55.88
48 Wockhardt* 50.00 60.00 -16.67
49
Max Neeman
International
48.40 40.00 21.00
50 Clinigene 43.00 39.00 10.26
51 Strand Life Sciences 42.00 35.00 20.00
52 Hester Biosciences 41.97 37.53 11.83
53 Indovax 38.74 36.94 4.87
55 Nath Seeds 27.49 22.10 24.39
56 Celestial Labs* 27.35 24.62 11.09
57 Suven Life Sciences 24.48 33.50 -26.93
58 Zytex 21.00 18.00 16.67
59 Semler Research India 19.70 3.80 418.42
60 Maps (India) 19.60 19.10 2.62
61 Shreya Life Sciences* 15.00 18.00 -16.67
62 Mutliplex Biotech* 14.00 13.00 7.69
63 Excel Industries 12.13 8.24 47.21
64 Bhat Biotech 12.11 12.04 0.58
65 Metahelix 11.00 6.00 83.33
66 Zenotech Laboratories 8.56 6.57 30.29
67 Richcore Life Sciences 7.34 3.91 87.72
68
Vivan Life Sciences
(formerly Varda)
4.15
69 ARA Heathcare 4.00
70 Polyclone BioServices 4.00
71 Transgene BioTek 3.98 4.04 -1.49
72 Abexome 3.70
73 Imgenex 3.00
74 Inbiopro 3.00
75 Navya Biologicals 2.50
76 Xcyton 1.50
77 Bejo Sheetal Seeds 1.30
78 Geschickten 0.65
CompanyRanking
BioSpectrum-ABLE Survey
Records the Biotech
Industry Pulse
This is the 9th year that BioSpectrum & ABLE have collaborated to track the
biotechnology industry growth in India. This yearly survey is eagerly awaited
by all the stakeholders interested in the status report and growth opportuni-
ties in this vibrant knowledge-based industry.
It is clear from the revenue statistics that the trend of growth in this industry
has continued and the industry has crossed `18,000 crore or $4 billion in dol-
lar terms, posting a 21 percent growth over previous years revenues of over
`14,000 crore (approx $3 billion).
However, despite the expectations, the industry has not touched $5 billion
yet perhaps the after effects of the severe recession in 2008 are still being
felt globally.
Established Players & New Entrants
It is interesting to note the overall ranking in this sector. While the top players
have maintained their positions with Biocon, Serum & Panacea leading the
way, Transasia and Ankur Seeds have posted exponential growth gures to
leapfrog to 10th & 11th position respectively. Continuing the trend of growth
in the seed business, Krishidhan Seeds has also climbed to join the top 20
rms.
Other biotech SMEs that have shown incredible growth over the last year are
Anthem Biosciences, JK Agrigenetics, Metahelix, Bayer Cropscience, Ecron
Acunova and Semler Research. Surprisingly though, many established play-
ers have seen a fall in revenues such as Shantha Biotech, Jubilant Life Sci-
ences and Suven Life Sciences.
The Southern-Western Leadership
The southern region is slightly ahead of the western region in terms of total
Dr Satya Dash is the
COO of Association
of Biotechnology Led
Enterprises (ABLE),
the pan Indian apex
biotechnology industry
body. He is based out of
Bangalore, India
Dr Satya Dash
Indian biotech firms are globalizing and
strategically partnering with other firms the
Pfizer-Biocon and Glenmark-Sanofi deals are
indicators of the kinds of new partnerships to
emerge
BioColumn
share of revenues, however, the south comfortably leads
in the number of rms (172 vs 137). Bangalore and Hyder-
abad are leading the way and the recent announcement of
building a cluster and incubator in Bangalore will help
maintain the leadership of this region. The north cluster
follows at the third spot but hopefully new clusters, es-
pecially in the NCR, will help close the gap in the future.
What is revealing is, that despite possessing huge bio-re-
sources and many leading institutions, the eastern part
of India is lagging in terms of proper biotech enterprises.
The states of Bihar, West Bengal, Orissa, Assam and the
North East need a focused strategy to seed bio-
tech enterprises.
The survey shows that there are now 362 rms
in India that are focussed on some aspects of
biotechnology. This is an important indica-
tor. The vibrancy of a knowledge intensive and
highly regulated industry such as biotech depends on the
number of new start-up rms that are establishing and in-
jecting fresh business ideas, solutions, and products built
on innovation. What do we need to have in policy terms
to say that India can treble the number of innovative bio-
tech rms in the next ve years to cross the one thousand
mark? How do we make the biotech landscape investor
friendly and ease the burden of establishing and operat-
ing start-ups? Indeed for the sector to grow even further
several concomitant factors have to be addressed:
Streamlining Regulation: Regulation that enables
innovation is the key. ABLE facilitated, as Knowledge
Partner a regulatory session at Bangalore INDIA BIO
last month. What became clear from discussions there
as well as from all other fora is, that Industry will like to
have a scientic evidence-based, clear and non-ambigu-
ous, streamlined and transparent regulatory mechanism
where procedural delays are minimized and technical
considerations are dealt with by expert committees that
are not created on an ad-hoc basis.
For India to achieve a leadership position in biotechnolo-
gy, this is foremost in all sectors of biotechnology, i.e., bi-
opharma (including diagnostics & devices), agri-biotech
and industrial biotech including food & nutrition. Indeed,
it goes without saying that investor condence is directly
linked to a clear and streamlined regulatory landscape.
Early Stage Funding
The unique nature of this sector necessitates very early
stage funding especially at the pre-prototype stage, for
this is where the risks are at their highest for both big and
small biotech rms alike. While SBIRIs and BIPPs have
injected much-needed early stage funding, India has to
nd a mechanism to scale-up these funding mechanisms.
The recent DBT-Wellcome Trust initiative in R&D for
affordable healthcare is indeed a step in the right direc-
tion. Another important bottleneck has been the DSIR
certication criteria for access to these funding schemes.
Perhaps streamlining the DSIR
certication process such that
valuable time and energies are
not lost for rms will go a long
way.
Access to Technology
Resources
Common access to efciently-
run technology platforms for the
industry is crucial as it saves cost
and time while it allows rms to
conduct cutting edge develop-
ment of products.
The Future Ahead
Indian biotechnology industry is showing signs of consis-
tent and mature growth in the 20 percent range. It has
done well despite the global recession. Indian biotech
rms are globalizing and strategically partnering with
other rms the Pzer-Biocon and Glenmark-Sano
deals are indicators of the kinds of new partnerships to
emerge.
It is clear that vaccines, diagnostics and devices along
with biosimilars will be key growth areas in biopharma.
The agri-biotech sector is poised to grow especially, the
seed business in the area of new hybrids. Regulatory clar-
ity in both biopharma/healthcare & agribiotech will be
crucial for the future. There is a perceptible dynamism in
systems biology (or BioIT) rms that are building predic-
tive models, both disease and organ models, and enabling
drug discovery research.
The growth potential of BioIT rms in India built on In-
dias strengths in IT and biology remains high. The CRO
industry has become highly competitive and many CROs
now have to show unique differentiation other than cost
arbitrage. Many CROs have chosen to follow a risk-shar-
ing model for growth to transition themselves into drug
discovery rms. While this transition might take years it
is a positive trend for the industry.
BioColumn
Regulation that enables
innovation is the key for
India to achieve a leadership
position in biotechnology
BS
T
he government of Denmark is looking to
attract Asian life science companies to in-
vest in Denmark, especially in the eld of
R&D. In a recent media visit organized by
Invest in Denmark, an investment promotion agen-
cy which is a part of the Ministry of Foreign Affairs,
Denmarks health minister Mr Bertel Haarder told Bio-
Spectrum that his government is working on several leg-
islations aimed at attracting private investments from
Asian countries, particularly from India and China.
It is noteworthy that Denmark will hold the presidency
of the European Union in the rst half of 2012, and ac-
cording to Mr Haarde, the health and life sciences indus-
try is one of the top agendas of his government. Under
the Health Innovation plan, the Danish government
is working on a legislation that would reduce the re-
view period of clinical trials in Denmark from 30 days
(fastest in Europe) to a minimum of seven days. Mr
Haarder believes that setting up research centers in
Denmark will help Indian companies get European
approvals, as the infrastructure in Denmark does not
allow excessive red tape.
The Danish government is also working on a stronger le-
gal framework for private-public partnership on research
in healthcare sector. Their primary focus is on pharma,
medtech and health technology. The government has
reserved 41.1 billion DKR for the implementation of a
new national hospital plan. Focus in the hospital plan is
greater specialization and hence better treatment, more
cost-efcient hospitals and better conditions for research
and development. The government has set up a new body
for e-health that will be responsible for governing the
implementation of the national electronic patient record
system by the end of 2013.
One of the major attractions for foreign investors is
our patient records. The Danish health registers enables
researchers to monitor patients across time, regions and
sector. The Danish Serum Institute is currently establish-
ing a national bio bank, granting access to serum samples
from all over the country, said Mr Haarder.
The Danish Council for Technology and Innovation has
invested in a Strategic Platform for Innovation and
Research (SPIR) within intelligent solutions for welfare
service challenges. The SPIR is a partnership between a
number of private companies and universities and aims
at basic research.
Funding for Danish health research on public facilities
has more than doubled in the last decade. This is due to
an increase in government funding, and success in taking
home donations from European and American founda-
tions such as the Novo Nordisk Foundation and the Lun-
dbeck Foundation. Health research comprises 33 percent
of Danish public research.
Denmark calls out
for Asian investment
Denmark boasts of
the third largest drug
pipeline in Europe
and is a leader in
areas of enzymes,
CNS, diabetes and
cancer reseach.
BioSpectrum explores
the infrastructure and
opportunities provided
by the country to its
biotech sector
BioSpecial
BioSpecial
The Danish government calls for Indian companies to
set up operations in Denmark. Denmark is a gateway
to most part of Northern Europe. Copenhagen, being a
major life sciences hub, is the ideal place for Asian com-
panies to set up their North European headquarters. This
will allow them to cover the market in Germany, Holland,
Belgium and UK. The company tax rate here is only 25
percent and expatriates can benet from a special tax re-
gime, said Rasmus Bjrn, business development man-
ager, Invest in Denmark.
Clinical trial hub
Approximately 1,000 clinical trials are approved and
carried out every year in Denmark and about 20,000
Danes participate in clinical trials each year. According to
Denmarks ministry of interior and health, Denmark
conducts the highest number of clinical trials in Europe
per million inhabitants. The country has a long tradi-
tion for patient and population registration. The Dan-
ish population is homogeneous with registered and
easily accessible data, providing unique information on
the patient population. Denmark has organized public
health and death registries and a unique social secu-
rity number system. Thus, data is available for studies,
making Denmark particularly suited for epidemiological
and clinical research. Some of the companies that chose
Denmark for conducting clinical trials are:
Pzer: The effect of low-dose human growth hormone
therapy in HIV infected patients on highly active antiret-
roviral therapy.
GlaxoSmithKline: Human papilloma virus vaccine
consistency and non-inferiority trial in young adult
women.
Astra Zeneca: Casodex vs Placebo in non-metastatic
early prostate cancer.
Merck: A comparison of two total hip replacements: hip
resurfacing system versus Mallory-Head/Exeter.
Novartis: A study to evaluate the effect of letrozole and
tamoxifen on bone and lipids in postmenopausal women
with breast cancer.
Sano-Aventis: Simvastatin as an add-on treatment
to copaxone for the treatment of relapsing multiple
sclerosis.
Eli Lilly & Co: Enzastaurin for patients with metastatic
colorectal vancer.
Highly qualified work force
Approximately 1.8 million people live in the Greater
Copenhagen Area, and if we include the Swedish side of
the Medicon Valley, there are approximately three mil-
lion people residing in this area. In total, they represent a
workforce of roughly 1.5 million people of whom 42,000
are employed within the life sciences sector. Medicon
Valley contains a highly educated work force, with 27
percent of people aged between 25 and 64 years holding
tertiary degrees. It is also the best place to access one of
Europes most skilled talent pools.
The Medicon valley
Medicon Valley is a bi-national life sciences clus-
ter that spans the island of Sealand in Eastern Den-
mark and the Skne region of Southern Sweden.
It is one of Europes strongest life science clusters
with a large number of pharmaceutical, biotech and
medical device companies and research institutions
located within a very small geographical area.
Local and international investors have provided the capital
need for the continued growth of these companies. Together
with specialized service providers such as different CROs,
CMOs, consultants and patent attorneys, all the compe-
tences required to bring new and innovative products to
the market are available. About 467 life sciences companies
from across the world operate from this cluster.
ASHISH SARAF
(The writer was in Copenhagen
at the invitation of Invest in Denmark)
Medicon Valley cluster (Fact file)
Population of approx 3.5 million.
Companies with R&D and/or production: Approx
100 (red) biotech companies, 25 pharma companies
(7 major) and 100 medtech companies.
International companies with afliates in Medicon
Valley: More than 200 pharma companies and 170
medtech companies.
Approx 40,000 employees in the private life science
sector.
Approx 10,000 life science researchers in the private
and public life science sector.
Twelve universities, ve of which supply life science
related educations.
Approx 150,000 students, 45,000 of whom study life
science.
Approx 2,600 life science PhD students are enrolled
at the universities of Copenhagen and Lund.
Approx 7,000 life science university students gradu-
ate every year.
Thirty two hospitals, 11 of which are university hos-
pitals.
Six science parks with a signicant focus on life sci-
ence.
Six incubators, two of which have a signicant focus
on life science.
More than 50 contract research organizations and
contract manufacturing organizations.
We will help India to
tap the EU market
Mr Freddy Svane, Ambassador, Royal
Embassy of Denmark, New Delhi
T
he Danish biotechnology industry is a major
world player, particularly in the areas of en-
zymes, CNS research, diabetes and cancer re-
search. Denmark, which boasts of the third larg-
est commercial drug development pipeline in Europe, is
continuously developing its research methodologies and
is thus at the forefront of cutting edge biotech and phar-
ma research. The excellent infrastructure provided by
Denmark along with the various socio-economic incen-
tives, being provided by the country, is attracting several
foreign companies to set up their business in Denmark.
The representative of the Kingdom of Denmark in
India, Mr Freddy Svane, the Danish Ambassador to India,
while speaking exclusively to BioSpectrum revealed that
the world leader in clean technology is looking forward to
collaborate with Indian rms to tread the path of success
in biotechnology.
What is the present scenario of co-operation
between Denmark and India?
Presently, we have more than 120 Danish companies that
have set up their own establishments and are heavily
investing in India. On the other hand, there are a lot of
opportunities for Indian companies to grow in Denmark.
I see many opportunities for interaction between the
Governments of Denmark and India and also between the
industries and the farmers of the two countries. We are
doing a lot of work at the embassy along with our Trade
Mission and our colleagues at Invest in Denmark in or-
der to take the co-operation between the two countries
to a higher level. Looking into the detailed collaboration
that the Danish government and the Indian government
currently have, we have a joint commission that sets out
joint priorities and biotech is perhaps the most important
priority.
Why do you think companies from India should
invest in Denmark?
Denmark is a small country with only 5.4 to 5.5 million in-
habitants. However, the number of clinical trials that we
have conducted total to more than 2,000 global clinical
trials in a year. The Danish government has decided to es-
tablish a fast track system that will drastically reduce the
time required to obtain permits for clinical trials. We have
the infrastructure in place which is important to developing
a new drug. Denmark has a model called as a exicurity
model that offers operational exibility to Indian compa-
nies that are planning to set up business in Denmark. Cor-
porate taxes are just about 25 percent, which is less than
the European Unions average. Denmark also has an Eng-
lish speaking population and a highly talented workforce.
The government spends around `63.68 crore (10 million)
every year to provide infrastructure for life sciences, IT and
clean tech sectors and also in education and in schemes
such as the industrial-PhD program. It is fair to say that
biotech companies in India, who want to come to Europe,
have the perfect hub in the form of Denmark. We have the
full range of products and services in place such as infra-
structure, top institutions and a lot of biotech and medtech
companies among others, which would attract the ambi-
tious Indian biotech industry.
Which Indian companies have invested in
Denmark until now?
During the last year, we had seen a large number of Indi-
an investments been made in Denmark. Vimta labs, one
of the leading clinical research organizations (CROs) of
India and Aurobindo Pharma have just established their
branch ofce, thus tapping into Europe by using Den-
mark as a hub. Also, a company called Ecron Acunova has
invested in Denmark. We also have a strategic alliance
with Aurigene. We are seeing a large number of Indian
rms showing their interest in the Danish market trying
to explore the facilities that we have.
SAPTARSHI CHAUDHURI IN BANGALORE
BS
BioSpecial
Dr Reddys Laboratories announced
its unaudited consolidated nancial
results for the quarter and full year
ending March 31, 2011 under Inter-
national Financial Reporting Stan-
dards (IFRS).
The rms consolidated revenues
were `7,470 crore in the nancial year
2011 as compared to `7,030 crore in
the nancial year 2010 with an year-
on-year growth of six percent. The
company witnessed good and sus-
tained growth across all key for-
mulation markets in the nancial
year 2011.
North Americas revenue witnessed a
growth of 18 percent in dollar terms
and 11 new products were launched
in the region. Sequential growth of
23 percent in Q4 FY11 over Q3 FY11
demonstrates the fth consecutive
quarter of sequential growth.
The business in Russia witnessed
revenue growth of 29 percent in dol-
lar terms, due to growth in volumes
and OTC initiatives. Indias revenue
growth was 15 percent, with sustained
growth of key brands and new prod-
ucts introduction.
In Germany, revenue declined 17
percent in Euro terms, however, im-
proved signicantly in protability.
During the year, the company
launched 135 new generic products,
led 107 new product registrations
and led 56 DMFs globally. The com-
pany also forayed into many strategic
initiatives.
The rm acquired a penicillin facility
to ll the portfolio gap in the anti-bac-
terial segment in the US. The com-
pany also collaborated with Valeant
Pharma to market Cloderm Cream in
the dermatology space in the US.
GlaxoSmithKline net sales up 11.4%
GSK announced its nancial results for the rst quarter, ending March 31,
2011. The overall sales increased by 11.4 percent and net sales of the pharma-
ceuticals business witnessed a rise of 12.4 percent, while prot after tax grew
by 16 percent.
Marketing approvals were also received for two innovative products includ-
ing, Votrient, which can be used for treating renal carcinoma and Revolade,
which can be used to cure platelet depletion. GSK expects to launch these
products in the ensuing quarter. GSK Pharmaceuticals is a subsidiary of Glax-
oSmithKline plc, one of the worlds leading research-based pharmaceutical
and healthcare companies.
Jubilant reports Q4 profit of `61 crore
Ranbaxy registers Q1 sales of `2,146 cr
Ranbaxy Laboratories declared its nancial performance for the rst quarter
ending March 31, 2011. The consolidated sales of the company for the quarter
were `2,146 crore as compared to `2,484 crore in the corresponding quarter
in the previous year.
Earnings before interest, tax, depreciation & amortization (EBITDA) was 20
percent of sales at `428 crore as compared to `983 crore. The Indian market
recorded sales worth `435 crore, which is a growth of 14 percent. Of this,
sales in the consumer healthcare business stood at `59 crore, a growth of 35
percent. The Asia Pacic region recorded sales of `76 crore, a growth of 17
percent, which was mainly driven by higher sales in some smaller markets.
The key highlights of this years performance of the company include the in-
crease in its market share to 4.78 percent, as compared to 4.63 percent in Q1
of 2010. Also, Ranbaxy redeemed the $440 million foreign currency convert-
ible bonds, on the due date. During the quarter, over 10 regulatory agencies
from across the globe, inspected and approved Ranbaxys API and dosage
form (DF) facilities, in multiple locations.
Dr Reddys Q4 net
profit dips 34%
Jubilant Life Sciences reported a consolidated net prot of `61.72 crore for
the fourth quarter ending March 31, 2011 as compared to `137.16 crore during
the same period in the previous scal year. The companys net sales for the
quarter stood at `890.34 crore as against `991.83 crore reported in the same
period during the last scal.
Commenting on the performance of the company, CMD Mr Shyam S
Bhartia, highlighted that during the nancial year 2011, the company
recorded a good revenue growth in its
products business, which was fueled by
a robust volume growth of 16 percent.
The rm has gained condence due to its
increased capacity utilization, commis-
sioning of new plants, innovation led new launches and expansion of market
geographies.
Bytes
BioNews
GVK to focus on neglected
diseases
GVK Biosciences has been selected as a preferred pro-
vider to a consortium of 14 global product development
partners (PDPs) for clinical services in Asia. It is the only
partner that is headquartered in India. The PDPs, fund-
ed in part by the Bill and Melinda Gates Foundation are
not-for-prot entities focused on developing new inter-
ventions for neglected diseases. Collectively, the 14 PDPs
would fund 85 clinical trials in the developing world over
the next two years and India features as a key developing
world country.
Indian CRO buys stake in
aCROnordic
Ecron Acunova acquired a majority stake in Denmark-
based aCROnordic, a CRO specialized in clinical research
in Sweden, Finland and Norway. The rm has its head-
quarters located in Denmarks leading bio-science park,
SCION DTU in
Hoersholm near
Copenhagen.
Mr DA Prasanna,
founder and chairman of Ecron Acunova, highlighted that
a recent change in the strategy of sponsors in the health-
care industry asks for a more global presence of preferred
provider CROs. Mr Sren Strh, founder and former own-
er of the rm will continue his role as CEO for the Nordic
region.
Glenmark and Sanofi
enter deal
Glenmark Pharmaceuticals announced that it entered
into an agreement with Sano Aventis to grant a license
for the development and commercialization of GBR 500,
a novel monoclonal antibody used for the treatment of
Crohns Disease and other inammatory conditions. Sano-
will have exclusive marketing rights for North America,
Europe, Japan, Argentina, Chile and Uruguay and Glen-
mark will co-market in Russia, Brazil, Australia and New
Zealand.
Glenmark will retain exclusive marketing rights in India
and other countries in the rest of the world. Glenmarks
other biologics molecules include GBR 600 which has
completed phase I studies, GBR 401 which is in pre clini-
cal studies and GBR 900 which again is at early stages of
development.
Bytes
BioNews
BioNews
Indegene bags seven Hermes awards
Indegene Lifesystems, a scientic partner to global pharmaceutical and life
sciences companies, won seven awards at the prestigious Hermes Creative
Awards 2011. Hermes Creative Awards is an international competition for cre-
ative professionals involved in the concept, writing and design of traditional
materials, programs, and emerging technologies. They are administered and
judged by the Association of Marketing and Communication Professionals.
There were about 4,400 entries in this years competition. This year Indegene
won four platinum awards under the categories of Overall Website, e-Learn-
ing Solutions, and Advertising Campaign. In the Gold awards grouping, In-
degene won three awards under the categories of Overall Website, e-Learn-
ing, and Video-Marketing Services. As a leading commercialization and
marketing service provider to pharmaceutical companies across the globe,
Indegene has a proven track record of winning awards year-on-year for some
of its most creative medical and marketing initiatives. Last year, the company
won two awards, including one Gold and one Platinum award at the Hermes
Creative Awards 2010.
Jubilant repays $202 mn for FCCBs
Jubilant Life Sciences, the largest custom research and manufacturing ser-
vices company in India, announced the prompt repayment of $202 million
on account of outstanding FCCBs includ-
ing YTM of $60 million. The company has
repaid all the outstanding FCCBs on time,
as per schedule, in line with the terms
and conditions of the FCCB instruments,
showing its commitment to meet its obligation on time and also demonstrat-
ing its nancial strength. Jubilants CMD, Mr Shyam S Bhartia, and co-CMD,
Mr Hari S Bhartia, highlighted that the rms objective is to strengthen the bal-
ance sheet by using a more optimal mix of capital. They also revealed that after
the repayment of the previous FCCBs, worth $202 million, there is no major
debt repayments that is due for the next three years. Jubilant Life Sciences has
good visibility of growth and has exciting plans to augment capacities, intro-
duce products and enter new markets across the various lines of businesses,
thereby driving revenue and earnings growth momentum of the company.
TN beats Karnataka in biofertilizer use
Tamil Nadu has overtaken Karnataka in biofertilizer usage according to the data
on use of biortilizer released by the Ministry of Agriculture, on May 18, 2011. In
2009-10, Tamil Nadu produced 3,733 tonnes of bio-fertilizers followed by Karna-
taka 3,696 tonnes. The other major producers of bio-fertilizers are Kerala (1,937
tonnes), Maharashtra (1,861 tonnes) and Madhya Pradesh (1,588 tonnes).
Studies on the benets and the usefulness of bio-fertilizers on agriculture pro-
duction reveal that on an average 10-20 percent increase in production can be
realized by the use of bio-fertilizers. In terms of nutrients, bio-fertilizers can pro-
vide 10-20 kg nitrogen and can solublize 10-12 kg of phosphorous pentoxide per
hectare per cropping season. Use of bio-fertilizers also improve soil health by
helping other benecial micro-organisms to grow.
ICMR for human
biologics committee
A committee has been formed by the
director general of the Indian Coun-
cil for Medical Research (ICMR) in
order to consider the cases related to
the transfer of human biological ma-
terial for commercial purposes.
The committee has been set up in ac-
cordance with the guidelines issued by
the Ministry of Health, Government of
India (vide O.M.No.19015/53/1997-
IH Pt.) dated November 19, 1997.
For transfer of samples, the Indian
applicant should follow the Guid-
ance on regulations for the transport
of Infectious substances (2009-10)
as published by the WHO. There are
specic packing instructions as per
United Nations class (6.2) specica-
tions that are to be followed during
transport of infectious substances.
Unless declared otherwise, the bio-
logical materials such as blood and/
or other blood components; dried
blood spots and faecal occult blood
and medical or clinical wastes are to
be considered under the infectious
substance category.
The applicants are required to indi-
cate the category under which the
infectious substances or organism
falls. In addition to categories indi-
cated as per UN class specications
in the WHO guidelines (2009-10),
the applicant should also refer to the
relevant categories mentioned under
SCOMET items in schedule of Indias
Foreign Trade Policy classication as
well as Animal and Human patho-
gens scheduled as risk groups in the
Ministry of Environment and Forests
Notication, GoI,1989.
Bytes
Briefs
BS
BioResearch
Nano antibodies to treat diseases
The National Research Center on Camel (NRCC), Bikaner, initiated a study
to test camel immunology in collaboration with the Bhabha Atomic Research
Centre, Mumbai. Since camels immunology is unique, the antibodies produced
in its blood stream are very special and are called nano antibodies, which have
the potential to treat various diseases. These antibodies are also expected to be
used for human disease diagnostics as well as treatment. Dr N V Patil, direc-
tor, NRCC, highlighted that the institute was working with the Bhabha Atomic
Research Centre to study the effectiveness of these antibodies on diseases like
TB and also in the diagnosis and treatment of thyroid cancer.
Interestingly, NRCC is also collaborating S P Medical College, Bikaner, to de-
velop an anti-snake venom. Dr Patil said that the nano antibodies traverse
through the animal and human body extremely fast to reach their target,
passing internal barriers like the blood-brain barrier and placental barrier.
He also pointed out that there is great prospect in this area for developing
drugs for diseases of animals and human.
Indo-German disease R&D initiative
The Indian Council of Medical Research (ICMR) and Helmholtz Association
of German Research Centres (HGF), Germany, have launched a fellowship un-
der the Indo-German Science Centre for Infectious Diseases (IG-SCID) for the
nancial year 2011-2012. IG-SCID is a joint initiative of HGF and ICMR with
the mission to strengthen Indo-German cooperation in the eld of infection
research. The purpose of this fellowship is to provide opportunities to Indian
and German researchers to undertake research in thematic areas of infectious
diseases. Six fellowships, each of a duration of three months, would be granted
each year by both the Indian and the German organization. Thematic research
areas of infectious diseases for training include, genetic susceptibility, viral
diseases (HIV/HCV) vaccine and anti-infectives, zoonoses & animal models of
infectious diseases. The programme will enable Indian scientists to visit sev-
eral German institutes such as, the Helmholtz Centre for Infection Research
(HZI), Braunschweig; TWINCORE Centre for Experimental and Clinical In-
fection Research, Hannover; MHH Medical University, Hannover and Helm-
holtz Institute for Pharmaceutical Research Saarland (HIPS), Saarbrcken.
ICMR constitutes Vector Science Forum
The emerging and re-emerging vector borne diseases like dengue, chikungu-
nya, japanese encephalitis, chandipura virus, nipah viruses, malaria, laria-
sis, and visceral leishmaniasis have posed a great challenge to researchers,
disease control programme planners and implementers in the country. In this
context, the Indian Council for Medical Research (ICMR) has now constitut-
ed a Vector Science Forum in order to promote research on vectors and to
develop a common platform for all vector biologists, entomologists, programme
people and experts embarking upon common issues. The projects would be
funded by ICMR and will involve extensive research in selective priority
areas. ICMR expects the forum to help in the eld of evaluation trials to evalu-
ate new insecticides, vector control tools in different vector eco-systems and
evaluation of diagnostic kits and assays for parasite detection.
Gene therapy to
cure AMD
A new in vivo study by researchers at
Tufts University School of Medicine
revealed that a new gene therapy ap-
proach using a protein called CD59,
or protectin, has a lot of potential to
slow the signs of age-related macular
degeneration (AMD). The team, which
was led by senior author Dr Rajendra
Kumar-Singh demonstrated for the
rst time that CD59 delivered by a
gene therapy approach signicantly
reduced the uncontrolled blood ves-
sel growth and cell death that is typi-
cal of AMD, which is the most com-
mon cause of blindness in the elderly.
Activation of the complement system,
a part of the immune system, leads
to the generation of pores known as
membrane attack complex or MAC
in cell membranes, which leads to the
killing of the cells in the back of the
eye and causes AMD. CD59 is known
to block the formation of MAC. Using
an established mouse model of AMD,
they found that the eyes had 62 per-
cent less uncontrolled blood vessel
growth and 52 percent less MAC than
the controls. The current standard
treatment for some forms of AMD
requires an injection directly into the
eye approximately every four weeks.
According to Dr Kumar-Singh, gene
therapy approaches to treat AMD are
especially attractive because they will
allow patients to be treated less fre-
quently, reducing patient discomfort
and lowering chances of infection.
The study received grants from The
Ellison Foundation, the National Eye
Institute, the National Institutes of
Health, the Virginia B Smith Trust,
the department of ophthalmology at
TUSM, the Lions Eye Foundation and
Research to Prevent Blindness.
Bytes
in
BS
T
he three-day-long Bangalore India BIO 2011,
which is Indias premier biotechnology event
covering all the major trends in biotechnology
and its related elds, attracted over 800 del-
egates from different parts of India and saw participa-
tion from countries such as France, Denmark, Singapore,
Australia, USA and several other nations from the Euro-
pean Union.
Mr BS Yediyurappa, chief minister, Government of Kar-
nataka, inaugurated the conference and exhibition at
the Bangalore International Exhibition Center (BIEC)
on May 4, 2011. He handed over the Letter of Intent to
Mr Vishal Goel, managing director, Alexandria Equities
Management for developing Bangalore Helix, a biotech-
nology park to be built in public-private partnership, on
56 acres of land in Bangalore.
Mr Goel said, The park is being built at a cost of `500
crore and will come up in a record two-year time, with the
construction commencing from October this year.
The chief minister also handed over cheques worth `50
lakh to 12 biotech nishing schools, which will be com-
mencing the specialized courses from the June 2011 aca-
demic year. These nishing colleges will offer specialized
courses that would enable students to focus on one par-
ticular topic of their choice, such as fermentation, bio-
informatics, clinical trials or clinical data management,
instead of covering the entire eld of biotechnology.
Mr M N Vidyashankar, principal secretary, Department
of IT, Biotechnology and S&T, Government of Karnataka,
said, The event has truly become a gateway to India for
the international biotech community. I am glad that the
Bangalore Helix project will be put on fast track with the
completion of selection process. The state governments
commitment to create the much-needed talent pool for
the biotech sector will be met through initiatives like the
biotech nishing schools, which was launched by the
Government of Karnataka in this event.
Dr V S Acharya, minister for Information Technology and
Biotechnology released the program document of Banga-
lore India BIO 2011. Dr V M Katoch, secretary to Govern-
ment of India, Department of Health Research, Ministry
of Health and Family Welfare released the Frost & Sul-
livan report named Opportunities in pharma biotech
Special focus on biosimilars as the next biotechnology
sector for India.
Dr Kiran Mazumdar-Shaw, chairperson, Karnatakas
Vision Group on Biotechnology and chairman & man-
aging director, Biocon, said, The biotech world is all
about partnering, collaborations, leveraging each others
strengths and synergizing them to deliver affordable in-
novation. It is also about making sure that entrepreneurs
are recognized, celebrated and born every day. This is
Over 800 delegates attend
Bangalore India Bio 2011
BioEvent
Dignitaries releasing the Bangalore India BIO 2011 document on the inauguration of 11th edition of Bangalore India BIO 2011, which was held from
May4-6 at Bangalore. Seen in picture from L-R: Dr Kiran Mazumdar-Shaw, chairperson, Karnatakas Vision Group on Biotechnology and CMD,
Biocon; Mr Jerome Bonnafont, Ambassador of France to India; Mr BS Yeddyurappa, chief minister of Karnataka; Dr VS Acharya, Minister for Higher
Education, Planning & Statistics, Muzrai, Information Technology and Biotechnology, Government of Karnataka; Mr Freddy Svane, Ambassador of
Denmark to India; Dr VM Katoch, secretary to the Government of India, Department of Health Research, Ministry of Health and Family Welfare; and
Mr Aravind Jannu, director, Directorate of IT & BT and managing director, KBITS, Government of Karnataka.
what Bangalore India BIOs focus has always been and
this is what the event will do in the years to come. Next
year, the conference will focus on safety, security and sus-
tainability.
Speaking on how value creation can be achieved through
innovation, in the eld of biotechnology, Dr Kiran Ma-
zumdar-Shaw, said that, We need to create an experi-
mental culture, foster an entrepreneurial environment,
and incentivize business differentiation. Concept and
ideas arent enough, they need to be translated and
implied in a manner that is benecial to others.
The mega event was organized by the Department of
Information Technology, Biotechnology and Science &
Technology, Government of Karnataka; Vision Group on
Biotechnology; MM Activ Sci-Tech Communications and
Association of Biotechnology Led Enterprises (ABLE),
a consortium of Indian biotechnology companies. The
event, whose focus theme was Biotech for a better
tomorrow, consisted of multi-track conferences, inter-
national trade shows, biopartnering meetings, a CEO
conclave and a bio-excellence award ceremony among a
host of other events.
Multi-track conferences consisted of 21 sessions and
featured 116 speakers. The sessions were attended by
815 delegates and 450 organizations from 22 countries
including Denmark, France and Belgium.
Agri and industrial biotech day was inaugurated with the
vision talk by Prof Samir K Brahmachari, who is the direc-
tor general of Council of Science and Industrial Research
(CSIR) and is also the secretary to the Government of India,
Department of Scientic and Industrial Research (DSIR).
The BioPartnering India initiative received a phenomenal
response with over 530 business meetings. Bio Excellence
Awards were presented in the categories of bio-pharma,
agri-bio, bio-services, industrial-biotech and bio-infor-
matics. The selection of the various award winners were
conducted by ABLE.
Dr Kiran Mazumdar-Shaw announced that the next Ban-
galore India BIO will be held on February 6-8, 2012.
Multi-track conferences consisted of
21 sessions and featured 116 speakers.
The sessions were attended by 815
delegates and 450 organizations from
22 countries
BioEvent
D
r N Prabhu Dev, vice chancellor of Bangalore
University, presented Bio Excellence Awards
and Emerging Company of the Year Awards
to 10 companies belonging to different sectors
such as bioindustrial, biopharma and healthcare, bioser-
vices, bioagri and bioinformatics & systems biology.
Rossari Biotech got the Bio Excellence award under bio-
industrial category and Richcore Lifesciences bagged the
Emerging Company of The Year award under biopharma
& healthcare. Concord Biotech got the Bio Excellence
award and Stempeutics Research was named the Emerg-
ing Company of The Year award. Ecron Acunova and
Suven Lifesciences both received the Bio Excellence
award as there was tie between the two rms under the
bioservices category, while Anthem Biosciences got the
Emerging Company of The Year award.
Nath Seeds got the Bio Excellence award under the catego-
ry of bioagri. Under the bioinformatics & systems biology
category, Strand Life Sciences got the Bio Excellence award
and Cellworks Research India was awarded the Emerg-
ing Company of the Year Award. Dr Kiran Mazumdar
Bio Excellence Award winners
-Shaw, CMD, Biocon, India, said, There are several pa-
rameters based on which the awards have been given. A
few of these parameters included the growth of the com-
pany, success of commercialization, the kind of products
produced by the company, innovation, exports and invest-
ment attracted by the company among others.
Dr Vijay Chandru, chairman & CEO, Strand Life Sci-
ences and president, ABLE said, Giving recognition
to emerging companies not only boosts the companys
morale but in turn it encourages the smaller rms.
T
o boost up the developments in the agri-biotech
space, the Karnataka government will set up an
innovation centre for agri-biotech in Bangalore,
worth `80-100 crore in association with the
Council of Scientic and Industrial Research (CSIR). The
center will come up on a joint (50:50) partnership basis
and would be spread across an area of 200,000 sq ft.
Mr M N Vidyashankar, principal secretary to the Govern-
ment, Dept of Information Technology, Biotechnology
and Science & Technology, Government of Karnataka
said, The facility would be a greeneld project. The cen-
ter would be commissioned within 18 to 24 months. The
center would be dedicated to promoting R&D of innova-
tive technologies. There would also be an area earmarked
for testing and quality control studies.
ABLE forms new group for regenerative medicine & cellu-
lar therapies. Considering the activities that are happen-
ing in the eld of stem cells and regenerative medicine in
India, the Association of Biotechnology Led Enterprises
(ABLE), a consortium of Indian biotechnology compa-
nies, announced the formation of regenerative medicine
Agri innovation center in Bangalore
& cellular therapies group (RMCT) with three members
from different background in the eld of stem cells.
The members of the new group include, the Institute for
Stem Cell Biology and Regenerative Medicine (inStem),
an autonomous institute of the Department of Biotech-
nology; Life Cell International, Indias rst private cord
blood bank that facilitates the cryogenic preservation of
umbilical cord blood stem cells at its unique facility in
Chennai and Stempeutics Research, a leading stem cell
company developing stem cell based medicinal prod-
ucts, with facilities in Bangalore and Manipal (India) and
Kuala Lumpur (Malaysia).
BioEvent
One of the exhibitors explaining the details to the delegates of Bangalore
India Bio 2011 1
From L-R: Mr Balaji Iyengar, CEO-India, Ecron Acunova; Mr B N
Manohar, CEO, Stempeutics Research; Mr D A Prasanna, CMD, Ecron
Acunova CRO (winner-Bio Excellence Award in bioServices sector); Dr
N Prabhudev, VC, Bangalore University and Mr M.N Vidyashankar,
principal secretary, Department of IT, Biotechnology, Karnataka.
BS
This Month
Biosimilars: Drugs for life
June 1, 2011
Chandigarh
URL: www.biztradeshows.
com/india/india-tradeshows.
mp?industry=medical-pharma
The conference will be a platform
to learn and explore the future of
the industry in the next few years.
It will provide the perfect oppor-
tunity to examine and understand
the regulated and semi-regulated
market for product development
and commercialization.
International Conference &
Exhibition on Pharmaceutical
Biotechnology
June 6-8, 2011
Hyderabad, Andhra Pradesh
URL: www.omicsonline.org
Biopharma-2011 attracts scientists,
researchers, academicians, depart-
ment managers, lab directors and
decision makers from all corners of
the pharma, biotech and health care
industries.
Pharmacovigilance Summit
India
June 27-29,2011
Mumbai, Maharashtra
URL: www.iqpc.com
Pharmacovigilance India is designed
to bring together an exclusive panel
of experts who will discuss the vari-
ous aspects of pharmacovigilance
practices and strategies to ensure
drug safety development from pre-
clinical to post marketing stages.
BIO International Convention
June 26-30, 2011
Washington, US
URL: www.lifescienceshealth.com
The convention is the largest global
event for the biotechnology indus-
try. The event would offer key net-
working and partnering opportu-
nities, provide significant insights
into the functioning of the biotech-
nology industry and provide inspi-
ration based on the major trends
affecting the life sciences sector.
Meditec Clinika
July 2, 2011
Bangalore, Karnataka
URL: www.meditec-clinika.com
BEST India 2011
July 26-29, 2011
Bangalore, Karnataka
URL: www.ableindia.in/best_2011
Healthex
August 5, 2011
Bangalore,India
www.healthex.co.in
2nd Annual Pharmacovigilance
2011
August 19, 2011
Mumbai, India
URL: www.virtueinsight.com/site/
Pharma.aspx
The Conference will bring together
top pharma, biotech and regulatory
representatives under
one roof that will address the key
issues of the industry.
International Pharmaceutical
Federation Congress
September 1-8, 2011
Hyderabad, India
URL: www.phyderabad2011.com
Pharmac India
September 17, 2011
Ahmedabad, Gujarat
URL: www.pharmacindia.com
Bio India International Partnering
Conference
September 21-22, 2011
Hyderabad, Andhra Pradesh
URL: www.bio.org/events
P-MEC India 2011 Convention
November 30-December 2011
Mumbai, India
URL: www.pmec-india.com
India Lab Expo 2010
December 8, 2011
New Delhi, India
URL: www.indialabexpo.com
ISTINGS L
SnapShot@India Lab Expo 2010
(L-R): Mr Vishal Goel, MD, Alexandria Equities Management (India) receiv-
ing the Letter of Intent to set up Bangalore Helix (biotech park) from Mr
B S Yeddyurappa, chief minister of Karnataka at the inauguration of the
11th edition of Bangalore India BIO 2011, held from May 4-6 at Bangalore.
Also seen in picture - Dr Kiran Mazumdar-Shaw, chairman & MD, Biocon;
Mr Jerome Bonnafont, Ambassador of France to India; Dr V S Acharya,
minister for Higher Education, Planning & Statistics, Muzrai, Information
Technology and Biotechnology, Government of Karnataka and Mr Freddy
Svane, Ambassador of Denmark to India.
BioEvent
Lastword
Ovarian cancer treatment
Indian healthcare market
clocked $69 billion in 2010.
Medical tourism in India will
attract revenues worth $3 billion
by 2013.
RNCOS
The Indian retail pharmaceuti-
cal market grew at 16.5 percent to
reach $10.2 billion in 2010.
Human mixtard 30/70, a hu-
man insulin product from Novo
Nordisk, was the top performing
product in India that fetched $51.9
million in 2010
IMS Health
India will join the league of the
top 10 global pharmaceutical mar-
kets in terms of sales by 2020, with
the total value being estimated at
$50 billion.
PricewaterhouseCoopers
Figure Facts
They are in you and me; they created us, body and mind; and their
preservation is the ultimate rationale for our existence ... they go
by the name of genes, and we are their survival machines.
F
i
r
s
t

P
e
r
s
o
n
A
54-year-old patient with
ovarian cancer has been
successfully treated with
AIET (Autologous Immune
Enhancement Therapy) by Nichi-In
Centre for Regenerative Medicine
(NCRM), Chennai, India. NCRM
along with its collaborating institutes
used proven Japanese technologies to
achieve theis feat. The cancer, which
spread to liver and spleen of the pa-
tient, stopped
growing further
and other me-
tastases also wit-
nessed shrinkage. According to a pa-
per on this clinical work, which was
presented in the Second Internation-
al Immunotherapy Congress, held re-
cently at Budapest, Hungary, the pa-
tient is now carrying out her chores as
before. The results have been lauded
by the international faculty.
Generally, advanced stage ovarian
cancer has a very poor prognosis. In
the case presented at the internation-
al congress, the patient was operated
for ovarian cancer and given chemo-
therapy in June 2009. The cancer re-
curred in July 2010 and spread to the
liver, the spleen and the lymph nodes
(stage IV) for which only limited
treatment options were available.
Along with chemotherapy the pa-
tient was given the AIET, which uses
the patients own natural killer (NK)
cells, the key immune cells that con-
tinuously do the surveillance for can-
cer cells and viruses and curtail any
cancer in the bud. These NK cells are
taken from the patients blood and
multiplied in the laboratory and re-
injected to destroy the cancer cells.
This has been in clinical practice in
Japan since 1990s and the technol-
ogy for multiplication of NK cells
using patients own serum was de-
veloped by Dr Hiroshi Terunuma of
Biotherapy Institute of Japan, Tokyo,
who is also a co-author of the work.
The patient
showed signi-
cant improve-
ment in her quality of life and the
cancer markers which were above
230 (CEA-125) before the treat-
ment, come down to normal around
to about four U/mL according to Dr
Ramanan, oncologist, Chennai, who
is following up the clinical status.
The AIET employs the innate poten-
tials of our immune system to ght
cancer. In this patient, as her own
immune cells are used, there is no re-
jection or adverse reactions. It is well
proven in randomized clinical studies
published in peer-reviewed journals.
The safety and efcacy of the cell based
immunotherapy, when combined with
other conventional modalities of treat-
ment is also well established.
NCRM, an Indo-Japan joint venture
institute, has been providing AIET
for cancer since 2005. It is prob-
ably Indias only centre providing
Autologous NK cells-based cancer
treatment.
- Richard Dawkins, British ethologist, evolutionary biologist and author
Autologous Immune
Enhancement Therapy
BS

9th Survey

Uploaded by

Copyright:

Available Formats

9th Survey

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

9th Survey

Uploaded by

Copyright:

Available Formats

6 BioSpectrum | June 2011 | www.BioSpectrumIndia.

com | A CyberMedia Publication

BHAT BIOSCAN (X-GAL-IPTG ) BLUE WHITE SPRAY CONVENTIONAL METHOD

You might also like